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Preface 
 
 This thesis is organized in 5 Chapters, preceded by an 
summary written in Portuguese and in English. Chapter 1 
consists of a general introduction to the themes discussed 
throughout the thesis, and includes a published review article. 
Chapter 2, 3 and 4 consist of experimental work published during 
the thesis period. Chapter 5 is and extended discussion 
integrating the published work presented in the previous 
chapters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Sumário 
 O sistema imune é fundamental para a manutenção da 
viabilidade do hospedeiro em casos de infecção. No entanto, os 
mecanismos usados pelo sistema imune para controlar infecções 
podem também causar destruição tecidual, levando ao 
desenvolvimento de imunopatologia. Para sobreviver a infecções 
o hospedeiro precisa controlar a proliferação do agente 
infeccioso e, ao mesmo tempo, evitar os efeitos deletérios da 
resposta imune em seus tecidos. Para alcançar este objetivo, o 
hospedeiro utiliza as seguintes estratégias: aumento da 
capacidade tecidual de suportar danos infligidos pelo sistema 
imune e/ou controle da ativação exacerbada do sistema imune. 
Nesta Tese buscou-se aprofundar o conhecimento sobre os 
mecanismos utilizados pelo hospedeiro para empregar de 
maneira bem sucedida tais estratégias. 
Para estudar o papel de células do sistema imune na 
regulação da magnitude de respostas imunológicas, analisamos 
a capacidade das células dendríticas (DC) de expandir células T 
reguladoras (TREG). Utilizando um sistema de co-cultura de 
células in vitro, demonstrou-se que as DC são capazes de 
induzir a expanão da população de TREG com capacidade 
supressora. É de realçar que, a expansão de TREG foi maior 
quando as DC apresentavam antígenos não-próprios. Estes 
resultados sugerem que a expansão da população de TREG 
durante uma resposta imunológica pode servir como um 
mecanismo regulador da ativação exacerbada do sistema imune. 
Dessa maneira, interações entre células do sistema imune 
podem ser suficientes para atenuar o desenvolvimento de uma 
resposta imune patológica e prevenir o desenvolvimento de 
imunopatologia. 
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Os mecanismos envolvidos na prevenção da 
imunopatologia através do aumento da capacidade tecidual de 
suportar danos causados pelo sistema imune, foram estudados 
em dois modelos experimentais de infecção, malária e sepse. 
Utilizando o modelo experimental de sepse, estudou-se o efeito 
da enzima heme oxigenase-1 (HO-1) na proteção dos tecidos 
contra danos causados pela resposta imune. Para tal, foram 
utilizados ratinhos com o gene da enzima HO-1 intacto 
(Hmox1+/+) e ratinhos em que este gene foi inativado (Hmox1-/-). 
A indução de sepse em ratinhos Hmox1+/+ acarretou modesto 
dano tecidual a orgãos viatis, enquanto o mesmo procedimento 
em animais Hmox1-/- causou severo dano tecidual a orgãos vitais 
levando à falência dos mesmos. É importante notar que apesar 
da diferença observada na severidade dos danos aos orgãos 
vitais, a resposta imune à infecção induzida pela sepse foi muito 
similar em ambos os genótipos. Esses dados sugerem que na 
ausência da expressão de HO-1 há um aumento na 
susceptibilidade dos orgãos a danos causados pelo sistema 
imune. A maior suscetibilidade observada em animais Hmox1-/- 
ocorre, ao menos parcialmente, devido ao maior nível de heme 
em circulação nestes animais. É de realçar que, a administração 
de heme a animais Hmox1+/+ após a indução de sepse 
desencadeou severo dano tecidual a orgãos vitais, enquanto a 
retirada de heme da circulação preveniu o desenvolvimento de 
sepse severa. Esses resultados reforçam a noção de que o 
heme atua como uma molécula capaz de potencializar danos 
teciduais a orgãos vitias em animais com sepse. 
Utilizando um modelo experimental de malária cerebral 
(ECM), demonstrou-se que mutações na hemoglobina conferem 
proteção contra o desenvolvimento dessa doença. Animais 
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transgênicos que expressam moléculas de hemoglobina 
mutadas (HbSAD), o que acarreta uma forma leve de anemia 
falciforme, não desenvolvem ECM, enquanto animais com 
hemoglobina normal (HbWT) sucumbem à doença. É de realçar 
que, a proteção conferida pela HbSAD possui dois componentes: 
o aumento da capacidade dos tecidos em suportar danos 
infligidos pelo sistema imune e, o controle da responsta 
imunológica evitando o desenvolvimento de uma resposta 
exacerbada. Como observado no modelo experimental de sepse, 
a expressão de HO-1 em animais com HbSAD é essencial para 
manter baixos níveis de heme durante a infecção e, assim, evitar 
a potencialização dos danos causados pelo sistema imune. Por 
outro lado, a HbSAD possui um efeito immunoregulatório, ainda 
sem mecanismo definido, que é independente da expressão de 
HO-1. Esse efeito induz uma drástica redução na expansão e 
ativação de células T CD8+, essenciais para o desenvolvimento 
da ECM. 
 Os resultados apresentados sugerem que o 
desenvolvimento de imunopatologia pode ser evitado por 
mecanismos que atuam tanto no tecido quanto no sistema 
imune. A compreensão de que estes dois compartimentos 
podem ser alvo de intervenções terapêuticas para evitar o 
desenvolvimento de imunopatologia abre novas possibilidades 
para o desenvolvimento de terapias para doenças em que 
grande parte da patologia é reflexo de uma resposta imune 
exacerbada. 
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Summary 
The immune system is fundamental to maintaining the 
host’s viability upon infection. Nonetheless, the mechanisms 
used to control pathogens may also cause tissue damage, 
leading to the development of immunopathology. The host’s 
capacity to survive infections depends on its ability to control the 
pathogen burden, while avoiding the deleterious effect of immune 
responses on its own tissues. To achieve this goal, the host may 
apply the following strategies: increasing tissue resilience to 
immune-mediated insult and/or controlling exacerbated immune 
activation. This Thesis sought insight into the mechanisms used 
by the host to successfully employ both strategies.  
To study the role of immune cells in regulating the extent 
of immune activation, we analyzed the capacity of dendritic cells 
(DC) to expand regulatory T cells (TREG). By using an in vitro co-
culture system, it was demonstrated herein that DC can induce 
the expansion of TREG with suppressive activity. Importantly, TREG 
expansion is greater when DC are loaded with non-self antigens. 
These findings suggest that the expansion of the TREG 
compartment during an immune response might serve as a 
mechanism to avoid unfettered immune activation that could 
result in immunopathology. In this way, the interactions among 
the cells of the immune system might, per se, be sufficient to 
prevent the development of immunopathology. 
The mechanisms operating in tissues to prevent 
immunopathology were investigated in two experimental models 
of systemic infections, malaria and sepsis. Analysis of wild type 
(WT) and heme oxygenase-1 deficient (Hmox1-/-) mice 
undergoing sepsis, induced by cecal ligation and puncture (CLP), 
revealed that, while WT animals showed signs of mild tissue 
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damage and organ failure, Hmox1-/- mice suffered from extensive 
tissue damage leading to multi-organ failure. Importantly, this 
occurred despite apparently similar overall levels of immune 
activation in WT and Hmox1-/- mice, suggesting that in the 
absence of HO-1 tissues become less resilient to insults 
perpetrated by the immune system and, therefore, more prone to 
immune-mediated damage. The diminished resilience to immune 
insult is at least partially due to increased heme levels in Hmox1-/- 
mice. In line with the pathological effect of heme in precipitating 
tissue damage in sepsis, its administration caused mild sepsis to 
become lethal in WT type animals, while heme scavenging 
rescued mice from developing severe sepsis. 
 The action of increased tissue cytoprotection acts 
together with the control of unfettered immune response to afford 
protection against experimental cerebral malaria (ECM) by 
mutations in hemoglobin. Transgenic animals carrying a mutated 
form of hemoglobin (HbSAD), leading to a mild sickle cell disease 
phenotype, were protected from ECM development while animals 
with normal hemoglobin (HbWT) succumbed. The protection 
afforded by HbSAD derives from a composite effect of increased 
tissue cytoprotection in addition to immunoregulation. As in 
sepsis, HO-1 protects against ECM development by decreasing 
heme levels upon infection, thereby protecting tissues from the 
highly deleterious effects of combined exposure to pro-
inflammatory mediators and heme molecules. On the other hand, 
the immunoregulatory effect of HbSAD works by a yet unidentified 
mechanism, independent of HO-1 expression, and leads to the 
marked suppression of CD8+ T cells proliferation and activation. 
 Overall, these findings suggest that immunopathology can 
be counteracted by mechanisms that operate in tissues by 
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increasing their capacity to bear immune-mediated insult, or 
within the immune system, by limiting unfettered activation. The 
realization that both tissues and the immune system can be 
actively modulated in order to decrease immunopathology opens 
new venues for the development of therapies for diseases in 
which the underlying cause of pathology is immune-mediated. 
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Chapter 1: General Introduction 
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1. The immune system 
 
The immune system is comprised of a wide range of 
molecules and cell types spread along the body surface and 
strategically placed to detect and rapidly respond to invading 
pathogens and/or insulting agents. Its importance in maintaining 
host viability is strikingly demonstrated in the rare cases of 
natural mutations affecting molecules of the immune system in 
human subjects, leading to increased susceptibility to infections1-5 
or to the development of autoimmune diseases6. 
The normal course of a protective immune response is often 
characterized by the concerted action of the innate and adaptive 
immune system (see sections 1.1 and 1.2). The initial steps in 
this process require activation of the innate immune system 
through the recognition of evolutionarily conserved molecules 
expressed by microorganisms, termed broadly Pathogen-
Associated Molecular Patterns (PAMP), and/or host-derived 
molecules associated with tissue damage or malfunction, termed 
broadly Danger-Associated Molecular Patterns (DAMP). This 
recognition process occurs through a multitude of germ-line 
encoded receptors, generally termed Pattern Recognition 
Receptors (PRR), and leads to innate immune cell activation. 
Upon activation, cells of the innate immune system termed 
antigen presenting cells (APC) (see section 1.1), migrate to 
secondary lymphoid organs, carrying processed antigenic 
peptides. The recognition of peptides in the context of major 
histocompatibility complex (MHC) molecules, coupled with co-
stimulation and cytokine production by APC, initiates the process 
of T cell activation. This process encompasses several rounds of 
proliferation with posterior acquisition of effector function, 
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characterized by the ability to produce large quantities of 
cytokines and/or kill target cells upon antigenic re-stimulation. B 
cells can be directly activated by PRR stimulation alone or in 
combination with B cell receptor ligation, but normally require 
help from T cells in order to achieve full differentiation. After 
activation B cells differentiate into plasma cells and start 
producing large quantities of antibodies.  
Importantly, unlike innate immune cells, T and B cells have 
their specificities determined by receptors generated randomly 
through somatic gene rearrangements. This randomness allows 
the generation of a repertoire of receptors capable of recognizing 
virtually any antigen, although each lymphocyte caries only a 
single receptor. This single lymphocyte receptor can recognize a 
range of antigenic determinants. Therefore, APC and antigens 
migrate to secondary lymphoid organs in order to increase the 
likelihood that the rare specific T and B cell clones recognizing 
the antigen in question will be activated. Once the adaptive 
immune system is activated it will further instruct innate immune 
cells with molecular cues, such as cytokines, in order to control 
or eliminate the harmful insult. After the insult is controlled, the 
majority of the T and B cells in the antigen-specific pool that 
underwent massive expansion die, and the ones surviving 
differentiate into memory cells, able to respond more rapidly, with 
greater intensity and specificity to subsequent antigenic 
challenge. The acquisition of immunological memory, i.e. the 
ability to respond faster and with greater intensity and specificity 
to a second exposition to the same harmful insult, is a specific 
characteristic of adaptive immune cells as innate immune cells 
do not acquire immunological memory after responding to a 
given pathogen and/or insult. Importantly, all the processes, from 
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innate immune activation to adaptive immune effector function 
and memory acquisition, need to be tightly regulated to avoid 
excessive tissue damage and/or development of autoimmunity 
(see sections 1.1, 1.2). 
A more detailed description of the innate and adaptive 
immune response will be given below. 
 
1.1 Innate immunity 
 
The innate immune system is the host’s first line of defense 
against invading pathogens and/or harmful insults. The cellular 
components of the innate immune system include myeloid cells, 
such as macrophages and dendritic cells (DC), neutrophils, mast 
cells, basophils, and natural killer (NK) cells. More recently, 
previously uncharacterized cell populations with innate 
characteristics, and mainly involved in inducing T helper 2 
responses (TH2) (see section 1.2), have been described and 
termed nuocytes, multi-potent progenitor type-2 (MMPtype2), 
innate type 2 helper cells, and natural helper cells7. Innate-like 
lymphocytes such as γδ T cells and NKT cells, have lymphocyte 
characteristics but that respond to stimulation in a time frame that 
is compatible with innate immune responses. Soluble molecules 
such as the complement system, pentraxins, and lectins, form 
the humoral arm of the innate immune system. The anatomical 
localization of innate immune cells is such that they can survey 
the surfaces of the host likely to be exposed to pathogens and/or 
harmful insults, such as the skin8 and mucosal surfaces9-11, and 
induce rapid and powerful inflammatory responses upon 
activation. 
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 The activation of the innate immune system can be 
depicted schematically as a process that relies on detection of 
pathogens and/or insults, with the subsequent activation of 
intracellular signaling cascades leading to gene expression of 
effector molecules. These effector molecules will, in turn, act to 
eliminate the insult through a multitude of mechanisms.  
 The process of detecting pathogens relies on the 
recognition of evolutionarily conserved molecular structures that 
are essential for microorganism survival, such as components of 
the cell wall or nucleic acids, and, therefore, are unlikely to suffer 
major modifications without consequent loss of pathogen fitness. 
These conserved structures are recognized by germ-line 
encoded receptors expressed in a variety of cell types, broadly 
termed PRR12. Importantly, PRR can also recognize or respond 
to concentration changes in endogenous molecules produced or 
released upon cellular stress or damage, i.e. ATP13, uric acid14,15, 
serum amyloid A16, amyloid-β17 , endogenous nucleic acids18-21, 
and high-mobility group box-1 (HMGB1)22. 
 Four families of PRR have been described so far: Toll-like 
receptor (TLRs), Nucleotide-binding oligomerization domain-like 
receptors (NLRs), retinoic acid inducible gene I (RIG-I)-like 
receptors (RLRs), and C-type lectin receptors (CLRs). The 
cellular localization of these receptors varies. TLRs are 
expressed at the cell surface and in intracellular endossomal 
compartments23, NLRs and RLRs are found in the cytoplasm24,25, 
while CLRs are exclusively expressed at the cell surface26. There 
are clear distinctions among these families but, nonetheless, they 
share a similar overall program of detection, signal transduction 
and subsequent production of effector molecules.  
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The signals initiated by PAMP recognition via PRR 
culminate in the activation of key transcription factors that are 
primarily responsible for the transcription of effector molecules. 
Among these transcription factors are nuclear factor kappa B 
(NF-κB), activating protein-1 (AP-1), nuclear factor of activated T-
cells (NFAT) and interferon regulatory factor (IRF) 3 and 723-26. 
The intensity of the signaling pathways leading to the activation 
of these transcription factors will dictate the specificity of the 
resultant response27. Importantly, in the case of pathogens, most 
often more than one PRR will be triggered upon recognition. The 
overall production of effector molecules will, therefore, depend on 
the net effect of activation and inhibitory signals received by the 
cell. As a general principle, PRR stimulation will lead to NF-κB, 
NFAT, and AP-1 activation that will, in turn, initiate the 
transcription of proinflammatory cytokines, chemokines and 
molecules involved in direct pathogen killing such as 
antimicrobial peptides, nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase subunits, and nitric oxide synthase 
(iNOS). The production of type I interferons will occur through the 
activation of IRF3 and IRF728.  
 The relative specificity in the response triggered by 
different PRR relies in great deal on the intermediate signaling 
molecules used to achieve the final activation of transcription 
factors. In the TLR family, signaling is dependent on two crucial 
adaptor molecules, i.e. myeloid differentiation primary response 
gene 88 (MyD88) and TIR-domain-containing adapter-inducing 
interferon-β (TRIF). All TLRs signal via MyD88, except TLR3 that 
uses TRIF exclusively, and only TLR4 uses both adaptors29. 
Other signaling molecules such as MyD88-adaptor-like (Mal)30-32, 
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and TRIF-related adaptor molecule (TRAM)33 are also involved in 
TLR signaling, and distinct combinations among them upon 
stimuli generate specific patterns of gene transcription. 
CLRs signal through tyrosine-based motifs such as 
immunoreceptor tyrosine-based activation motifs (ITAM), 
hemITAM (resembling half of normal ITAM motifs) and 
immunoreceptor tyrosine-based inhibitory motifs (ITIM). While the 
latter might work by increasing the threshold for innate cell 
activation34-36, the first two activate innate cells. Importantly, not 
all CLRs have an intracellular domain capable of transducing 
signal and are, therefore, coupled with adaptors, such as the Fc 
receptor γ chain, that contain tyrosine-based motifs and are 
responsible for signal transduction upon PAMP stimulation26. The 
ITAMs and hemITAMs will recruit and activate spleen tyrosine 
kinase (Syk) and the ITIM will recruit phosphatases, i.e. SHP-1 
and SHP-226. Upon Syk activation, recruitment of the adaptor 
molecule CARD9 normally ensues and leads to the activation of 
downstream transcription factors, such as NF-κB37,38. 
 NLRs form a large family of cytoplasmic receptors that 
have a particular structure containing a nucleotide-binding 
domain (NBD) and leucine-rich repeat domain (LRR). NOD-1 and 
NOD-2 induce the production of proinflammatory cytokines using 
the adaptor molecule RIP2 to activate NF-κB, and mitochondrial 
antiviral signaling protein (MAVS) to induce IRF-dependent type I 
interferon production24. Importantly, a subfamily of NLRs named 
NLRP or NALP, is involved in forming a multiprotein structure 
termed inflammasome39. Signals that induce inflammasome 
assembly and activation include increased cellular potassium 
efflux40, reactive oxygen species (ROS)41-43 and leakage of 
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lysosomal contents into the cytoplasm17,44, i.e. cathepsin B. The 
activation of inflammatory caspases follows inflammasome 
assembly and may lead to different outcomes such as the 
conversion of pro-IL-1β and pro-IL-18 to active forms or cell 
death39.  
RLRs constitute the smallest family of PRR. It is 
composed of the cytoplasmic RNA helicases retinoic acid 
inducible gene 1 (RIG-I), melanoma differentiation associated 
factor 5 (MDA5), and laboratory of genetics and physiology 2 
(LGP2). Unlike the other PRR families, RLRs seem to be 
restricted in the array of pathogens they recognize, being limited 
to viral detection, and more specifically, to viral RNA detection25. 
Upon RNA binding, RLRs associate with the adaptor protein 
MAVS and induce NF-kB-dependent transcription of 
proinflammatory genes and IRF3 and IRF7-dependent 
transcription of type I interferons25. Some of the characteristics 
and ligands of the different PRR families are summarized in table 
1.1. 
To avoid exacerbated inflammation and potential tissue 
damage, innate immune responses are regulated by a myriad of 
regulatory mechanisms. Some examples are discussed in further 
detail below. 
 Animals deficient for IRAK-M (Irak-m-/-) have increased 
intestinal inflammation upon Salmonella thyphimurium infection45 
and succumb to influenza infection due to an uncontrolled 
inflammatory response46. Accordingly, Irak-m-/- cells present 
increased NF-kB45, p38 mitogen-activated protein (MAP) kinase 
45,47, c-Jun N-terminal kinase (JNK)45 and extracellular-signal 
regulated kinase (ERK) 1/245 activation upon stimulation with 
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PAMP. 
Table 1.1. Characteristics of PRR from different families.  
PRR  Cellular localization Ligands 
Proximal adaptor 
molecule 
TLR       
    
TLR2 Plasma membrane Lipoprotein MyD88 
TLR3 Endolysosome Double Stranded RNA TRIF 
TLR4 Plasma membrane LPS MyD88 and TRIF 
TLR5 Plasma membrane Flagelin MyD88 
TLR7 Endolysosome Single stranded RNA MyD88 
TLR9 Endolysosome CpG-DNA MyD88 
TLR10 Endolysosome Profilin-like molecule MyD88 
    
NLR       
    
NOD1 
 
Cytoplasm 
 
γ-D-glutamyl-
mesodiaminopimelic 
acid RIP2 
NOD2 Cytoplasm muramyl dipeptide RIP2, MAVS 
    
CLR       
    
Dectin-1 Plasma membrane β-Glucan Syk/CARD9 
Dectin-2 Plasma membrane β-Glucan Syk/CARD9 
Mincle Plasma membrane SAP130 Syk/CARD9 
DNGR-1 Plasma membrane Unknown content of dead cells Syk 
    
RLR       
    
RIG-I Cytoplasm Short double stranded RNA MAVS 
MDA5 Cytoplasm Long double stranded RNA MAVS 
Note: Adapted from references 23-26,29,39. 
 
The ubiquitin-editing enzyme A20 is an essential and 
absolutely required regulator of innate immune activation. A20 
functions by deubiquitinating or polyubiquitinating key signaling 
molecules involved in PRR and cytokine receptor signaling 
pathways, leading to their functional inactivation or degradation 
by the proteassome48. Primarily described as an inhibitor of TNF-
mediated apoptosis49, the ability of A20 to regulate NF-κB 
activation by modulating several upstream signaling molecules 
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was later described. A20-deficient mice (A20-/-) die shortly after 
birth showing severe multi-organ inflammation, an effect at least 
partially attributable to uncontrolled NF-κB activation50. 
Subsequently, A20 was shown to modulate signaling by 
TLRs51,52, NLRs53 and RLRs54 as well. Importantly, A20 
expression is induced upon NF-κB activation and, therefore, acts 
in a negative feedback loop to contain exacerbated activation of 
the former48. Other ubiquitin-editing enzymes such as 
deubiquitinating enzyme A (DUBA)55 and CYLD56,57 have also 
been shown to act as negative modulators of innate immune 
activation. 
There are several other mechanisms described to limit 
innate immune cell activation such as, but not limited to, the 
expression of molecules with RNase activity inducing rapid decay 
of inflammatory cytokine RNA58, microRNAs59, inhibitory 
receptors36,60,61, and suppression of innate immune cells by 
specific subsets of T lymphocytes62-64. Of note, heme oxygenase-
1 (HO-1) is proposed to be one of the molecules involved in 
controlling activation of innate immune cells65. Data supporting 
this notion is described in detail in section 2.  The existence of 
many diverse systems implicated in controlling excessive 
inflammation highlights its importance in maintaining host 
viability. Importantly, one common feature of  deregulated  innate 
immune cell activation is the consequent unfettered activation of 
the adaptive immune compartment58,60, a process thought to be 
mainly driven by activated dendritic cells (DC). 
DC are innate immune cells with matchless capacity to 
activate adaptive immune cells, in particular T cells, as 
demonstrated in the seventies by Steinman and colleagues66-70. 
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Later, data using transgenic mice allowing for transient DC 
depletion confirmed that DC are essential in vivo for T cell 
priming71-75 and re-stimulation76,77. This unique capacity relies on 
DC’s ability to provide T cells with adequate amounts of MHC-
peptide complex, costimulation and cytokines, when properly 
activated by PAMP78,79. 
The cytokines produced by DC during T cell activation 
play a major role in instructing which sort of T cell response will 
be generated80,81. Notwithstanding their role in initiating adaptive 
immune responses, DC also play a predominant role in 
central82,83 and peripheral immunological tolerance84-86 (see 
section 1.2 and 1.3). The mechanisms employed by DC to 
generate and maintain peripheral tolerance are discussed in 
further detail below. 
 
1.2 Adaptive Immunity 
 
1.2.1 T cell activation 
 
Cells from the adaptive immune system, i.e. T and B 
lymphocytes, carry a single receptor generated by somatic 
recombination of defined gene segments. The recombination 
process occurs randomly, generating a massive diversity in the 
receptor repertoire and endowing T and B cells with the ability to 
recognize virtually any antigen. That, per se, poses a threat to 
the organism since these lymphocytes could strongly react with 
self-antigens and, therefore, cause autoimmunity. In an attempt 
to avoid self-reactivity, T and B cell repertoires undergo selection 
processes during development to ensure that a minimal amount 
of potentially self-reactive lymphocytes mature. These processes 
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are generically termed “central tolerance” and, although essential 
to maintain host viability, fall out of the scope of this thesis and 
will not be described in further detail. The focus will be given to 
mechanisms inducing effector function on the major T cell 
subsets, i.e. CD4+ and CD8+, and on mechanisms involved in 
maintaining immunological tolerance in the periphery and 
avoiding immunopathology. 
Both major T cell subsets, i.e. CD4+ and CD8+, are 
activated via a similar process that is comprised of signals given 
to the T cell by the APC. The first signal inducing T cell activation 
is triggering of the T cell receptor (TCR) by cognate recognition 
of antigenic peptides presented by APC, particularly DC, in the 
context of MHC class I and II molecules, for CD8+ and CD4+ T 
cells respectively. Together with TCR stimuli, APC will deliver 
costimulatory signals by engaging several pairs of receptors on 
the APC and the T cell surface such as CD80/86 and CD2887,88, 
4-IBB and 4-IBBL89,90, CD70 and CD2791,92. The costimulatory 
signals will convey proliferative, survival and, in some cases, 
instructive signals to T cells. Cytokines are the third signal 
provided by APC to T cells. They work as instructive signals that 
transmit to T cells information regarding the kind of pathogen 
encountered and, therefore, gear T cells to differentiate into the 
appropriate effector phenotype79. The net effect of available 
antigen amount, costimulation and instructive cytokines will 
ultimately lead to the generation of the adequate T cell response.  
As described above, cytokines are the distinctive signal 
required for the differentiation of CD4+ T cells into different 
effector TH cell lineages, although some costimulatory molecules 
have also been reported to provide signals that drive TH cell 
differentiation93,94. The essential cytokine requirements for the 
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differentiation of the main TH cell subsets, i.e. TH1, TH2 and TH17, 
are well defined. Briefly, TH1 cells rely on IL-12 signaling for their 
differentiation95, TH2 rely on IL-496, and TH17 relies on TGF-β and 
IL-697,98. Each of these subsets will produce a determined set of 
signature cytokines that will mediate their effector function (see 
table 1.2). Importantly, the main cytokines produced by each TH 
cell lineage, will reinforce their own phenotype while inhibiting the 
conversion of naïve cells into any other TH cell phenotype80. 
Signaling through cytokine receptors will lead to activation of 
specific signal transducers and activators of transcription (STAT) 
transcription factors. STAT activation, in turn, will lead to 
expression of lineage specification transcription factors that 
reinforce TH lineage commitment, largely through epigenetic 
modifications of target genes99. An overall view of the cytokines 
and transcription factors involved in TH cell differentiation can be 
found on table 1.2. 
 
Table 1.2. Minimal cytokine requirements for TH cell lineage 
commitment. 
 
Lineage 
Inducer 
cytokines 
Cytokine 
signal 
transduction 
Lineage 
transcription 
factor 
Effector 
cytokines/molecules 
TH1 IL-12 STAT4 T-bet IFNγ, TNF 
TH2 IL-4 STAT6 GATA-3 IL-4, IL-5, IL-13 
TH17 IL-6+TGF-β STAT3 RORγT IL-17, IL-22, IL-21 
TREG TGF-β+IL-2 Smad3/ 
STAT5 
Foxp3 IL-10, TGF-β, 
CLTA4 
Note: Cytokine requirements based on in vitro differentiation of 
naïve T cells in the presence of TCR triggering and 
costimulation80.  
 
Importantly, each of the T cell subsets described will be 
differentiated in specific microenvironments, generated as a 
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response to signals received by innate immune cells via their 
PRR. Therefore, upon recognition of PAMP from fungi APC will 
produce higher amounts of IL-6 and IL-2337,38 and induce TH17 
responses. On the other hand, Gram-positive bacteria95 or PAMP 
from protozoan parasites, such as Toxoplasma gondii100, will 
induce IL-12 production and the consequent generation of TH1 
cells. In the context of helminth infection IL-4, most probably 
derived from innate cells101-103, has been shown to play a 
predominant role and will orchestrate the development of a TH2 
response. 
The requirements of TCR stimulation, costimulation and 
instructive cytokines are also necessary for CD8+ T cell 
activation. In the case of CD8+ T cells, antigen is recognized 
coupled to MHC class I molecules and delivered together with 
costimulation by APC. It is also possible for CD8+ T cells to 
become producers of cytokines analogous to those produced by 
TH2 and TH17 cells however, the relevance of these 
subpopulations is currently poorly understood104-107. In fact, the 
cytokine milieu present during CD8+ T cell activation is thought to 
influence more dramatically the acquisition of effector versus 
memory potential108,109. When fully activated, CD8+ T cells will 
become IFNγ and TNF producers and will express cytotoxic 
molecules, i.e. perforin and granzyme B. 
Type I IFN and IL-12 are largely produced upon viral 
infection and, together with IL-2, drive expansion and generation 
of fully activated short-lived cytotoxic CD8+ T cells expressing 
IFNγ and granzyme B110-114. Importantly, under a high 
proinflammatory setting the generation of memory CD8+ T cells is 
impaired108,109,115. Presence of IL-21, on the other hand, favors 
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the generation of memory CD8+ T cells rather than short-lived 
effector cells, as observed by the abnormal accumulation of 
memory CD8+ T cells in mice overexpressing IL-21116  and the 
inability to control chronic viral infection when IL-21 signaling is 
disrupted117-119. Activation of the mammalian target of rapamycin 
(mTOR) pathway seems to be critically involved in driving CD8+ T 
cell differentiation towards an effector versus a memory 
phenotype. IL-12-induced expression of the transcription factor T-
bet is blocked by rapamycin with a concomitant increase in 
expression of the transcription factor Eomesodermin120. 
Importantly, while T-bet promotes effector CD8+ T cell response, 
Eomesodermin is associated with memory CD8+ T cell 
generation121,122. 
Complete activation of CD8+ T cells with concomitant 
acquisition of cytotoxic potential has been shown to depend on 
CD4+ T cell help in some contexts. Particularly, this seems to be 
the case when CD8+ T cells are activated in the context of non-
immunogenic antigen presentation that is, when there is no 
previous activation of the innate immune system123-125. This 
notion is supported by reports demonstrating acquisition of full 
blown effector function by CD8+ T cells during infection in the 
absence of CD4+ help126,127. Nonetheless, CD4+ help seems 
crucial in the development of CD8+ T cell memory128-130, possibly 
by serving as a source of IL-21. However, the necessity of CD4+ 
help even in the presence of a highly inflammatory milieu might 
depend on the model being studied. This is illustrated in the case 
of Plasmodium infection where CD4+ help is required to induce 
full CD8+ T cell activation in liver stage131 and blood stage132,133 
infection (see section 4.2). 
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1.2.2 Regulation of immune responses by T cells 
 
 Regulatory T cells (TREG) are the main cell type involved 
in regulating immune reactivity in homeostatic conditions. Unlike 
TH cells, TREG cells exit the thymus already committed to this 
lineage, and with a phenotype resembling that of 
activated/effector T cells134. Mice that had their thymus removed 
shortly after birth, allowing TH but impeding TREG migration to the 
periphery, develop autoimmune disease135. The master 
transcription factor implicated in TREG differentiation is forkhead 
box P3 (Foxp3) and animals and humans deficient in this 
transcription factor show loss of immunological tolerance and 
develop severe autoimmunity136-139. Importantly, TREG are 
fundamental throughout life as its conditional ablation in adult 
animals leads to severe autoimmunity64.  
 Many different mechanism(s) have been described via 
which TREG suppress immune responses. These include inhibition 
of stable contact formation between DC and naïve TH cells in the 
lymph-node140,141, production of the anti-inflammatory cytokines 
TGF-β142,143 and IL-10144,145, and use of membrane bound 
molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-
4)146,147. Most likely, all the mechanisms described above, and 
possibly others, will act in concert to maintain homeostasis. 
Importantly, during infections the control of ongoing immune 
responses to pathogens by TREG needs to be tightly regulated to 
ensure pathogen clearance and, at the same time, avoid 
immunopathology148-151. 
Although TREG were at first thought to be exclusively of 
thymic origin, naïve CD4+ T cells can be differentiated, in vitro 
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and in vivo, towards a TREG phenotype. In vitro, TCR stimulation 
with concomitant IL-2 and TGF-β signaling induce naïve CD4+ T 
cells to express the transcription factor Foxp3 and to acquire 
suppressive function152,153. In vivo, DC were shown to be an 
important cell type in maintaining peripheral tolerance, partially 
through de novo generation and maintenance of TREG in the 
periphery. Several different mechanisms used by DC to maintain 
and generate peripheral tolerance have been demonstrated. 
Non-immunogenic antigen presentation by DC was shown to 
delete CD4+84 and CD8+ T85,86 cell clones in the periphery, 
leading to antigen-specific unresponsiveness. DC were also 
shown to recirculate into the thymus carrying peripherally 
acquired antigens and inducing deletion of T cell clones reactive 
to these antigens82.  
The induction and expansion of T cells with regulatory 
properties in the periphery by DCs, including IL-10 producing 
type-1 T regulatory cells (Tr1)154,155 and TREG156-159, was also 
demonstrated. Until recently the differences between thymic 
derived TREG and peripheral induced TREG cells were very poorly 
understood. However, in 2010 the transcription co-factor 
homeodomain-only protein (Hopx) was described as being 
fundamental for the suppressor function of TREG generated by DC 
in the periphery, without interfering with the function of thymic-
derived TREG160. Importantly, a specific DC subpopulation present 
in the gut was described to be especially tailored to induce TREG 
via a pathway that involves TGF-β and retinoic acid161-163. Most 
recently, it was demonstrated that in order to avoid TH cell-
mediated autoimmunity both thymic and peripheral TREG are 
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necessary, presumably because the peripheral conversion of 
naïve T cells expands the TCR repertoire of TREG164. 
Of note, recent reports have suggested that TREG cells 
can themselves be subdivided into different lineages capable of 
suppressing distinct types of immune responses. It was 
demonstrated that TREG expressing the transcription factor IRF4, 
involved in TH2 differentiation, were more efficient in suppressing 
TH2 responses165. That was also the case for the expression of 
STAT3 in TREG involved in suppressing TH17 responses166, and T-
bet in TREG suppressing TH1 responses167. These findings 
suggest that TREG would be generated or instructed outside the 
thymus as an immune response begins, and that the cues 
involved in TH differentiation could also serve to endow TREG with 
specific capacity of controlling the TH response in question.  
An interesting feedback loop controlling DC and TREG 
numbers has been described in vivo. Adult mice engineered to 
express the diphtheria toxin receptor along with Foxp3 show a 
sharp increase in the number of DC upon TREG ablation64. This 
increase in DC numbers is thought to be partially responsible for 
the deregulated TH cell response that followns TREG ablation.  It 
was later demonstrated that the mechanism underscoring the 
increase in DC numbers relies on the fact that TREG ablation 
increases the amount of available Flt3L, a cytokine that induces 
the proliferation of DC precursors in secondary lymphoid 
organs168. Interestingly, loss of DC also induces loss of TREG cells 
and consequent T cell activation169. Conversely, increasing DC 
numbers also increases the number of TREG, to the extent that 
limits the development of autoimmune diabetes in autoimmune 
prone non-obese diabetic (NOD) mice169. These findings 
demonstrate that DC and TREG are engaged into an important 
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regulatory loop to avoid unregulated immune activation and 
immunopathology. 
Interestingly, not only cells with clear regulatory 
phenotypes, such as TREG and Tr1 cells are able to restrain 
immune activation. CD8+ and CD4+ T cells were shown to 
regulate innate immune activation after PAMP administration, in 
vivo and in vitro, in an antigen and TREG-independent manner62. 
Strikingly, effector/memory CD4+ T cells specifically block NLRP1 
and NLRP3 activation in macrophages via signaling pathways 
initiated by ligation of receptors of the TNF family63. 
 
1.3 Tolerance to infection 
 
 In animals, the most studied mechanism to survive 
infections is resistance. It relies on the ability of the host to 
prevent disease by diminishing pathogen load. Many 
mechanisms used by innate and adaptive immunity work by 
reducing pathogen load and are, therefore, involved in host 
resistance. Acting in concert with resistance, tolerance to 
infection encompasses mechanisms that limit the decrease in 
host health status to a given pathogen load. Tolerance has been 
well documented and studied in plants, but is still poorly 
understood in animals170,171. 
 Tolerance to a given pathogen is given by the slope of the 
curve that determines host health status versus pathogen load. 
That is, how much host health is affected by a given pathogen 
load. The more the host health is affected by a given pathogen 
load, the more steep is the curve and less tolerant is the host.  
Host health status can be determined as follows170,172,173: 
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  HHS = uHS + bH.I 
 
HHS: host health status or fitness 
uHS: health status of an uninfected host 
bH: slope of the relationship between HHS and I, or 
tolerance 
I: pathogen load 
 Given the above, it is possible to conclude that HHS upon 
infection depends on host’s health status when uninfected (UHS) 
and on how much its health status declines at a given pathogen 
load during infection (BH.I). 
 An example of how one can compare tolerance among 
hosts is shown in figure 1.1. Figure 1.1A shows two genotypes 
that share the same health status when uninfected. However, 
upon infection the decline in health status as a function of 
parasite load is greater in the green genotype, i.e. the slope is 
steeper, than in the red genotype. In this case the red genotype 
is more tolerant to infection, by the specific pathogen in question, 
than the green genotype. 
 
 
 
 
 
 
 
 
 
      
 
Figure 1.1. Variation in host tolerance. (A) Two different genotypes, depicted as red and green lines, 
are subjected to infection and tolerance is determined by the slope of the decline in health status as a 
function of pathogen load. In this case, the red genotype shows increased tolerance to the hypothetical 
pathogen infection, since its health status decline less than the one of the green genotype to any given 
pathogen load. (B) An extra genotype, depicted as a blue line, has been added to the picture depicted in 
A. The blue genotype presents a lower uHS but presents a higher tolerance to infection than the green 
genotype, since the decline in the former health status is lower to a given pathogen load than the 
decline in the latter. Compared to the red genotype, the blue one presents lower uHS and the same 
tolerance. uHS: uninfected health status; bH: tolerance. 
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In figure 1.1B a somewhat more complex scenario is 
depicted. In this case a third genotype (blue) is added which has 
an uninfected health status that differs from genotypes red and 
green. Upon infection, however, the health status decline of the 
blue genotype follows the same slope as that of the red 
genotype, which is flatter than the green slope. In this case, 
although through a great extent of the pathogen load gradient, 
the total health status of the blue genotype is lower than the 
green and red, the blue genotype shows increased tolerance as 
compared to the green genotype and the same tolerance as the 
red one. The difference in health status observed is given by a 
lower uninfected health status of the blue genotype. 
Intriguingly, some of the mechanisms involved in 
resistance to infection might also alter tolerance and vice-versa. 
This was clearly demonstrated by Raberg et al174 when 
addressing tolerance of different mouse strains to Plasmodium 
chabaudi infection. The authors demonstrated in this study, using 
the slope of the relationship between health status and parasite 
load as a measure of tolerance, that different mouse strains have 
distinct levels of tolerance to Plasmodium chabaudi infection. 
Importantly, mouse strains that had increased tolerance to 
infection presented decreased resistance, suggesting that these 
properties negatively regulate each other in this model of 
infection. However, it is important to underline that this inverse 
correlation might not be true for the interaction among different 
pathogens and a single host. In Drosophila melanogaster it has 
been shown that a single mutation can cause variation in 
resistance and/or tolerance in the same genotype depending on 
the pathogen used175. 
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There is data in the literature suggesting that mechanisms 
that alter tolerance to infection operate during mouse models of 
infectious diseases. Nonetheless, this data is frequently 
generated in studies addressing resistance to infection. Some 
examples of molecules possibly involved in increasing or 
decreasing tolerance to infection are given below. 
Molecules involved in increasing tolerance to infection 
can be uncovered by studies where deficiency of such molecules 
induces a worst disease outcome without changes in parasite 
load. Lack of IL-10 causes a massive and deleterious 
inflammatory response in mice infected with Toxoplasma gondii, 
causing premature death of IL-10 deficient mice (Il-10-/-) animals 
due to immunopathology, while parasite loads remained 
unchanged176. Furthermore, Il-10-/- mice, despite presenting 
significantly lower parasitemias than wild type animals when 
infected with Trypanosoma cruzi, die earlier due to a shock-like 
syndrome caused by excessive TNF production177. Using a 
mouse model of malaria infection, it was also shown that mice 
lacking HO-1 are more susceptible to infection with Plasmodium 
berghei ANKA as compared to WT mice without changes in 
parasite load178. This mechanism seems to operate also to 
protect mice from non-cerebral forms of severe malaria179.  
On the other hand, some cytokines and PRR can reduce 
tolerance to infection. This fact is uncovered when deletion of 
genes encoding such molecules are beneficial to the host without 
altering pathogen load.  In a model of oral infection with 
Toxoplasma gondii, death is accompanied by massive intestinal 
immunopathology in WT mice. IL-18 deficient mice (Il-18-/-) are 
protected from the ensuing immunopathology after infection 
without changes in parasite load in intestines or liver as 
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compared to WT mice180. Lethal outcomes of dengue virus 
infection can be avoided by blocking the CLR CLEC5A, thus 
avoiding unfettered proinflammatory cytokine production and 
vascular permeability, without changing host’s ability to clear viral 
infection181. Lack of inflammasome components was shown to be 
protective in Schistosoma mansoni182 and Mycobacterium 
marinum183 infection by diminishing immunopathology associated 
with infection, not by altering pathogen load.  
Although these studies suggest a role for tolerance to 
infection in determining disease outcome, since they have not 
been designed to specifically address tolerance to infection, i.e. 
determining the slope of health status in relation to varying 
pathogen load, it is difficult to unequivocally conclude that these 
molecules alter uniquely tolerance instead of, or in addition to, 
overall health status. 
 
2. Heme Oxygenase-1 
 
Part of section 2 was adapted from “Immunoregulatory effects of 
HO-1: How does it work?” Soares, MP, Marguti I, Cunha A, 
Larsen R, published in Current Opinion in Pharmacology, August, 
2009, volume 9, issue 4, pages 482-48965. 
 
2.1 Heme catabolism and its by-products 
 
 Heme oxygenases (HO) are heme (iron protoporphyrin 
IX) catabolizing enzymes. Two isoforms of HO are present in 
human and mice, heme oxygenase-1 (HO-1, encoded by the 
Hmox1 gene) and heme oxygenase-2 (HO-2, encoded by the 
Hmox2 gene). A third HO isoform, heme oxygenase-3, is a 
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Figure 1.2. The heme/HO-1 system. Free heme is highly pro-oxidant, as its Fe atom can participate in 
the Fenton reaction via which hydrogen peroxide (H2O2) is converted into the highly reactive hydroxyl 
radical (OH). This pro-oxidant effect is controlled by several mechanisms including heme catabolism by 
HO-1, a reaction assisted by NADPH and Cytochrome P450. Contrary to heme-Fe, labile Fe (yellow 
circles) can be neutralized by ferritin (FtH).  
pseudogene184. Both isoforms, HO-1 and HO-2, are ubiquitously 
expressed but while HO-2 is expressed constitutively and not 
upregulated under cellular stress conditions, HO-1 is strongly 
upregulated under these circumstances. Therefore, HO-1 is   
termed a  stress-responsive enzyme. Its expression is induced by 
a multitude of different stimuli such as, but not limited to, 
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oxidative stress, hypoxia, heat shock, cytokines, and TLR 
ligation185. The reaction leading to heme catabolism by HO 
enzymes opens the protoporphyrin ring leading to the generation 
of equimolar amounts of carbon monoxide (CO), biliverdin and 
labile iron (Fe2+) (Figure 1.2). Biliverdin is  further  converted  into  
the  potent anti-oxidant bilirubin by the enzymatic action of 
biliverdin reductase (BVR), and labile iron is secluded by ferritin 
multimers preventing its pro-oxidant activity186. 
 A major effect of heme catabolism by HO-1 is the 
avoidance of unfettered oxidative damage generated by heme 
molecules once they have been uncoupled from hemoproteins. 
The iron molecule inside the protoporphyrin ring of heme can 
generate large amounts of hydroxil radicals (HO•) from hydrogen 
peroxide (H2O2), through the Fenton reaction187. The extremely 
reactive HO• can, in turn, cause DNA breaks, lipid peroxidation 
and protein denaturation188. As HO-1 cleaves the protoporphyrin 
ring, the iron molecule is freed and becomes available to be 
taken up and stored intracellularly by ferritin molecules, which 
has its expression increased in response to iron. Ferritin 
molecules oxidize iron to its ferric (Fe3+) state, thus impairing its 
pro-oxidant activity, and store the iron inside its cage-like 
structure189. In addition, with the opening of the protoporphyrin 
ring, biliverdin and subsequently bilirubin, a potent anti-oxidant, 
are generated, providing further protection against oxidative 
damage. 
The most in depth studied by-product of heme catabolism 
is CO, and it has been shown to exert several biological effects. 
CO can inhibit apoptosis190, avoid unlocking of heme from 
hemoproteins178, and regulate inflammatory responses191. 
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Several lines of evidence suggest that many of the effects of CO 
are mediated via the modulation of the p38 MAP kinase pathway. 
CO can prevent cell death by modulating the p38 MAP kinase 
pathway190,192. The anti-inflammatory effect of CO on 
macrophages, i.e CO-mediated inhibition of TNF production, is 
also dependent on p38 MAP kinase 191, and on an initial burst of 
ROS production by the mitochondria induced by CO193. 
Furthermore, it is proposed that the protective effects of CO rely 
on its capacity to interact with heme inside hemoproteins 
preventing their oxidation and release from heme pockets, a 
process that would render heme pro-oxidant178,188,194. 
Biliverdin/bilirubin also have been demonstrated to induce 
protection against cell death and inflammation, presumably by 
their anti-oxidant properties195. Cell death mediated by either NO 
or H202 has been shown to be prevented by bilirubin196,197. 
Biliverdin/bilirubin are also implicated in regulating immune 
responses, as discussed below (see section 2.3). Finally, the 
labile iron generated by heme catabolism is thought to afford 
cytoprotection by inducing the expression of ferritin, an iron 
storage molecule198. The iron storage capacity of ferritin also 
underlies its ability to prevent TNF-mediated cell death. Iron 
sequestration by ferritin prevents excessive ROS production and 
sustained JNK activation, therefore preventing cell death in this 
system199. 
 
2.2 Regulation of HO-1 expression 
 
Expression of HO-1 is mainly transcriptionally regulated. 
The Hmox1 gene contains binding sites for different transcription 
factors such as NF-E2-related factor-2 (Nrf2), NF-κB, heat shock 
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factors (HSF), and Activator Protein-1 (AP-1) in its promoter and 
enhancer regions200. The broad array of transcription factors 
capable of regulating HO-1 expression might explain the 
induction of HO-1 expression by a variety of stimuli.  
Under homeostasis, the transcriptional repressor Bach1 
inhibits Hmox1 transcription by, in conjunction with small Maf 
proteins, blocking accessibility of transcription factors to Hmox1 
promoter. Both heme and oxidative stress can induce 
conformational changes in Bach1 leading to its export from the 
nucleus, ubiquitination and degradation188. Concomitantly, ROS 
can also activate Nrf2. When cells are under normal conditions, 
Nrf2 is found in the cytoplasm bound to Kelch-like ECH-
associating protein 1 (Keap1) that blocks Nrf2 migration to the 
nucleus and also facilitates Nrf2 polyubiquitination and 
degradation. Under oxidative stress conditions, alterations in 
Keap1 key cysteine residues liberate Nrf2 from sequestration in 
the cytoplasm and degradation. Furthermore, oxidative stress 
can also modify cysteine residues on Nrf2 nuclear export signals 
(NES) facilitating its concentration in the nucleus201. Of note, 
environmental stress, such as the ones posed by cigarette 
smoke and xenobiotics, also leads to Nrf2 activation and 
transcription of other detoxifying and cytoprotective enzymes 
besides HO-1202. 
Importantly, HO-1 expression controls the outcome of a 
variety of pathologic conditions in which uncontrolled immune 
responses cause significant damage, e.g. ischemia/reperfusion 
injury203, graft rejection204, arteriosclerosis205, autoimmune 
neuroinflammation206, severe sepsis207, experimental cerebral 
and severe non-cerebral malaria178,179. These observations 
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suggest that HO-1 expression is key to control of immune 
responses and/or the resulting immunopathology. 
 
2.3 Immunoregulatory effects of HO-1 
 
The notion that HO-1 is an immunoregulatory molecule is 
supported by the observation that Hmox1 deficiency leads, in 
mice and humans, to the spontaneous development of a chronic 
inflammatory pathology characterized by increased blood 
leukocyte count, serum immunoglobulin M (IgM), accumulation of 
polymorphonuclear (PMN) cells, and monocyte/macrophages in 
the spleen, as well as in nonlymphoid tissues, and widespread 
oxidative tissue injury208-210. Data supporting the notion that the 
immunoregulatory effects of HO-1 are exerted via its expression 
on innate and adaptive immune cells, as well as by its expression 
in non-lymphoid tissues where it affords cytoprotection against 
oxidative injury, will be discussed below. 
 
2.3.1 Effects of the heme/HO-1 system on innate immunity 
 
Under homeostasis, heme exists essentially as a 
prosthetic group in several hemoproteins. However, under 
pathologic conditions noncovalently bound heme can be released 
from those hemoproteins178,194. The heme produced in this 
manner can be recognized by TLR4, triggering the production of 
proinflammatory cytokines by macrophages211. Furthermore, 
heme can induce neutrophil migration and ROS production by 
directly activating a G-protein-coupled receptor212 and/or by 
inducing the production of leukotriene B4213. Although this is the 
case for in vitro experiments and for exogenous administration of 
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heme, it remains to be established whether this is the case in 
more physiological settings, since heme can bind to several 
proteins194 and lipids188 in plasma  and, therefore, might have its 
ability to activate TLR4 or G protein-coupled-receptors212 altered.  
Interestingly, the anti-inflammatory effect of 
immunoregulatory molecules such as IL-10214 and 15-deoxy-
Δ12,14-prostaglandin J2 (15D-PGJ2)215 on innate immune cells, 
appears to be exerted via the induction of HO-1 in macrophages. 
Consistent with a role for HO-1 in dampening inflammatory 
responses after stimulation of the innate immune system, is the 
observation that stimulation of Hmox1-/-splenocytes with LPS 
resulted in increased production of pro-inflammatory cytokines, 
as compared to Hmox1+/+ splenocytes216. Importantly, evidence 
that HO-1 does not control the inflammatory response in 
macrophages is also available. For instance, peritoneal 
macrophages isolated from Hmox1-/- or Hmox1+/+ mice have a 
similar proinflammatory response to LPS in vitro207,209, raising the 
possibility that HO-1 may differentially affect macrophage 
populations and/or other immune cells. 
Similar to macrophages, neutrophils can ‘sense’ heme, 
directly or indirectly, through a yet unidentified G-protein-coupled 
receptor212,217. As such, heme can act as a neutrophil 
chemoattractant, activating neutrophils to produce reactive 
oxygen species as well as proinflammatory cytokines212,217. Since 
heme can act as a potent pro-oxidant catalyst via the Fenton 
chemistry, this latter effect might exacerbate macrophage as well 
as neutrophil-driven oxidative tissue injury. Therefore, by limiting 
the availability of heme, HO-1 might inhibit neutrophil chemotaxis 
and activation, and thus, oxidative tissue injury. This notion is 
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supported by the observation that Hmox1 deficiency, in mice and 
humans, is associated with widespread neutrophil activation and 
tissue infiltration, as well as with oxidative tissue injury208-210,218. In 
addition, pharmacologic induction of HO-1 inhibits the activity of 
the p47phox, p67phox, and gp91phox subunits of NADPH oxidase, 
thereby reducing the production of reactive oxygen species by 
activated neutrophils and macrophages219,220, contributing further 
to limit oxidative tissue injury.  
CO can also modulate TLR signaling. This inhibition can 
occur via two independent non-exclusive pathways: one that 
involves enhanced caveolin-1 binding to TLR, and one that is 
dependent on CO-mediated inhibition of ROS formation by 
NADPH oxidase. Upon LPS stimulation HO-1 colocalizes with the 
caveolin-1/TLR4 complex, a process dependent on p38 MAPK 
activity. Importantly, HO-1-generated CO was shown to enhance 
caveolin-1 interaction with TLR4, inhibiting downstream signaling 
and production of pro-inflammatory cytokines221. A broader role 
for CO in inhibiting TLR function has been shown to depend on 
its ability to decrease ROS formation, via modulation of NADPH 
oxidase activity, upon TLR 2, 4, 5 and 9, stimulation and 
consequently inhibition of TLR recruitment (specifically TLR4 
recruitment) towards lipid rafts222. This data shows that CO 
generated by HO-1 can interfere with the molecular machinery 
involved in proximal TLR signaling. 
Importantly, there is a large body of evidence suggesting 
that CO can modulate cytokine production by macrophages. The 
first description of CO-mediated anti-inflammatory effects in 
macrophages indicated that through the p38 MAPK signaling 
pathway CO could decrease the amount of TNF production while 
increasing IL-10 production by these cells191. Furthermore, CO 
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was shown to induce the production of TGF-β, a potent anti-
inflammatory cytokine, by macrophages, through a pathway that 
involves stabilization of hypoxia-inducible factor-1 α (HIF-1α) via 
mitochondrial-generated ROS223. Generation of ROS by the 
mitochondria is also involved in CO-mediated upregulation of 
peroxisome proliferator-activated receptor-γ (PPAR-γ), an event 
shown to be crucial for the anti-inflammatory effects of CO in 
macrophages224. Most importantly, in an in vivo model of LPS-
mediated shock, exogenous CO blocks pro-inflammatory 
cytokine production and promotes survival of mice challenged 
with a lethal dose of LPS225. 
Mouse immature DC express negligible levels of HO-1, 
inducing its expression upon activation226,227. Intriguingly, rat and 
human immature DC express HO-1 constitutively, 
downregulating its expression upon activation228. In any case, 
pharmacologic induction of HO-1 inhibits mouse, rat, and human 
DC activation and immunogenicity206,228,229 (Figure 1.3a), an 
effect mimicked by pharmacologic delivery of CO229 or 
biliverdin/bilirubin230 (Figure 1.3a). This suggests that CO and/or 
biliverdin/bilirubin mediate the immunosuppressive effects 
associated with pharmacologic modulation of HO-1 expression in 
DC (Figure 1.3a). However, the physiological relevance of these 
observations is somehow questioned by the observation that the 
pharmacologic modulators of HO-1 used in these studies can 
exert immunosuppressive effects in DC independently of HO-
1226. However, if proven correct under physiological 
circumstances, the effects of HO-1 on DC might impact the 
generation of adaptive immunity, which, in turn, can explain in 
part the salutary effect of HO-1 expression in diseases where the 
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major cause of pathology is immune-mediated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 Effects of the heme/HO-1 system on adaptive immunity 
 
Several in vitro observations suggest that HO-1 exerts 
immunoregulatory effects by inhibiting T cell activation, 
proliferation and/or acquisition of effector function. First, the 
activation of human CD4+ T cells is associated with a significant 
induction of HO-1 expression231 (Figure 1.3b). Second, 
pharmacologic induction of HO-1 inhibits human CD4+ and CD8+ 
T cell activation231. Third, CO inhibits CD4+ T cell activation231 and 
induces apoptosis in Jurkat T cells232 (Figure 1.3b). Fourth, 
biliverdin/bilirubin inhibits mouse and human CD4+ T cell 
activation230 (Figure 1.3b). In keeping with these observations, 
 
 
Figure 1.3. Regulation of 
adaptive immunity by the 
heme/HO-1 system. 
Immunoregulatory effects 
attributed to HO-1 
expression in (a) DC, (b) 
activated TH cells, and (c) 
TREG cells. In all three 
models (panels a, b and c) 
HO-1 exerts 
immunoregulatory effects 
via the paracrine action of 
the end-products of heme 
catabolism, namely CO, 
BV/BR, or by a yet 
unidentified mechanism 
associated with  
pharmacologic induction of 
HO-1. AICD: activation 
induced cell death, BV/BR: 
biliverdin/bilirubin,TEFF: 
effector T cell (TH  or TC). 
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pharmacologic induction of HO-1 in vivo can drive activated CD4+ 
T cells to undergo apoptosis via activation-induced cell death 
(AICD)233 (Figure 1.3b), and can promote dominant peripheral T 
cell tolerance against transplanted organs234. This latter effect is 
mimicked by biliverdin/bilirubin, which suppresses T cell-driven 
inflammatory pathologies such as the rejection of transplanted 
organs230,235 and autoimmune neuroinflammation43. The 
immunoregulatory effects of biliverdin/bilirubin are mediated via 
inhibition of the transcription factors, NFAT and NF-κB, which 
suppresses IL-2 production by CD4+ T cells230,235. Whether these 
effects of BV/BR are mediated by its anti-oxidant activity is still 
unclear, although data suggests that this might not be the 
case230. Of notice, both biliverdin and bilirubin are endogenous 
ligands for the aryl hydrocarbon receptor (AHR)236, which can 
determine the differentiation of CD4+ T cells towards an anti-
inflammatory TREG phenotype or a proinflammatory TH17 effector 
phenotype237,238. Although speculative, it is possible that the 
immunoregulatory effects of HO-1 might be exerted, to at least 
some extent, through the production of these endogenous AHR 
ligands. 
More recently, it was shown that HO-1 expression in 
myeloid lineages has protective effects in a model of autoimmune 
neuroinflammation. This study shows that lack of HO-1 in the 
myeloid lineages leads to decreased production of IFN-β, a 
cytokine that blocks the development of pathogenic IL-17 
producing CD4+ T cells. Consequently, animals in which Hmox1 
gene was deleted developed more severe disease. This was the 
first work published using animals in which the Hmox1 gene was 
flanked by loxP-sites, and deletion could be achieved in specific 
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cell populations through the activity of Cre-recombinase. It is 
important to highlight that in this system the authors did not 
observe the pathologic features associated with total Hmox1 
deletion, i.e. diminished fertility and progressive inflammatory 
disease, allowing for a more clear evaluation of the mechanisms 
responsible for exacerbating disease239 in the absence of HO-1.  
HO-1 has been suggested to exert immunoregulatory 
effects by modulating TREG cell function240 (Figure 1.3c), a notion 
supported by the following set of observations. First, human and 
mouse TREG cells express HO-1 constitutively241,242 (Figure 1.3c). 
Second, pharmacologic inhibition of HO-1 suppresses human 
TREG cell function in vitro243. Third, the suppressive activity of 
Hmox1+/+ TREG cells is compromised, in vitro, by the presence of 
Hmox1-/- DC244. This finding, however, was not reproduced when 
total irradiated splenocytes were used as APCs242. While these 
observations suggest that HO-1 regulates TREG cell function in 
vitro, the finding that TREG cell development as well as peripheral 
maintenance and function, in vitro and in vivo, are normal in 
Hmox1-/- mice242, questions the physiologic relevance of the 
effects attributed to pharmacologic modulation of HO-1 in TREG 
cells. Of note, the function of Hmox1-/- TREG has not yet been 
tested in conditions where there is strong innate and adaptive 
immune activation, such as in an infectious disease model. It 
would be interesting to address whether the increased production 
of proinflammatory cytokines by Hmox1-/- spleen cells upon 
stimulation216 might, somehow, affect TREG function. 
A role for HO-1 in controlling antibody responses has not 
yet been the subject of a profound analysis. Nevertheless, data 
show that naïve Hmox1-/- have increased IgM levels in serum 
when compared with Hmox1+/+ mice216. More recently, a report 
 43 
suggests that heme might control B cell differentiation into 
plasma cells by interacting with the transcriptional repressor 
Bach2 and inducing its degradation. Bach2 degradation, in turn, 
leads to increased expression of the transcription factor B 
lymphocyte-induced maturation protein 1 (Blimp-1), diminished 
class switch recombination and somatic hypermutation, and 
increased plasma cell differentiation245. 
 
2.3.3 Cytoprotective effects of HO-1 
 
Many if not all immune-mediated inflammatory diseases 
are associated with the production of free radicals, leading to 
some level of cellular oxidative stress and oxidative tissue injury. 
If not controlled, oxidative stress can drive cells to undergo 
necrosis, a form of cell death associated with the release of their 
intracellular content, including uric acid246 and HMGB122 (Figure 
1.4). These intracellular components can be recognized by PRR 
expressed in innate immune cells, such as macrophages and 
DC, and thus act as proinflammatory agonists247. Given the 
above, mechanisms regulating cell death/survival in tissues 
should exert immunoregulatory effects that impact on the 
outcome of immune-mediated inflammatory diseases248. The 
cytoprotective effect of HO-1might act in such a manner (Figure 
1.4).  
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Figure 1.4. Cytoprotective effect of the heme/HO-1 system. Activation of innate immune cells, 
including Mø and PMN cells is associated with the production of ROS and proinflammatory cytokines, 
leading to oxidative stress. Expression of HO-1 in response to oxidative stress (i.e. Hmox1+/+) is 
cytoprotective and prevents the release of endogenous proinflammatory ligands from injured cells, thus 
promoting the resolution of inflammation and the return to homeostasis. When expression of HO-1 is 
impaired (i.e. Hmox1-/-) oxidative stress leads to widespread programmed cell death resulting in 
impaired tissue function as well as release of endogenous proinflammatory ligands. By engaging PRR in 
innate immune cells, endogenous ligands sustain the activation of innate immune cells (inflammation) 
and exacerbate tissue injury, an effect that might promote the development of immune-mediated 
inflammatory diseases. 
 
When challenged by a proinflammatory agonist such as 
LPS, Hmox1-/- mice succumb to unfettered oxidative stress, 
associated with widespread oxidative tissue injury and end-stage 
multi-organ failure209,249. This suggests that HO-1 prevents the 
pathologic outcome of inflammatory responses by affording 
cytoprotection against oxidative stress. In subsequent studies, 
the cytoprotective effect of HO-1 was associated with protection 
against many other immune-mediated inflammatory diseases186.  
Expression of HO-1, or exposure to the by-products of its 
enzymatic activity, is cytoprotective against oxidative injury in a 
wide variety of cells including fibroblasts, vascular endothelial 
cells, pancreatic β-cells, hepatocytes, kidney epithelial cells, 
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cardiac myocytes, astrocytes and neurons, among 
others185,186,188,250. This broad cytoprotective effect might account 
for the equally broad protective effects of HO-1 against the 
development of vascular diseases, diabetes, liver dysfunction, 
kidney failure, myocardial infarction as well as diseases of the 
central nervous system186.  
Presumably, the cytoprotective effect of HO-1 has a dual 
salutary role in that it sustains tissue/organ function while 
inhibiting the release of endogenous proinflammatory ligands 
from injured cells (Figure 1.4). In keeping with this notion, 
Hmox1-/- mice produce high levels of circulating endogenous 
proinflammatory ligands, for example HMGB1, in response to 
LPS251, and cecal ligation and puncture207, an effect that 
promotes the development of septic shock251-253. Moreover, 
pharmacologic induction of HO-1 affords tissue cytoprotection 
and inhibits the production of extracellular HMGB1 in response to 
LPS252.  
Assuming that tissue cytoprotection contributes to the 
salutary effects of HO-1, other cytoprotective genes should also 
prevent the pathogenesis and/or progression of immune-
mediated inflammatory diseases. The mechanism underlying the 
salutary effect of HO-1 against immune-mediated inflammatory 
diseases is not completely elucidated. However, this might be 
related to the finding that heme can sensitize tissue cells to 
undergo programmed cell death, a deleterious effect that should 
promote the pathogenesis of a number of immune-mediated 
inflammatory diseases179,207. 
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3. Iron metabolism and immunity 
  
Iron is a fundamental trace element for organisms, being 
implicated in the function of crucial proteins such as cytochrome 
c and hemoglobin254. Nonetheless, iron molecules, present or not 
in heme groups, that are not inside a functional protein moiety 
can be extremely toxic. As such, iron levels need to be tightly 
regulated both systemically and intracellularly. Importantly, 
mammals are not proficient in excreting iron, increasing the 
relevance of a delicate regulation of systemic iron levels. The 
regulation of systemic iron levels occurs mainly by controlling 
dietary iron absorption and mobilization from cellular iron stores, 
while intracellular iron status is regulated by iron storage and 
import/export189.  
Recycling iron molecules contained in heme groups 
supplies the majority of the iron needed by mammals. The daily 
need for iron is approximately 20 milligrams, while the dietary 
intake is normally not greater than 1-2 milligrams per day189. In 
that context, one of the fundamental roles of heme oxygenases is 
to recycle iron contained in the protoporphyrin ring of heme. 
Unlocking iron form the protoporphyrin ring serves at least two 
functions: a) recycle iron present in heme groups of 
hemoproteins and, b) avoid oxidative stress generated by the 
iron molecules inside heme, by converting it into labile iron able 
to be stored by ferritin inside cells and transported by transferrin 
(Tf) in circulation. The former is especially relevant for recycling 
iron present in hemoglobin once RBC become senescent and/or 
damaged and are destroyed by macrophages. In fact, about 60% 
of body iron content in humans is present in hemoglobin heme, 
further emphasizing the importance of recycling iron from 
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hemoproteins, especially hemoglobin189. The regulation of 
systemic iron status in mammals is subject to modulation by 
different stimuli such as anemia, inflammation, hypoxia and 
changes in erythropoietic rate255,256. 
Intracellularly, iron levels are regulated by two major 
mechanisms:  a) storage by ferritin molecules and, b) modifying 
mRNA stability of proteins involved in import/export of cellular 
iron256. Ferritin molecules normally contain the majority of the 
intracellular iron pool. Ferritin is composed by the assembly of 
multiple L and H-ferritin chains, encoded by different genes, 
forming a cage-like structure capable of oxidizing and 
subsequently store iron molecules in a non-reactive state189. On 
the other hand, ferroportin (FPN) controls cellular iron efflux, and 
regulation of its levels determines the amount intracellular iron189. 
Interestingly, mRNA from iron transport and storage molecules, 
e.g. ferritin, transferrin receptor 1 (TfR1), ferroportin, contain, in 
its 3´ and/or 5´ untranslated regions, iron responsive elements 
(IREs) that are responsive to iron regulatory proteins (IRPs) that, 
in turn, respond to iron levels. The interaction between IRPs and 
IREs can either stabilize or destabilize the mRNA of target 
molecules and thus regulate intracellular iron availability257-259. 
The master regulator of iron systemic homeostasis is 
hepcidin. Hepcidin is a hormone that in its active form is 
composed of 25 amino acids, produced mainly by the liver but 
also by the heart, hematopoietic cells and the pancreas260,261. It 
controls intra and extracellular iron pools by regulating the 
expression of FPN in duodenal enterocytes, thus regulating the 
rate of dietary iron intake, and on macrophages and hepatocytes, 
regulating the amount of iron stored inside these cells (mainly 
stored in ferritin molecules) or available in circulation (bound to 
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Tf)262. In situations where there is anemia, iron deficit, hypoxia 
and/or increased erythropoiesis, hepcidin expression is 
decreased, allowing increased iron absorption from dietary 
sources and iron mobilization from cellular stores. The reverse is 
true in cases of iron excess and inflammation263.  
The fundamental role of hepcidin in iron regulation is 
demonstrated by the severe iron overload phenotype that occurs 
when the hepcidin gene is disrupted264,265 and, on the other hand, 
by the severe iron deficiency associated with hepcidin 
overexpression266,267. Induction of hepcidin expression is thought 
to occur by at least two different pathways, one involved in 
homeostatic hepcidin expression and another involved in the 
fluctuations in hepcidin levels during inflammation. In 
homeostasis, hepcidin transcription responds to transferrin (Tf)- 
bound iron levels. Tf-bound iron is sensed by Tf receptor-1 
(TfR1) that, under normal iron levels, is coupled with the 
hemochromatosis gene (HFE), a non-classical MHCI molecule268, 
on the surface of hepatocytes. When serum Tf-bound iron levels 
increase, its binding to TfR1 dislodges HFE from the complex 
allowing the association of the latter with the Tf receptor-2 (TfR2). 
These induced changes initiate hepcidin transcription via a still 
uncharacterized pathway256. An alternative pathway can induce 
SMAD4-dependent hepcidin transcription via activation of the 
bone morphogenetic protein (BMP) receptor in complex with its 
co-receptor hemojuvelin269,270. 
Under inflammatory conditions, hepcidin production is 
increased in response to IL-6271. In such situations, upregulation 
of hepcidin transcription is mediated via the signal transducing 
subunit of the IL-6 receptor, gp130. Upon IL-6 binding it induces 
STAT3 phosphorylation, translocation to the nucleus, binding to 
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the hepcidin promoter and hepcidin transcription272-274. This 
response is thought to be a defense strategy used by the host to 
limit the amount of iron in circulation, thus limiting pathogens 
access to it275. 
Molecularly, hepcidin acts by binding to FPN expressed 
on membranes of enterocytes, macrophages and hepatocytes, 
and targeting it for degradation, thus impairing iron export from 
cells. As FPN is targeted for degradation, these cells become 
incapable of exporting iron, leading to a decrease in the 
extracellular iron pool276. Given the above, when hepcidin levels 
are elevated there is a decrease in the expression of FPN and a 
consequent decrease in extracellular and increase in intracellular 
iron content. The reverse happens in cases of low hepcidin 
expression (see Figure 1.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The major protein involved in carrying iron in serum is 
transferrin (Tf). Tf is mainly produced by the liver and assures, by 
binding to free iron molecules, that circulating iron in the body is 
 
 
Figure 1.5. Regulation of hepcidin expression. Under homeostasis hepcidin expression is 
controlled by fluctuation in iron levels. When systemic iron levels are elevated hepcidin levels rise 
leading to ferroportin degradation and, consequently, to diminished dietary iron intake and reduced 
mobilization of iron from iron stores. Conversely, when systemic iron levels fall hepcidin expression 
is decreased leading to stable ferroportin expression and increased dietary iron intake and 
mobilization from cellular stores. Pathological conditions might also alter hepcidin production. While 
inflammation increases hepcidin expression, anemia, hemochromatosis and increased 
erythropoiesis decrease hepcidin levels. 
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devoid of its pro-oxidant activity. Tf carries up to two iron 
molecules and is responsible for carrying it to where it is needed, 
i.e. the liver for storage or the bone marrow for red blood cell 
(RBC) generation255. The majority of the iron present in the body 
is used by the erythroid bone marrow in the generation of heme 
groups to be used in hemoglobin molecules in emerging RBC. 
The delivery of iron to erythroblasts, nucleated precursors of 
RBC, is mediated by transferrin that, once bound to TfR1, is 
taken up by erythroblasts. The Tf-iron/TfR1 complex is 
internalized and degraded, iron is reduced to its Fe2+ form and 
becomes ready to be used in the confection of new heme 
groups255. Disruption of the TfR1 gene leads to defective 
erythropoiesis277,278.  
Deregulation of hepcidin production by mutations in 
hepcidin, TfR2, HFE or hemojuvelin, leads to the development of 
hemochromatosis a condition characterized by iron overload. In 
the four cases, hepcidin production is diminished. Mutations in 
FPN can also lead to a hemochromatosis-like disease. In the 
latter case, iron overload is found predominantly inside 
macrophages262. The study of the effects of iron status in immune 
functions greatly benefited from the occurrence of natural 
mutations causing hemochromatosis, and from the development 
of mouse models to mimic these pathologies262. 
Iron has been shown to modulate the activation of 
transcription factors involved in the inflammatory response, such 
as NF-κB and HIF-1α, in opposing ways. While high iron 
contents might increase NF-κB activation279-282, it inhibits HIF-
1α by targeting it for degradation283. Other signaling molecules, 
such as JNK284, and PRR, such as NALP343, have been shown to 
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be regulated by ROS levels and, therefore, might respond to 
changes in intracellular iron levels, since iron can foster ROS 
production. 
Importantly, the study of animal models of 
hemochromatosis, especially the model induced by targeted 
disruption of the hemochromatosis gene (Hfe), has provided 
insight on the molecular mechanisms involved in the regulation of 
immune responses by intracellular iron levels. Hfe-deficient mice 
(Hfe-/-) have lower hepcidin production leading to increased FPN 
expression by cells and, consequently, low intracellular iron level. 
Macrophages with low intracellular iron content present 
diminished production of IL-6, TNF and IFN-β upon stimulation 
via TLR4 and Salmonella infection. Importantly, the decreased 
production of pro-inflammatory cytokines led to decreased 
intestinal inflammation upon Salmonella infection, but also to 
increased bacterial load285,286. Furthermore, administration of 
compounds able to block hepcidin production recapitulate the 
protective effects against excessive inflammation seem on Hfe-/- 
animals285. The mechanisms responsible for these changes rely 
on diminished translation of inflammatory genes286 and on 
impairment of the TRIF signaling pathway downstream of 
TLR4285.  
  The process of FPN degradation induced by hepcidin 
can also induce transient suppression of proinflammatory 
cytokine production by macrophages. FPN degradation is 
dependent on Janus-kinase 2 (JAK2) activation upon hepcidin 
binding to FPN and, in some circumstances can lead to STAT3 
activation, which induces suppressor of cytokine signaling 3 
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(SOCS3) transcription and transient suppression of cytokine 
production287. 
 The effects of iron status on the adaptive immune system 
seems to be related with the need of iron uptake for normal cell 
proliferation. T and B cell development is impaired in TfR1-/- 
mice278. Also, mature human B and T cells proliferate less when 
stimulated in the presence of anti-TfR1 antibodies288 indicating 
that iron uptake is critical for an adequate adaptive response.  
 
4. Sepsis and malaria as models of immune-mediated 
diseases 
 
 Although apparently very distinct conditions, sepsis and 
malaria, at least in experimental models, share similarities. In 
both cases, after infection there is an exuberant immune 
response aiming at eliminating the pathogen(s). Notwithstanding, 
the pathology observed after infection has as its major causative 
agents the same immune response that inadvertently targets 
host tissues causing immunopathology. Some of the 
mechanisms leading to the frequent lethal outcomes of these two 
diseases will be discussed below. 
 
4.1 Sepsis 
 
 In humans, sepsis is one of the possible facets of 
systemic inflammatory syndrome (SIRS). SIRS is characterized 
when individuals present simultaneously at least two of the 
following symptoms: abnormally high or low body temperature 
(higher than 38ºC or lower than 36ºC), elevated heart and 
respiratory rate, and alterations in white blood cell counts. Sepsis 
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is characterized when SIRS is coupled with infection289. In the 
USA alone it is estimated that around 750.000 sepsis cases 
occur annually290,291.  Most important, mortality rates in septic 
patients are extremely high as demonstrated by a large study 
involving 11.000 patient from 37 countries where the mortality 
associated with sepsis was around 50%292. 
 The immune system plays a fundamental role in the 
pathogenesis of sepsis. In fact, in 1972 the idea that an 
exacerbated host response, and not infection per se, was the 
driving force for pathology was put forward by Lewis Thomas293. 
Curiously, the observation that in cases of human sepsis 
antibiotics are often used but only with limited effectiveness294 
supports Lewis´ claim.  
“Cytokine storm” is the term normally employed to 
designate the massive generation of proinflammatory mediators, 
e.g. cytokines, chemokines, lipid mediators, which takes place in 
the initial phases of sepsis. The characteristic symptoms of 
sepsis start occurring when the levels of the proinflammatory 
mediators are high enough to impair physiological processes295. 
In accordance, mice deficient in molecules involved in the 
inflammatory response296, i.e NALP3297, Myd88298, TLR4299 and 
TLR9300, components of the complement cascade301,302, TNF 
receptor 1 and 2303 and chemokines304-307, show attenuated 
severity in animal models of sepsis. 
During the initial phase of sepsis there is massive 
lymphocyte308 and DC apoptosis309,310, and interventions aiming 
at modulating apoptosis have been shown to ameliorate the 
disease outcome311. Death of these critical immune cells is 
thought to play a role in the “immunoparalysis” observed in late 
phases of sepsis. This phenomenon is characterized by inability 
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to control secondary infections after sepsis resolution and is 
thought to involve, besides depletion of key immune cells, the 
generation of an overall unresponsive state in the host, possibly 
as a negative feedback on the previous excessive inflammatory 
state. Alterations in neutrophil functions312, decreased production 
of proinflammatory cytokines such as IL-12, IL-1α and IFNγ308, 
increased production of the anti-inflammatory cytokine IL-10308, 
and increased numbers of TREG cells leading to TH cell 
unresponsiveness313, are all thought to play a role in 
”immunoparalysis”. 
HO-1 and its by-products have been shown to be 
protective in animal models of sepsis. Biliverdin administration to 
rats undergoing cecal ligation and puncture (CLP), considered as 
the gold standard animal model of sepsis294,   ameliorated 
disease severity, an effect that was associated with expression of 
reduced amounts of proinflammatory molecules314. Hmox1-/- mice 
are more susceptible to CLP315 and to LPS-mediated shock251. In 
the first case, CO-mediated enhancement of bacteria 
phagocytosis is proposed as the underlying protective 
mechanism. This notion is supported by the observations that 
administration of CO-releasing molecules (CO-RM) and 
transgenic mice overexpressing HO-1, present lower bacterial 
load after CLP315. In the second report, the protective effects of 
HO-1 were proposed to work by inhibiting the release of the 
highly proinflammatory molecule HMGB122 after LPS 
administration. Importantly, the protective effect of HO-1, with 
concomitant decrease in HMGB1 release, could be mimicked by 
exogenous biliverdin and CO-RM administration251. Notably, 
HMGB-1 release by dead cells or by activated innate immune 
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cells316 has been proposed as a major mediator of the unfettered 
inflammatory response in sepsis253,317. 
 
4.2 Malaria 
  
 Malaria is caused by infection with Plasmodium parasites. 
Natural infection occurs when infected Anopheles mosquitoes 
bite the host delivering Plasmodium infective sporozoites to 
host’s bloodstream. Subsequently, sporozoites travel to the liver 
and invade hepatocytes, where they replicate generating 
thousands of merozoites before reentering the bloodstream, 
ending the liver stage and initiating the blood stage of infection. 
During the blood stage merozoites will infect RBC and replicate 
until RBC burst, releasing merozoites into the bloodstream and 
reinitiating the blood stage infection318. Importantly, while the liver 
stage of infection is asymptomatic, during the blood stage of 
infection malaria symptoms arise319,320.  
In 2009 the World Health organization reported a total of 
225 million cases of malaria infection worldwide, with 781 
thousand leading to death 
(http://www.who.int/malaria/world_malaria_report_2010/en/). The 
most lethal form of malaria is cerebral malaria (CM), which 
affects mainly children in Africa and adults in Southeast Asia. CM 
develops in individuals infected with Plasmodium falciparum and 
is characterized by development of impaired consciousness, 
seizures and subsequent coma. The mortality associated with 
CM development is about 20 percent321,322. The mechanisms 
involved in CM development in humans are not well 
characterized, but are thought to involve parasite sequestration in 
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brain microvasculature, coupled with production of inflammatory 
mediators, culminating in dysfunction of the blood brain barrier322.  
A long known observation, first put forward as an 
hypothesis by Haldane323, is the fact that hemoglobinopathies 
affecting hemoglobin production or structure, afford protection 
against severe forms of malaria324,325. These hemoglobinopathies 
include α+-thalassemia326, sickle cell trait (HbAS)327, hemoglobin 
C (HbC)328 and hemoglobin E (HbE)329.  
Several studies have tried to clarify the mechanisms by 
which protection is conferred to these individuals, and all sorts of 
mechanisms have been implicated in the protection granted by 
hemoglobinopathies.  These include early removal of infected 
RBC330, early acquisition of antibodies against Plasmodium 
proteins331, improper expression of Plasmodium falciparum 
erythrocyte membrane protein 1 (PfEMP1) on RBC surface 
presumably leading to reduced adherence of RBC to the 
microvasculature332, and decreased parasite multiplication333. 
Most probably more than one mechanism will operate 
concomitantly, but defining the basis for protection against 
severe forms of malaria conferred by hemoglobinopathies has 
proven a difficult assignment. 
Animal models resembling CM have been developed in 
mice and have helped to define mechanisms underlying the 
development of CM. The mouse model of CM, frequently termed 
experimental cerebral malaria (ECM), consists of a combination 
of a specific mouse strain, C57Bl/6, and a specific murine 
Plasmodium strain, Plasmodium berghei ANKA (P. berghei 
ANKA). Using this mouse model to dissect the mechanism of 
ECM development, several lines of evidence showed that, as it 
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happens in sepsis, the immune response generated by the host 
is the main driver of ECM pathology.  
 Several studies have reported that Plasmodium can 
trigger innate immune activation by engaging different PRR. 
Malarial hemozoin, a polymer of heme molecules produced by 
the parasite after digestion of hemoglobin inside RBC334,335, is a 
potent activator of the innate immune system. Hemozoin, 
coupled or not with parasite DNA, can activate TLR9 in innate 
immune cells, particularly DC, inducing the production of 
proinflammatory cytokines336-338. Importantly, interfering with 
TLR9’s ability to recognize Plasmodium-derived PAMP prevents 
ECM development339.  Although some controversy exists on the 
exact Plasmodium-derived ligand for TLR9 in DC, it seems clear 
that Plasmodium-derived products engage this receptor. 
NALP3 has also been reported to be activated by 
hemozoin and, again, some polemic exists about the actual 
ligand and molecules involved in NALP3 activation. Nonetheless, 
three independent studies have shown that NALP3 deficient 
animals (Nalp3-/-) have a modest but reproducible survival 
advantage over WT animals when infected with Plasmodium 
berghei ANKA340,341 or with Plasmodium chabaudi adami DS342. It 
is possible that the bona fide NALP3 activator is not hemozoin 
itself but rather uric acid released by damaged cells343-345. 
The activation of the adaptive immune system during 
Plasmodium infection has been shown to greatly rely on antigen 
presentation by DC. This is the case for the induction of antigen-
specific CD8+ T cells against liver stage Plasmodium71 infection, 
and for the unregulated adaptive immune activation observed 
during blood stage infection leading to ECM development346. 
Several lines of evidence suggest that ECM pathology is driven 
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by a concerted action of CD4+ and CD8+ T cells. First, 
recombination activating gene-2 deficient mice (Rag2-/-) or severe 
combined immune deficient (SCID) mice, both lacking T and B 
cells, are protected gainst ECM development132,347. Second, 
depletion of CD4+ cells early after infection and CD8+ cells until 
the first symptoms of ECM appear, can rescue mice from 
ECM348. Third, mice deficient for the chemokines CXCL9 and 
CXCL10, or the chemokine receptors CCR5 and CXCR3, have 
impaired CD8+ T cell activation and/or recruitment to the brain 
after Plasmodium infection and are protected from ECM 
development 349-351. Fourth, expression of the cytotoxic molecules 
perforin and granzyme B by CD8+ T cells is essential for ECM 
development352,353. Fifth, increasing TREG numbers during 
infection protects mice against disease, concomitant with 
reduced CD4+ and CD8+ T cell responses354. An interesting 
finding regarding the role of T cells in promoting ECM 
development is that they increase parasite sequestration in the 
microvasculature, a feature that is thought to be essential for 
disease development347,355,356. The exact mechanisms 
responsible for increased microvasculature sequestration are not 
fully elucidated yet. 
 Of note, HO-1 has been shown to be protective against 
ECM178 and non-cerebral forms of severe malaria179 by related 
mechanisms that involve controlling heme levels. The protective 
effect on ECM is thought to rely on HO-1-derived CO binding to 
hemoglobin released after RBC lyses. This process would avoid 
heme release from hemoglobin, hindering heme’s deleterious 
effects178. In the case of severe non-cerebral malaria, HO-1 is 
thought to protect in two ways: a) by cleaving heme molecules 
and avoiding their pro-apoptotic effects on hepatocytes when in 
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conjunction with proinflammatory agonists such as TNF, and b) 
by acting as an antioxidant molecule179. Interestingly, HO-1 
seems to act, via CO and biliverdin, as a major anti-inflammatory 
molecule during Plasmodium liver infection, allowing for parasite 
replication and establishment of blood stage infection357. These 
findings suggest that during the liver stage of Plasmodium 
infection, HO-1 expression leads to decreased resistance 
allowing the establishment of infection and its progression to 
blood stage. 
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5. Thesis Aims 
 
 Although fundamental to protect hosts against infection, 
immune responses carry a danger within: the very same 
mechanisms operating to achieve pathogen clearance are also 
harmful to host’s tissues, leading to immunopathology. Therefore, 
the occurrence of immunopathology depends on the interplay 
between at least two compartments: the tissue being damaged 
and the immune system causing the harm. With that notion in 
mind, we hypothesized that avoidance of immunopathology might 
be achieved by mechanisms that operate on tissues and/or on 
the immune system. The present Thesis aims at achieving a 
better understanding of the mechanisms operating in these two 
compartments to counteract immunopathology. To address 
whether tissue’s capacity to sustain homeostasis in face of 
immune-mediated insult could prevent immunopathology, we 
assessed the role of the cytoprotective enzyme HO-1 in the 
outcome of an animal model of sepsis. On the other side of the 
spectrum, we used an in vitro co-culture system to assess 
whether DC could expand TREG under different experimental 
conditions, being TREG expansion a putative mechanism 
operating to avoid unfettered immune activation. Furthermore, by 
using ECM as a model where pathology is adaptive immune 
driven, we addressed the role of tissue cytoprotection and 
immune regulation in the protection afforded by mutations in 
hemoglobin. 
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1. ABSTRACT 
 
Dendritic cells (DCs) are the most important antigen-
presenting cells of the immune system and have a crucial role in 
T-lymphocyte activation and adaptive immunity initiation. 
However, DCs have also been implicated in maintaining 
immunological tolerance. In this study, we evaluated changes in 
the CD4+CD25+Foxp3+ T cell population after co-culture of lymph 
node cells from BALB/c mice with syngeneic bone marrow-
derived DCs. Our results showed an increase in 
CD4+CD25+Foxp3+ T cells after co-culture which occurred 
regardless of the activation state of DCs and the presence of 
allogeneic apoptotic cells; however, it was greater when DCs 
were immature and were pulsed with alloantigen. Interestingly, 
syngeneic apoptotic thymocytes were not as efficient as 
allogeneic apoptotic cells in expanding the CD4+CD25+Foxp3+ T 
cell population. In all experimental settings, DCs produced high 
amounts of transforming growth factor (TGF)-β. The presence of 
allogeneic apoptotic cells induced interleukin (IL)-2 production in 
immature and mature DC cultures. This cytokine was also 
detected in the supernatants under all experimental conditions 
and enhanced when immature DCs were pulsed with the 
alloantigen. CD4+CD25+Foxp3+ T cell expansion during co-
culture of lymph node cells with DCs strongly suggests that the 
presence of alloantigen enhanced the number of regulatory T 
cells (TREG) in vitro. Our data also suggest a role for both TGF-β 
and IL-2 in the augmentation of the CD4+CD25+Foxp3+ 
population. 
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2. INTRODUCTION 
 
 Dendritic cells (DC) are professional antigen presenting 
cells with a unique capacity to activate T lymphocytes and induce 
adaptive immune responses. This capacity, however, is 
dependent on the activation state of the DC. Upon encounter with 
pathogens and recognition of “pathogen associated molecular 
patterns” (PAMP), or under inflammatory environments, DC 
become activated. The activation process involves several 
phenotypic and functional changes on DC, including up 
regulation of co-stimulatory molecules, migration to lymph nodes 
and production of cytokines, which, acting in concert, will lead to 
proper T cell activation1. 
 Despite its ability to initiate adaptive immune responses, 
evidences also show that DC play a role in generating T cells 
with regulatory properties and in maintaining peripheral 
tolerance. In the steady state, presentation of antigens derived 
from apoptotic bodies to T lymphocytes leads to tolerance 
induction2. The mechanisms involved are not clear but evidences 
suggest that DC that have internalized apoptotic bodies remain 
immature3-5 and, therefore, are not efficient in inducing effector T 
cell responses6-8. Several other mechanisms have also been 
implicated in the maintenance of peripheral tolerance. DC treated 
with interleukin-10 (IL-10) were shown to induce anergy in CD4 
and CD8 T cells9,10. Further studies have shown that IL-10 
treated DC11, or DC generated from bone marrow precursors in 
the presence of this cytokine12, were capable of generating IL-10 
producing T cells endowed with regulatory properties. Other 
studies have also highlighted the ability of DC to delete T cell 
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clones in the periphery as a way of maintaining tolerance to 
self13-15. 
Over the last decade regulatory T cells (TREG) have been 
described as an indispensable cell population in maintaining 
peripheral tolerance16. TREG cells develop in the thymus17 and are 
characterized by the expression of CD4, CD25 and the 
transcription factor Foxp318. In the periphery, one of the 
requisites for TREG survival is its ability to respond to IL-219. In 
accordance, mice lacking this cytokine20 or components of its 
receptor21 develop spontaneous autoimmune syndrome. 
Interestingly, it has been demonstrated that TREG cells can also 
be generated from naïve T cells in the periphery22,23. Recently, 
the interactions between TREG and DC have been explored in an 
attempt to elucidate the contribution of the latter to the 
maintenance of the TREG population in the periphery. Importantly, 
these studies have shown that TREG can either proliferate or be 
converted from naïve T CD4+ lymphocytes after interaction with 
DC24-30.  
Herein we show that immature DC pulsed with allogeneic 
apoptotic thymocytes were more efficient in expanding 
CD4+CD25+Foxp3+ cells in vitro as compared to DC pulsed with 
syngeneic apoptotic thymocytes. We established an experimental 
system to better understand the contribution of apoptotic cells in 
the expansion of the CD4+CD25+Foxp3+ population as well as the 
activation state of dendritic cells in this process. We co-cultured 
mature or immature bone marrow-derived DC, previously pulsed 
with apoptotic allogeneic thymocytes, with syngeneic lymph node 
cells. Our results show that mature and immature DC are 
capable of expanding CD4+CD25+Foxp3+ T cells. Importantly, we 
observed an enhanced percentage of CD4+CD25+Foxp3+ cells in 
 65 
conditions where immature DC were previously loaded with 
apoptotic allogeneic cells. 
 
3. RESULTS 
3.1 Characterization of bone marrow-derived dendritic cells  
 Dendritic cells were generated in vitro from BALB/c mice bone 
marrow cells using rmGM-CSF. At the end of the culture period 
approximately 80% of these cells were CD11c+CD11b+CD4-CD8-B220-. 
Upon stimulation with LPS, DC enhanced the expression of MHC-II 
and the costimulatory molecules CD80, CD86 and CD40 (Figure 2.1). 
To evaluate the functional properties of bone marrow-derived DC we 
tested their capacity to induce allogeneic spleen cells proliferation. 
Immature or mature DC were cultured with spleen cells from C57Bl/6 
mice, and the proliferative response was evaluated. Splenocytes alone 
were used as control. As shown in Figure 2.2, both immature and 
mature DC were capable of inducing allogeneic T cell proliferation, with 
mature DC being more efficient at all time-points analyzed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Phenotypic analysis of immature dendritic cells (iDC) and mature dendritic cells 
(mDC). DC were generated from bone marrow cells from BALB/c mice with recombinant murine 
granulocyte–macrophage colony-stimulating factor (rmGM-CSF). Cells were stimulated with 
lipopolysaccharide (LPS) or left unstimulated for 24 hr and were labelled with fluorescent antibodies 
against surface molecules. (-) isotype control; (-) surface marker. The mean fluorescence intensity (MFI) 
is indicated.  
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Figure 2.2. Induction of allogeneic splenic cells 
proliferation by bone marrow-derived dendritic cells 
(DC). Immature or lipopolysaccharide (LPS)-matured DC 
from BALB/c mice were co-cultured with total spleen 
cells from C57Bl/6 mice at different DC:splenocytes 
ratios (1 : 5 and 1 : 10) for 48, 72 and 96 hr, in a 96-well 
U-bottom plate. Proliferation was measured by 
[3H]thymidine incorporation. Data is shown as mean ± 
standard deviation and are representative of three 
independent experiments. ***P < 0,001 compared with 
immature DC. c.p.m., counts per minute; iDC, immature 
DC; mDC, mature DC. 
3.2 Phagocytosis of apoptotic thymocytes by dendritic cells 
 Since we wanted to evaluate the effect of apoptotic cells-
derived antigens in the generation of CD4+CD25+Foxp3+ T cells we 
setup a condition in which 
allogeneic cells would be 
apoptotic during the incubation 
period with DC. Thymocytes 
from C57Bl/6 mice were 
incubated with dexamethasone 
for 4 hours, extensively washed 
and added to DC cultures for 
18 hours. Phagocytosis of 
apoptotic thymocytes by 
immature and mature DC at 
different DC:apoptotic cell ratios and at different time-points was 
evaluated. Data on figure 2.3 show the number of DC that had 
phagocytosed apoptotic cells after 2 and 4 hours. No differences were 
observed between immature and mature DC and there was a 
progressive and modest, but not statistically significant, increase in the 
phagocytosis rate when apoptotic cells were added in higher numbers.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2.3. Phagocytosis of apoptotic 
allogeneic thymocytes (APOs) by dendritic 
cells (DC). Immature DC (iDC) or 
lipopolysaccharide (LPS)-matured DC (mDC) 
were incubated with APOs and phagocytosis 
was evaluated after 2 and 4 hr of incubation. 
Cells were collected and transferred to glass 
slides by cytospin and stained with 
haematoxylin and eosin. Upper panel  an iDC 
(left); an apoptotic thymocyte (arrow) that has 
been phagocytosed by an iDC (right). In the 
lower graph results are presented as the mean 
± standard deviation of both time-points 
combined and are representative of three 
independent experiments. 
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3.3 Effect of apoptotic cells on dendritic cell maturation 
 We next evaluated the expression of MHC II and costimulatory 
molecules, as well as the production of cytokines by DC after 
incubation with apoptotic allogeneic thymocytes. Mature DC population 
showed a slightly decrease in the percentage of MHC IIhigh cells upon 
incubation with apoptotic cells. No changes were observed in the 
expression of costimulatory molecules (CD80, CD86 and CD40) 
neither in immature nor in mature DC after incubation with apoptotic 
cells (Figure 2.4). The production of IL-10, IL-12, TNF-α (Figure 2.5 A) 
and TGF- (Figure 2.5 B) by mature DC was not altered in the 
presence of apoptotic cells. However, the secretion of IL-2 was 
increased (Figure 2.5 C). Regarding immature DC, all cytokines with 
the exception of TGF-β were below the detection limit of the assay. 
The presence of allogeneic apoptotic thymocytes induced only IL-2 
production (Figure 2.5 C) and did not modulate the production of TGF-
β (Figure 2.5 B). Taken together, this data shows that in our system, 
allogeneic apoptotic cells have no interference in the maturation state 
of DC but are able to induce IL-2 production in immature DC and 
enhance the secretion of this cytokine by mature cells.  
 
3.4 Evaluation of the CD4+CD25+Foxp3+ T cell population after co-
culture of lymph node cells with DC 
 Our next step was to study the influence of the maturation state 
of DC and the presence of apoptotic cells on the expansion of the 
CD4+CD25+Foxp3+ T cell population in vitro. We cultured total lymph 
node cells from BALB/c mice with syngeneic DC that were previously 
incubated with apoptotic allogeneic thymocytes from C57Bl/6 mice, 
and evaluated the percentage of CD4+CD25+Foxp3+ lymphocytes 
obtained after co-culture. Under all conditions the CD4+CD25+Foxp3+ 
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population was as expanded compared to the population observed in 
of the lymph nodes  from  naïve  mice   (Figure 2.6 A).  The  maturation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
state of DC did not influence the expansion of TREG cells since both 
immature and mature DC were capable of enhancing the percentages 
of CD4+CD25+Foxp3+ cells (Figure 2.6 B). Interestingly, immature DC 
 
Figure 3.4. Activation phenotype of immature dendritic cells (iDC) or mature dendritic cells 
(mDC) incubated or not with apoptotic allogeneic thymocytes (APOs). DC were generated from 
bone marrow cells from BALB/c mice with recombinant murine granulocyte–macrophage colony-
stimulating factor (rmGM-CSF), as described in the main text. On day 6, cells were stimulated with 
lipopolysaccharide (LPS; 1 µg/ml) or left unstimulated for 24 hr. On day 7, iDC and mDC were incubated 
with APOs for 18 hr. Cells were collected and evaluated for the expression of MHC-II, CD80, CD86 and 
CD40. Data are representative of three independent experiments.  
 
 
Figure 3.5. Cytokine production by mature dendritic cells (mDC) and immature dendritic cells 
(iDC) incubated or not with apoptotic allogeneic thymocytes (APOs). DC were generated from 
bone marrow-derived cells from BALB/c mice treated with rmGM-CSF for 6 days. On day 7, cells (5x105) 
were transferred to a 96-well flat-bottom plate and stimulated with lipopolysaccharide (LPS; 1 µg/ml) or 
left unstimulated in the presence or absence of APOs (2,5x106) for 24 hr. Supernatants were harvested 
and (a) interleukin (IL)-12, tumour necrosis factor (TNF)-α and IL-10, (b) transforming growth factor 
(TGF)-β and (c) IL-2 were measured by enzyme-linked immunosorbent assay (ELISA) in triplicate for 
each experimental condition. Results are presented as mean ± standard deviation and are 
representative of two independent experiments. 
 69 
pulsed with apoptotic allogeneic cells lead to increased percentages of 
TREG cells compared to other experimental conditions, and these cells 
were suppressive in vitro (Figure 2.6 B and D). Apoptotic syngeneic 
thymocytes were not as efficient as allogeneic thymocytes in inducing 
TREG cells in immature DC cultures (Figure 2.7 A). We also evaluated 
IL-2 in the supernatants of DC-lymph node co-cultures in all conditions. 
Interestingly, IL-2 production was significantly enhanced in the 
supernatants of iDC cultures that were previously incubated with 
allogeneic apoptotic cells compared to the other conditions (Figure 2.6 
C) as well as compared to apoptotic syngeneic-incubated iDC assays 
(Figure 2.7 B). This observation indicates a correlation between 
production of IL-2 and expansion of CD4+CD25+Foxp3+ cells. 
 
3.5 Expansion of the CD4+CD25+Foxp3- T cell population in 
CD4+CD25+ depleted cultures 
 In the experiments described previously we have shown that 
mature and immature DC were efficient in expanding 
CD4+CD25+Foxp3+ cells however, the CD4+CD25+Foxp3- population 
was not observed. This could be due to efficient TREG suppression of 
naïve T cells proliferation or to poor antigen presentation. To evaluate 
these hypotheses we co-cultured immature or mature DC, pulsed or 
not with apoptotic allogeneic cells, with lymph node cells depleted of 
CD4+CD25+ T cells. We were able to obtain a highly purified 
population, eliminating approximately 98% of the CD4+CD25+ cells 
(Figure 2.7 A, right). In all assays we observed expansion of 
CD4+CD25+Foxp3+ and CD4+CD25+Foxp3- T cells and in almost all of 
them the percentages of both populations were very similar (Figure 
2.7 B). Exception was made when lymph node cells were cultured with 
mature DC loaded with apoptotic thymocytes. In this condition 
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activated CD4+CD25+Foxp3- T cells showed almost a two-fold 
expansion when compared with CD4+CD25+Foxp3+ cells (Figure 2.7B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Generation of CD4+CD25+Foxp3+ cells after co-culture of lymph node cells (LN) from 
naïve mice with dendritic cells (DC) pulsed or not with apoptotic allogeneic thymocytes (APOs). 
Mature dendritic cells (mDC) or immature dendritic cells (iDC) were incubated with APOs at a ratio of 
1:5 (DC:APOs) for 18 hr. APOs were harvested and DC were co-cultured with syngeneic total lymph 
node cells for 5 days (1:5 DC:lymph node cell ratio). Cells were collected and labelled with fluorescent 
antibodies for CD4, CD25 and Foxp3. (a) Dot plot and (b) bar chart presentations of CD4+CD25+Foxp3+ 
cells (gated on CD4+ cells) are shown. Lymph node cells alone are presented as a control. (c) 
Interleukin (IL)-2 was evaluated in the supernatants by enzyme-linked immunosorbent assay (ELISA). 
(d) CD4+CD25+Foxp3+ cells generated in iDC cultures in the presence of APOs were sorted and added 
to a mixed lymphocyte reaction (MLR) assay (2,5x105 responder cells: 2,5x105 stimulator cells at 
different ratios [TREG:T effector cells] in a 96-well U-bottom plate for 5 days. Proliferation was evaluated 
by [3H]thymidine incorporation. Data are presented as mean ± standard deviation. In (b) *P < 0.05 and 
**P < 0.01 (LN compared to all groups); in (c) **P < 0.01 and in (d) *P < 0.05 and **P < 0.01 compared 
with proliferation in the absence of Tregs. Results regarding the generation of CD4+CD25+Foxp3+ cells 
are representative of four independent experiments and those for the suppressor assay are 
representative of two independent experiments. c.p.m., counts per minute. 
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suggesting that these TREG cells might not be able to efficiently control 
reactive T cell response. Again, the expansion of TREG was increased 
in immature apoptotic-loaded DC cultures (Fig 2.7 B and C). These 
results suggest that antigen presentation occurred, and that in our 
model the presence of CD4+CD25+ T cells is responsible for 
suppressing the proliferation of reactive T cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Syngeneic apoptotic 
thymocytes are less efficient in expanding 
CD4+CD25+Foxp3+ cells compared with 
allogeneic apoptotic thymocytes. 
Immature dendritic cells (iDC) were 
incubated with allogeneic (ALOs) or 
syngeneic (SYNs) apoptotic thymocytes at a 
ratio of 1:5 (DC:apoptotic cells) for 18 hr. 
Apoptotic cells were harvested and DC were 
co-cultured with syngeneic lymph node cells 
for 5 days (1:5, DC:lymph node cell ratio). 
Cells were collected and labelled with 
fluorescent antibodies for CD4, CD25 and 
Foxp3. (a) Dot plot of CD4+CD25+Foxp3+ 
cells (gated on CD4+ cells). Lymph node 
cells alone are presented as control. (b) IL-2 
was evaluated in the supernatants of 
immature DC/total lymph node cells co-
culture by enzyme-linked immunosorbent 
assay (ELISA). Data are presented as mean 
± standard deviation and are representative 
of two independent experiments; ***P< 0.001. 
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4. DISCUSSION  
 
 In this study we showed that both immature and mature bone 
marrow-derived DC are able to promote expansion of the 
CD4+CD25+Foxp3+ T cell population in vitro. We also showed that 
expansion of TREG reached its maximum when immature DC were 
incubated with allogeneic apoptotic thymocytes, and that TREG 
generated in this way were suppressive in vitro.  
The bone marrow-derived DC used in this study showed 
phenotypic and functional aspects of immature cells. They expressed 
low levels of co-stimulatory molecules, did not produce 
proinflammatory cytokines and had a reduced capacity of priming 
allogeneic T cells. Importantly, when activated with LPS, DC were 
 
Figure 2.8. Expansion of CD4+CD25+Foxp3+ cells from lymph node cells initially depleted of 
CD4+CD25+ cells. mDC or iDC were incubated with APOs at a ratio of 1:5 (DC:APOs) for 18 hr. APOs 
were harvested and DC were co-cultured with syngeneic total lymph node cells (LNs) depleted of 
CD4+CD25+ cells for 5 days (1:5, DC:lymph node cell ratio). Cells were collected and labelled with 
fluorescent antibodies for CD4, CD25 and Foxp3. (a) Percentage of CD4+CD25+ T cells in lymph node 
cell suspensions before (left) and after (right) depletion. (b) dot plot of CD25+Foxp3+ cells after co-
culture in different conditions (gated on CD4+ cells). (c) Percentage of CD4+CD25+Foxp3+ and (d) of 
CD4+CD25+Foxp3- cells after co-culture with DC. Data are representative of two independent 
experiments.  
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efficient in inducing T cell proliferation, enhanced the expression of co-
stimulatory molecules and produced proinflammatory cytokines. These 
results show that the DC population used throughout the study has 
features of immature DC, and that upon activation with LPS were 
completely able to mature. 
Herein we used a system where non-self antigen is delivered to 
DC via allogeneic apoptotic thymocytes, and we evaluated the 
influence of that on TREG expansion. There are some considerations 
that must be made here about the antigen delivery system used. One 
of our goals was to evaluate the influence of exogenous antigens on 
TREG expansion, and assure that immature DC would remain immature 
during antigen presentation; therefore, we choose to work with 
allogeneic apoptotic cells. Many studies have shown that apoptotic 
cells can play an important role in the generation of peripheral 
tolerance, possibly by maintaining DC in an immature state and/or 
inducing tolerogenic properties on these cells36-38. In fact, in our system 
the activation status of DC was not altered after contact with allogeneic 
apoptotic thymocytes. The absence of immunoregulatory effects of 
apoptotic cells on mature DC in our system might be due to the fact 
that DC were fully matured when apoptotic cells were added to the 
culture. In this way, the expected immunomodulatory properties of 
apoptotic cells would be unable to reverse the activation state of 
mature DC.  
The efficiency of mature DC in expanding CD4+CD25+Foxp3+ 
cells has previously been shown in mouse33,34 and humans35. There is 
also evidence that induction of TREG proliferation by mature DC is 
dependent of exogenous IL-234. In our system, exogenous IL-2 was not 
necessary for expansion of TREG population. In our cultures, IL-2 
production by DC occurred after maturation with LPS and when DC 
were in contact with apoptotic thymocytes. Therefore, it is possible that 
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contact with apoptotic bodies induces IL-2 production by DC that, in 
turn, facilitates TREG expansion. Of note, the presence of 
proinflammatory cytokines, as observed when DC were activated by 
LPS, seems to decrease TREG expansion, as compared to expansion 
by immature DC, even in the presence of high IL-2 levels. 
Our data also suggests that in the absence of proinflammatory 
cytokines, the amount of IL-2 might directly affect TREG expansion. In 
lymph node/DC co-cultures where immature DC had been in contact 
with allogeneic apoptotic cells, increased IL-2 levels were observed, 
compared with co-cultures were DC had been in contact with 
syngeneic apoptotic cells. In the first case, there was also an increased 
expansion of the TREG population, suggesting that IL-2, in the absence 
of high levels of proinflammatory cytokines, contributes to TREG 
expansion. Whether the sources of IL-2 in these cultures were DC or 
lymph node cells is currently not clear, but it is likely that the presence 
of non-self antigen induces some degree of T cell activation leading to 
IL-2 production. 
 Our results suggest that efficient alloantigen presentation 
occurs in our system. This notion is supported by the observation of 
increased percentages of activated T cells (CD4+CD25+Foxp3-) when 
DC were pulsed with allogeneic apoptotic cells, and co-cultured with 
lymph node cells that had been depleted from CD4+CD25+ T cells. 
These observations indicate that DC have captured, processed, and 
were able to present alloantigens to T cells in our culture conditions. 
It is not clear in our system if the expansion of the TREG 
population is due to CD4+CD25+Foxp3+ T cell proliferation after 
interaction with DC, or due to conversion of naïve CD4+CD25+Foxp3- T 
cells into Foxp3+ cells, or by a combination of the two mechanisms. We 
could not unquestionably answer this question, since we had 
contaminating CD4+CD25+ T cells still present in our cultures 
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(approximately 2%). Nonetheless, the sharp decrease in the TREG 
population when CD4+CD25+ T cells were depleted prior to co-culture 
with DC, suggests that expansion of existing CD4+CD25+Foxp3+ cells, 
and not conversion from naïve T cells, plays a major role in increasing 
TREG population in our system. 
Studies have demonstrated that CD4+CD25+Foxp3+ cells are 
more efficiently expanded by mature bone marrow-derived DC, as 
compared to immature DC25,26,39. Our data show that despite the fact 
that both mature and immature DC expand TREG, presentation of 
allogeneic peptides in a non-inflammatory environment lead to 
increased expansion of the TREG population. We were unable to detect 
production of IL-12 and TNF-α by immature DC, whereas mature cells 
produced large amounts of these cytokines. Importantly, both mature 
and immature DC secreted TGF-β and varying amounts of IL-2. These 
two cytokines have been implicate in homeostasis, proliferation, and de 
novo generation of TREG, in different experimental conditions22,28,29,41,42. 
Despite the enhanced production of pro-inflammatory cytokines by 
mature DC, the presence of TGF-β and IL-2 might interfere with the 
activation and/or acquisition of effector function by naïve T cells, while 
helping TREG maintenance and/or expansion. Overall, these 
observations indicate that TREG expansion might occur both in non-
inflammatory as well as in inflammatory environments, given the 
presence of IL-2 and TGF-β, and that the presence of pro-inflammatory 
cytokines might decrease the efficiency of this process. 
Our study provides a system that can be used to better 
comprehend the mechanisms involved in the expansion of the TREG 
pool by DC. The evaluation of the functional properties of our 
generated/expanded CD4+CD25+Foxp3+ cells in vivo is ongoing. 
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5. METHODS 
 
Mice 
Six to ten week-old BALB/c (H-2d) and C57Bl/6 (H-2b) female 
mice were obtained from the Department of Immunology animal facilitiy 
at the University of São Paulo and kept in microisolator cages under 
specific-pathogen free conditions. Experiments were performed 
following the guidelines for animal use and care approved by the Ethics 
Committee on Animal Research from the Instituto de Ciências 
Biomédicas of the University of São Paulo. 
 
Generation of Immature dendritic cell  
Immature dendritic cells were generated in vitro from bone 
marrow cells as described by Inaba et al32, with some modifications. In 
brief, bone marrow cells were removed from the femurs of BALB/c 
mice and cultured in complete medium (DMEM supplemented with 5% 
fetal bovine serum (Hyclone, Logan, UT), 10-5M 2-ME (Sigma 
Chemicals Co, St. Louis, MO, EUA) 2mM L-glutamine, 0.1 mM 
vitamins, 1mM sodium pyruvate, 0.1 mM non-essential amino-acids 
and 100µg/ml gentamicine all purchased from Gibco BRL (Rockville, 
NY)) in a 6-well plate (Sarstedt, Newton, NC, USA) at 2x106 cells/ml in 
a total volume of 5 ml/well, with 10ng/ml of recombinant murine (rm) 
GM-CSF for 7 days. rmGM-CSF was renewed on the 4th day of culture. 
For DC maturation, cells were stimulated for 24 hours with 1µg/mL of 
LPS on day 6.  
 
Flow cytometry 
Cells were incubated with anti-CD16/32 (FcBlock) for 30 minutes 
at 4oC in phosphate-buffer saline (PBS) containing 3% fetal calf serum 
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(FCS), and 0.01% sodium azide (FACS buffer). Cells were labeled with 
fluorescent antibodies against CD11c (PE), CD11b (FITC), CD8 
(FITC), B220 (FITC), MHC-II(I-Ad) (FITC), CD80 (FITC), CD86 (FITC), 
CD40 (FITC), CD4 (Cy5) and CD25 (FITC) (0.5µg/106 cells; all 
purchased from Pharmingen, BD, San Diego, CA), and incubated for 
30 minutes at 4oC. Cells were washed with 1ml of FACS buffer and 
ressuspended in 300 µl of the same buffer before analysis. For 
evaluation of Foxp3 expression cells were labeled with anti-CD4 (Cy5) 
and anti-CD25 (FITC) antibodies and were fixed, permeabilized and 
labeled with anti-Foxp3 (PE) antibody according to the manufacturer’s 
instructions (“PE anti-mouse/rat Foxp3 Staining Set”, eBiosciences, 
San Diego, CA). Cells were analyzed by flow cytometry using a 
FACScalibur (BD, San Diego, CA) with a CellQuest software (BD, San 
Diego, CA ). 
 
Cytokine evaluation 
Cytokine production by mature and immature DC, pulsed or not 
with apoptotic cells, was evaluated using the commercial kits OptEIA 
(BD, San Diego, CA, USA) for IL-12, IL-10 TNF-α and IL-2. For TGF- 
evaluation we used the “TGF-1 EMAX Immunoassay System” 
(Promega, Madison, WI, USA). After 6 days of culture, DC were 
harvested from 6-well plates and 5x105 cells/well were plated in 96-
well plates. DC were left immature or stimulated with LPS (1µg/ml) for 
24 hours. 2.5x106 apoptotic cells (1:5 DC to apoptotic cells ratio) were 
added in indicated groups. Supernatants were harvested 24 hours 
after and stored at -20oC until use. Cytokine measurement was 
performed according to the manufacturer’s instruction. 
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Induction of apoptosis in thymocytes 
Thymuses were obtained from 3 week-old C57Bl/6 female mice. 
Single cell suspension was prepared and cells were plated in six-well 
plates at a concentration of 107 cells/ml. Cells were treated with 10-7M 
of dexamethasone and kept in a 37oC, 5% CO2 incubator for 4 hours. 
Cells were washed with DMEM and ressupended in complete medium 
for culture. For evaluation of apoptosis after treatment with 
dexamethasone, 106 cells were washed in HEPES buffer (10 mM 
HEPES, 150mM NaCl, 5mM KCl, 1mM MgCl2 and 1.8mM CaCl2), 
ressuspended in the same buffer (100µl) and labeled with Annexin V-
FITC for 20 minutes in the dark at room temperature. After the 
incubation period, 350 µl of HEPES buffer were added to the 
suspension. Immediately before analysis 40µl of propidium iodide (100 
µg/ml) were added. Cells were analyzed by flow cytometry.  
 
Phagocytosis assay 
Immature and mature DC (4x104) were incubated in 1.5ml plastic 
conical tubes (Eppendorf, Hamburg, Germany) with varying quantities 
of apoptotic cells in order to obtain 1:1, 1:5 and 1:10 DC:apoptotic cell 
ratio. Cells were kept in contact for 2 and 4 hours at 37oC, 5% CO2 
atmosphere. After the incubation period the DC were transferred to 
glass slides by cytospin. The slides were stained using the “Hema 3 
Kit” (Biochemical Sciences Inc, Swedesboro, NJ) and the number of 
DC that had phagocytosed apoptotic cells were determined by optic 
microscopy.  
 
Allogeneic spleenocytes stimulation by DC 
Immature or mature dendritic cells (5x105) from BALB/c mice 
were co-cultured with total splenocytes from C57Bl/6 mice at different 
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responder:stimulator (1:5; 1:10) cell ratios for 5 days in a 96-well U 
bottom plate. 3H-thymidine (1µCi/well) was added at the last 18 hours. 
Plates were harvested and 3H-thymidine incorporation was evaluated 
in counts per minute (cpm). 
 
Dendritic cells and lymph node cell co-culture 
Immature or mature DC from BALB/c mice were cultured 
overnight in complete medium with apoptotic thymocytes from C57Bl/6 
animals at a 1:5 ratio (DC: allogeneic cells). After the incubation period 
allogeneic thymocytes debris were harvested from the culture by 
washing the cells with DMEM. DC were co-cultured in complete 
medium with syngeneic lymph node cells at a 1:5 ratio (DC: lymph 
node cells) for 5 days. At the end of the co-culture period, lymph node 
cells were harvested with DMEM, washed once and characterized by 
flow cytometry. 
 
Suppressor assay  
Spleens were harvested from BALB/c or C57Bl/6 mice and 
single cell suspensions were prepared. After red blood cells lysis with 
NH4Cl buffer, cells were washed with PBS, ressuspended in complete 
medium and tested for viability. A number of 2.5 x 105 cells from 
BALB/c mice were co-cultured with 2.5 x 105 irradiated cells (3000 
rads) from C57Bl/6 in a 96-well round-bottom plate together with 
different numbers of generated CD4+CD25+ T cells sorted from 
immature DC cultures previously incubated with apoptotic allogeneic 
thymocytes in a total volume of 200µl/well. After 5 days of culture cells 
were pulsed with 3H-thymidine (1µCi/well; Amersham International, 
Buckinghamshire, UK) for 18 hours. Cells were harvested and 3H-
thymidine uptake was measured using a β-counter.  
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Depletion of CD4+CD25+ T cells from lymph node cells 
suspensions 
For the depletion of CD4+CD25+ T cells from lymph node single 
cell suspensions we used the “CD4+CD25+ Regulatory T cell Isolation 
Kit” (Miltenyi Biotec Inc., Auburn, CA). The depletion was performed 
following manufacturer’s instructions. In all experiments purity obtained 
was higher than 97% in the population depleted of CD4+CD25+ T cells. 
 
Statistical analysis 
Data were presented as mean values + SD. Mann-Whitney’s or 
ANOVA with Tukey’s post test were performed using the GraphPad Prism 
4.0 software. Data were considered significant for p<0.05.  
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1. ABSTRACT 
 
Low-grade polymicrobial infection induced by cecal 
ligation and puncture is lethal in heme oxygenase-1–deficient 
mice (Hmox1−/−), but not in wild-type (Hmox1+/+) mice. Here we 
demonstrate that the protective effect of this heme catabolizing 
enzyme relies on its ability to prevent tissue damage caused by 
the circulating free heme released from hemoglobin during 
infection. Heme administration after low-grade infection in mice 
promoted tissue damage and severe sepsis. Free heme 
contributed to the pathogenesis of severe sepsis irrespective of 
pathogen load, revealing that it compromised host tolerance to 
infection. Development of lethal forms of severe sepsis after 
high-grade infection was associated with reduced serum 
concentrations of the heme sequestering protein hemopexin 
(HPX), whereas HPX administration after high-grade infection 
prevented tissue damage and lethality. Finally, the lethal 
outcome of septic shock in patients was also associated with 
reduced HPX serum concentrations. We propose that targeting 
free heme by HPX might be used therapeutically to treat severe 
sepsis. 
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2. INTRODUCTION 
 
Severe sepsis is a disease with limited treatment options 
that kills more than half a million individuals per year in the 
United States alone1. Severe sepsis can develop from an 
unfettered immune response to microbial infection that leads to a 
systemic refractory drop in blood pressure, disseminated 
intravascular coagulation, multiple end-stage organ failure, and 
eventually death2. The physiological and molecular mechanisms 
that underlie the pathogenesis of severe sepsis remain poorly 
understood2. 
In most cases of microbial infection, the innate and 
adaptive immune systems allow for pathogen clearance and a 
return to homeostasis3. In some cases, however, this host 
defense strategy, referred to as resistance to infection4-6, can 
lead to irreversible tissue damage and compromise host viability7. 
An alternative host defense strategy, referred to as tolerance to 
infection5,6, can limit disease severity irrespective of pathogen 
load4-6. Host genes conferring tolerance to infection include the 
stress-responsive enzyme heme oxygenase-1 (Hmox1), as 
previously demonstrated for malaria, the disease caused by 
Plasmodium infection8. 
Heme oxygenase-1 (HO-1) acts as the rate-limiting 
enzyme in the breakdown of heme (Fe protoporphyrin IX; 
FePPIX) into equimolar amounts of biliverdin, iron (Fe), and 
carbon monoxide9. Induction of HO-1 expression in response to 
stress caused by microbial infection suppresses the development 
of severe sepsis in mice10. This safeguarding action can act 
irrespective of pathogen load, relying instead on the 
cytoprotective effect of HO-1 against the excess free heme 
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produced via hemolysis during infection. 
Free heme induces programmed cell death in response to 
proinflammatory agonists, as demonstrated for tumor necrosis 
factor (TNF)8,11. We refer to this phenomenon as “heme 
sensitization” to programmed cell death, because the cytotoxic 
effect of free heme is revealed only in the presence of other 
cytotoxic agonists8,11. The molecular mechanism underlying the 
cytotoxic effect of free heme relies on its pro-oxidant activity8,11, 
driven by the divalent Fe atom contained within its protoporphyrin 
IX ring, which can promote the production of free radicals via 
Fenton chemistry12.  
Given that free heme can cause tissue damage and 
hence compromise host tolerance to infection, we investigated 
whether limiting this deleterious effect can be used for 
therapeutic purposes to enhance host tolerance against microbial 
infections and prevent the development of severe sepsis. 
 
3. RESULTS 
 
3.1 HO-1 affords host tolerance against polymicrobial 
infection 
Severe sepsis was produced in BALB/c mice by low-
grade polymicrobial infection induced by cecal ligation and 
puncture (CLP). Using quantitative reverse transcription 
polymerase chain reaction (RT-PCR), we measured the 
expression of the Hmox1 gene and found that it was induced in 
peritoneal infiltrating leukocytes, liver, lung, and kidney at various 
time points after CLP (Fig 3.1 A). Mortality increased from 13% in 
wild-type (Hmox1+/+) mice to 80% in Hmox1-deficient (Hmox1−/−) 
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mice when both were subjected to low-grade CLP (Fig. 3.1 B). 
Similar results were obtained in BALB/c severe combined 
immunodeficient (SCID) mice lacking B and T lymphocytes (Fig. 
1 B), demonstrating that the protective effect of HO-1 is not 
dependent on adaptive immunity. The mortality of heterozygous 
Hmox1+/− mice was similar to that of Hmox1+/+ mice (Fig. 3.1 B). 
The higher mortality of Hmox1−/− versus Hmox1+/+ mice was not 
attributable to the surgical procedure per se, as Hmox1−/− mice 
did not succumb to sham laparotomy, which mimicked CLP 
without polymicrobial infection. 
The mortality of Hmox1−/− mice after CLP was associated 
with the development of multiple end-stage organ failure, a 
hallmark of severe sepsis2. Plasma concentrations of aspartate 
aminotransferase (AST), blood urea nitrogen (BUN), and 
creatinine phosphokinase (CPK), markers of liver, kidney, and 
muscle dysfunction, respectively, were significantly increased in 
infected Hmox1−/− versus Hmox1+/+ mice (Fig. 3.1 C). Liver, 
kidney, and cardiac damage were confirmed by histological 
detection of centrolobular necrosis, tubular epithelial necrosis, 
and myocardial necrosis, respectively (Fig. 3.1 D). This 
demonstrates that induction of HO-1 expression in response to 
polymicrobial infection limits tissue damage and the development 
of severe sepsis.  
Exacerbated mortality of Hmox1−/− versus Hmox1+/+ mice 
did not result from higher pathogen (bacterial) load, as assessed 
by comparing the number of colony-forming units (CFUs) in the 
peritoneum and blood (Fig. 3.1 E), as well as in the liver, spleen, 
kidneys, and lungs (Fig. 3.1 G). Hmox1−/− mice also succumbed 
when challenged with heat-killed bacteria (60% mortality), 
whereas Hmox1+/− and Hmox1+/+ mice did not (0% mortality) (Fig. 
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3.1 F). This demonstrates that HO-1 affords tolerance against 
polymicrobial infection5,6 independently of its previously reported 
antimicrobial activity10. 
Production of several cytokines involved in the 
pathogenesis of severe sepsis [for example, TNF, interleukin-6 
(IL-6), and IL-10] was similar in Hmox1−/− versus Hmox1+/− or 
Hmox1+/+ mice subjected to low-grade CLP (Fig. 3.2, A, D, and 
G). Likewise, peritoneal or bone marrow–derived 
G 
 (F) Survival of Hmox1+/+ (n=7), Hmox1+/− (n=6), and Hmox1−/− (n=5) BALB/c mice after intraperitoneal 
administration of heat-killed bacteria (Bact.). (G) CFU in Hmox1+/+(n=5), Hmox1+/- (n=4) and Hmox1-/- (n=5) 
mice, 12 h after low-grade CLP. Each circle represents an individual mouse and bars indicate mean 
values. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. 
 
Figure 3.1. HO-1 affords 
tolerance against 
polymicrobial infection in 
mice. (A) Hmox1 messenger 
RNA (mRNA) expression in 
peritoneal leukocytes 
(Perit.leu.), lung, liver, and 
kidney after low-grade CLP in 
BALB/c mice, as determined 
by quantitative RT-PCR. Data 
are shown as mean ± SD (n = 
3 per group). (B) Survival of 
Hmox1+/+ (n=15), Hmox1+/− 
(n=12), Hmox1−/− (n=10), 
SCID.Hmox1+/+ (n=5), and 
SCID.Hmox1−/− (n=5) BALB/c 
mice after low-grade CLP. (C) 
Serological markers of organ 
injury in Hmox1+/+ (n =15 to 
17), Hmox1+/− (n=10 to 13), 
and Hmox1−/− (n=6) BALB/c 
mice 24 hours after low-grade 
CLP. Data are shown as 
mean ± SD. Dashed lines 
indicate basal plasma 
concentrations in naïve wild-
type BALB/c mice. IU, 
international units. (D) 
Representative examples of 
hematoxylin and eosin 
(H&E)–stained liver, kidney, 
and heart tissues from 
Hmox1+/+ and Hmox1−/− mice 
after low-grade CLP. 
Magnification, x400. Arrows 
indicate red blood cells 
(RBCs) associated with 
vascular congestion and/or 
thrombosis. CV, coronary 
vessel; M, myocardium; PV, 
portal vein; G, glomerulus. (E) 
Bacterial load (CFU) in the 
peritoneum and blood of mice 
subjected to low grade CLP 
(12 hours after CLP). Circles 
represent individual mice. 
Bars represent median 
values. ns, not significant. 
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monocytes/macrophages (Mø) from Hmox1−/− versus Hmox1+/+ 
mice produced similar amounts of IL-6 when exposed in vitro to 
bacterial lipopolysaccharide (LPS) or to live bacteria (Fig. 3.2, E 
and F), while producing slightly but significantly higher amounts 
of TNF when exposed to LPS (Fig. 3.2 B) but not to live bacteria 
(Fig. 3.2 C). Higher production of IL-10 also occurred in Hmox1−/− 
versus Hmox1+/+ Mø exposed to LPS or to live bacteria (Fig. 3.2, 
H and I). Because HO-1 regulates the expression of a subset of 
cytokines, including IL-10 (Fig. 3.2 H and I) in response to 
bacterial agonists such as LPS (Fig. 3.2 H) or live bacteria (Fig. 
3.2 I), we cannot exclude that this effect might contribute to the 
protective mechanism by which HO-1 suppresses the 
pathogenesis of severe sepsis. 
When exposed to LPS and interferon-γ (IFN-γ), peritoneal 
Mø from naïve Hmox1−/− mice produced slightly but significantly 
higher amounts of nitric oxide (NO) than did Hmox1+/+ peritoneal 
Mø (Fig. 3.2 J). Importantly, NOS2/iNOS expression, the major 
source of NO in LPS/IFN-γ-activated Mø, was similar in Hmox1-/- 
vs. Hmox1+/+ peritoneal Mø, suggesting that HO-1 modulates 
NOS2/iNOS activity but not its level of expression (Fig. 3.2 K). 
Whether reduced NO production contributes to the protective 
action of HO-1 remains to be established. 
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Figure 3.2. HO-1 does not modulate cytokine production in response to CLP. (A) TNF 
concentrations in peritoneal fluid following low-grade CLP. (B) TNF concentrations in supernatants of 
peritoneal leukocytes stimulated with LPS (6h). (C) TNF concentrations in supernatants of bone 
marrow-derived Mφ exposed to live Gram positive (Gpos; Enterococcus subspecies) or Gram negative 
(Gned; Escherichia coli) bacteria (8h). (D) IL-6 concentrations in peritoneal fluid following low-grade CLP. 
(E) IL-6 concentrations in supernatants of peritoneal leukocytes stimulated with LPS (24h). (F) IL-6 
concentrations in supernatants of bone marrow-derived Mφ exposed to live Gram positive (Gpos; 
Enterococcus subspecies) or Gram negative (Gned; Escherichia coli) bacteria (8h). (G) IL-10 
concentrations in peritoneal fluid following low-grade CLP. (H) IL-10 concentrations in supernatants of 
peritoneal leukocytes stimulated with LPS (24h). (I) IL-10 concentrations in supernatants of bone 
marrow-derived Mφ exposed to live Gram positive (Gpos; Enterococcus subspecies) or Gram negative 
(Gned; Escherichia coli) bacteria (8h). Cytokine concentrations were quantified by ELISA. Cytokine 
concentration in peritoneal fluid (A,D,G) was measured in Hmox1+/+ (n=13 at 6h and n=6 at 12h), 
Hmox1+/- (n=6 at 6h and n=4 at 12h) and Hmox1-/- (n=6 at 6h and n=3 at 12h) mice. Circles represent 
individual mice. (J) Concentration of nitric oxide (NO) in supernatants of peritoneal leukocytes of naïve 
Hmox1+/+ (n=3), Hmox1+/- (n=3) and Hmox1-/- (n=3) mice and stimulates in vitro with bacterial LPS plus 
IFN-γ (48h). Results are shown as mean±SD from one representative experiment using 3 animals 
(*p<0.05). (K) Inducible nitric oxide synthase (iNOS), HO-1 and α-tubulin were detected by western blot 
in peritoneal leukocytes from Hmox1+/+, Hmox1+/- or Hmox1-/- mice, 12h after low-grade CLP. Numbers 
indicate individual mice (n=3 per genotype). Data in (B, C, E, F, H,I) is shown as mean±SD from one 
representative experiment out of three (*p<0.05). 
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Figure 3.3. Hemoglobin, haptoglobin, heme and 
hemopexin during sepsis (A) Hemoglobin and 
haptoglobin plasma concentrations in Hmox1+/+ (n=10), 
Hmox1+/− (n=11), and Hmox1−/− (n=6) BALB/c mice 12 
hours after low-grade CLP. (B) Free heme and HPX 
plasma concentrations in Hmox1+/+ (n=10), Hmox1+/− 
(n=11), and Hmox1−/− (n=6) BALB/c mice, 12 hours after 
low-grade CLP. Circles represent individual mice. Bars 
represent median values. *P<0.05; **P<0.01; 
***P<0.001; ns, not significant. 
3.2 HO-1 prevents free heme from eliciting severe sepsis 
Free heme, the 
substrate of HO-1 
activity, is cytotoxic to red 
blood cells and causes 
hemolysis13. This 
produces cell-free 
hemoglobin and 
eventually more free 
heme14 (that is, heme not 
contained within the 
heme pockets of 
hemoglobin). This 
definition of free heme 
does not preclude the 
association of heme with 
other proteins or lipids in 
a manner that does not control its ability to induce oxidative 
stress11. We asked whether increased mortality of Hmox1−/− mice 
subjected to polymicrobial infection was associated with 
increased hemolysis, as well as with the accumulation of cell-free 
hemoglobin and/or free heme in plasma11. When subjected to 
low-grade CLP, Hmox1−/− mice, but not Hmox1+/+ mice, 
accumulated extracellular hemoglobin (Fig. 3.3 A) and free heme 
in plasma (Fig. 3.3 B), whereas plasma concentrations of the 
hemoglobin-binding protein haptoglobin15 (Fig. 3.3 A) and the 
heme-binding protein hemopexin (HPX)16 were decreased (Fig. 
3.3 B). 
We then asked whether accumulation of free heme in 
plasma contributes to the pathogenesis of severe sepsis. Heme 
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administration to wild-type (Hmox1+/+) mice subjected to low-
grade CLP led to severe sepsis (77% mortality) (Fig. 3.4 A), 
characterized by multiple end stage organ failure, as revealed 
serologically by increased AST, BUN, and CPK plasma 
concentrations (Fig. 3.4 B). Organ damage was confirmed 
histologically (Fig. 3.4 C). Heme administration to naïve wild-type 
(Hmox1+/+) mice, although not lethal per se (0% mortality), 
elicited kidney, but not liver or cardiac, damage (Fig. 3.4 B). 
Heme administration was also not lethal in mice subjected to 
sham laparotomy (0% mortality). Moreover, “iron-free” 
protoporphyrin IX failed to cause organ damage or to precipitate 
severe sepsis when administered to mice subjected to low-grade 
CLP (0% mortality) (Fig. 3.4 A). These observations demonstrate 
that free heme can precipitate the onset of severe sepsis in mice 
subjected to an otherwise benign (nonlethal) polymicrobial 
infection. They also reveal that the kidney is particularly 
vulnerable to the damaging effects of free heme. 
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Figure 3.4. Heme precipitates the development of severe sepsis (A) Survival of Hmox1+/+ BALB/c 
mice after low-grade CLP. When indicated, mice received vehicle (n = 6), protoporphyrin IX (NaPPIX; n 
= 8), or heme (FePPIX; n = 13). Protoporphyrins were administered (15 mg/kg i.p.) at 2, 12, and 24 
hours after CLP. Dotted line shows statistical comparison of vehicle and FePPIX-treated animals. (B) 
Measurement of serum AST, BUN, and CPK. Mice were treated as in (A), and serum biochemistry was 
analyzed 24 hours after low-grade CLP. Data are shown as mean ± SD (eight to nine mice per group). 
IU, international units. (C) Representative examples of H&E staining (magnification, x400) of tissue 
samples taken 24 hours after low-grade CLP from mice that received heme described as in (A). Arrows 
indicate red blood cells (RBC). PV, portal vein; G, glomerulus. Samples are representative results of 
three mice in each group. (F) Bacterial load in the peritoneum and blood of mice (n = 12 per group) 
treated as described in (A), 12 to 24 hours after CLP. Veh, vehicle; Heme, FePPIX. (G) Survival of 
BALB/c wild-type (Hmox1+/+) mice after intraperitoneal administration of a sublethal bolus of heat-killed 
bacteria (E. coli ) followed by heme administration as in (A) (eight mice per group). Circles represent 
individual mice. Bars represent median values. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. 
The number of CFUs in the peritoneum and blood was 
similar in mice subjected to low-grade CLP whether or not they 
received heme thereafter (Fig. 3.4 D). This demonstrated that the 
ability of free heme to precipitate severe sepsis in mice (Fig. 3.4 
A) was not associated with increased pathogen load (Fig. 3.4 D), 
thus revealing that free heme compromised host tolerance 
 96 
against polymicrobial infection. This notion was strongly 
supported by the observation that administration of free heme to 
wild-type (Hmox1+/+) mice subjected to a sublethal dose of heat-
killed bacteria led to 100% mortality, as compared to 12.5% 
mortality in control mice receiving vehicle (Fig. 3.4 E). 
We then asked whether the deleterious effect of free 
heme could be attributed to its previously described action on 
polymorphonuclear (PMN) cells17. The numbers of peritoneal-
infiltrating CD45+CD11b+GR1+ PMN cells in Hmox1−/− mice 
subjected to low-grade CLP were two to threefold higher than 
those in Hmox1+/− and Hmox1+/+ mice (Figs. 3.5 and 3.6, A and 
B). This was not the case for peritoneal natural killer (NK), T, or B 
cells (Fig. 3.6, C to E). Expression of the phagocytic NADPH 
(reduced form of nicotinamide adenine dinucleotide phosphate) 
oxidase gp91phox in peritoneal infiltrating leukocytes was also 
higher in Hmox1−/− versus Hmox1+/+ mice (Fig. 3.5 B). This effect 
was attributed to the increased numbers of PMN cells in 
Hmox1−/− versus Hmox1+/+ mice and was associated with 
enhanced oxidative activity in peritoneal leukocytes from 
Hmox1−/− mice relative to Hmox1+/+ mice (Fig. 3.5, D). Whereas 
heme administration to naïve Hmox1+/+ mice can elicit peritoneal 
PMN cell infiltration (Fig. 3.5 E)17, this effect was negligible when 
heme was administered to mice subjected to low-grade CLP (Fig. 
3.5 E). Although these data suggest that heme-driven PMN cell 
activation does not play a major role in the pathogenesis of 
severe sepsis, we cannot exclude that other putative effects of 
free heme on PMN cells, such as degranulation, might act in a 
detrimental manner to promote the pathogenesis of severe 
sepsis. 
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Figure 3.5. HO-1 modulates PMN cell activation in response to CLP. (A) Number of peritoneal PMN 
(GR1high) cells in naïve BALB/c mice (0h) vs. BALB/c mice subjected to low-grade CLP (6h and 12h). 
Circles represent individual mice and bars are median values for each genotype. Hmox1+/+ (n=7 at 0h, 
n=13 at 6h and n=5 at 12h), Hmox1+/- (n=5 at 0h, n=6 at 6h and n=5 at 12h) and Hmox1-/- (n=7 at 0h, 
n=6 at 6h and n=3 at 12h). Data for each time point was compared by regression analysis across 
genotypes. (B) Expression of the NADPH oxidase gp91phox subunit, HO-1 and 〈-tubulin, determined by 
western blotting in whole cell extracts from peritoneal leukocytes from Hmox1+/+(n=3), Hmox1+/- (n=3) 
and Hmox1-/- (n=3) mice subjected to low-grade CLP (12h). Numbers indicate individual mice. (C) 
Representative plots and histograms for free radical production in peritoneal infiltrating PMN cells 
(CD11b+Ly6Ghigh) and Mø (CD11b+Ly6Glow) from Hmox1+/+ (n=4), Hmox1+/- (n=4) or Hmox1-/- (n=5), 12h 
after low-grade CLP. Free radicals were detected using the broad-spectrum probe CM-H2DCFDA. (D) In 
vitro conversion of purified hemoglobin (Fe[II]) into met-hemoglobin (Fe[III]), determined 
spectrophotometrically after co-incubation of purified hemoglobin (Fe[II]) with peritoneal infiltrating 
leukocytes (3-5.106 cells) isolated from Hmox1+/+, Hmox1+/- or Hmox1-/- mice 12h after low-grade CLP. 
Circles represent data obtained with cells isolated from individual mice and bars are median values for 
each genotype (n=9 per genotype). A regression model was used to compare data across genotypes. 
(E) Number of peritoneal infiltrating PMN (GR1high) cells in BALB/c mice receiving heme (80 nM, i.p.) or 
vehicle (PBS) and subjected or not to low-grade CLP. Peritoneal infiltrates were collected 16h post-CLP. 
Notice that while the production of free radicals was similar in PMN cells and Mø from Hmox1-/- vs. 
Hmox1+/+ mice (C) the net “oxidative power” of peritoneal infiltrating leukocytes was significantly higher 
in Hmox1-/- vs. Hmox1+/+ mice, as assessed in vitro by the oxidation of purified hemoglobin (D). Rather 
than a consequence of increased free radical production in a per-cell basis, this pro-oxidant effect was 
due to the relative increase in the proportion of peritoneal infiltrating PMN cells, i.e. ~75% vs. 55%, in 
Hmox1-/- vs. Hmox1+/+ mice, respectively. ANOVA and t-tests were applied to compare different 
treatment conditions using Bonferroni correction for pairwise comparisons. *P<0.05; **P<0.01; 
***P<0.001; ns: non-significant. 
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Figure 3.6. Infiltrating leukocytes following CLP. Number of (A) 
peritoneal leukocytes, (B) CD11b+ (PMN and Mø), (C) NK cells, 
(D) T cells and (E) B cells were quantified by flow cytometry, 
before (0h) and after (6h and 12h) low grade CLP in Hmox1+/+ 
(n=7 at 0h, n=13 at 6h and n=5 at 12h), Hmox1+/- (n=5 at 0h, n=6 
at 6h and n=5 at 12h) and Hmox1-/- (n=7 at 0h, n=6 at 6h and n=3 
at 12h) mice. Circles represent individual animals. Bars represent 
median values in each genotype. A regression analysis was 
performed to describe CD11b+, NK, and B-cell data. T-cell 
samples did not follow a Normal distribution and was analyzed by 
Kruskal-Wallis and Mann-Whitney tests. *P<0.05; **P<0.01; 
***P<0.001; n: non-significant. 
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Figure 3.7. Red blood cell morphology in mice subjected to CLP. Blood smears from (A) naïve 
BALB/c mice, (B) BALB/c mice 48 h after low-grade CLP or (C) BALB/c mice 48 h after high-grade CLP 
(Giemsa staining, 1000x). Note the appearance of schistocytes (1), acanthocytes (2) and stomatocytes 
(3) as well as “ghost” cells (4), indicative of disseminated intravascular coagulation and hemolysis. 
3.3 Free heme is a 
critical component 
in the 
pathogenesis of 
severe sepsis 
    When subjected 
to high-grade CLP 
(>90% mortality) 
(Fig. 3.8 A), wild-
type (Hmox1+/+) 
mice displayed 
abnormal red blood 
cell morphology 
(poikilocytosis) (Fig. 3.7).  
 This was associated with the accumulation of cell-free 
hemoglobin in plasma (Fig. 3.8 B), compared to mice subjected 
to low-grade CLP (<20% mortality) (Fig. 3.8, A and B). Moreover, 
there was a decrease in haptoglobin plasma concentrations in 
Hmox1+/+ mice subjected to high-grade CLP compared to mice 
subjected to low-grade CLP (Fig. 3.8 C), confirming that 
hemolysis occurs in response to high-grade but not low-grade 
infection. Similarly, the concentration of free heme in plasma 
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increased (Fig. 3.8 D), whereas HPX plasma concentration 
decreased (Fig. 3.8 E), in mice subjected to high-grade relative to 
low-grade CLP. 
 
 
 
 
 
 
 
 
Given that mortality in response to polymicrobial infection 
is associated with high concentrations of free heme and low 
concentrations of HPX in plasma, we hypothesized that one 
might be able to prevent the onset of severe sepsis by restoring 
HPX plasma concentration, so that HPX is available to neutralize 
the rising amounts of free heme. Administration of purified HPX 
to wild-type (Hmox1+/+) mice subjected to high grade CLP 
reduced the mortality level to 22%, compared to 86 and 69% in 
control mice that received phosphate-buffered saline (PBS) (the 
HPX vehicle) or immunoglobulin G (IgG), respectively (Fig. 3.9 
A). The protective effect of HPX was associated with the return of 
liver, kidney, and cardiac function to homeostatic levels, as 
assessed by AST, BUN, and CPK plasma concentrations, 
respectively (Fig. 3.9 B), and as confirmed histologically (Fig. 3.9 
C). In contrast, control mice that received a non–heme-binding 
protein (IgG) after high-grade CLP succumbed to liver, cardiac, 
and kidney failure, as assessed by AST, BUN, and CPK plasma 
concentrations, respectively (Fig. 3.9 B). 
 
  A      B            C     D           E 
              
Figure 3.8. Severe sepsis correlates with increased hemoglobin and heme levels, and with 
decreased haptoglobin and hemopexin levels. (A) Survival of wild-type (Hmox1+/+) BALB/c mice 
subjected to “sham” laparotomy (n = 3), low-grade (LG) (n = 15) CLP, or high-grade (HG) (n = 11) CLP. 
(B to E) Hemoglobin (B), haptoglobin (C), free heme (D), and HPX (E) plasma concentrations in naïve 
(n = 6 to 8) mice or 12 hours after sham laparotomy (n = 10), LG CLP (n = 6), or HG CLP (n = 11 to 12). 
Circles represent individual mice. Bars represent median values. *P < 0.05; **P < 0.01; ***P < 0.001; ns, 
not significant. 
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3.4 Free heme elicits programmed cell death 
We have previously shown that free heme can promote 
programmed cell death in response to TNF8. We asked whether 
this effect is extended to other agonists involved in the 
pathogenesis of severe sepsis. Because hepatic failure is a 
central component of severe sepsis, we tested whether free 
heme induces oxidative stress and TNF-mediated programmed 
cell death in primary mouse hepatocytes in vitro. When exposed 
to free heme, hepatocytes did not produce significant amounts of 
intracellular free radicals, as assessed by flow cytometry with a 
broad free radical probe (Fig. 3.10 A). However, when exposed 
to free heme and TNF (Fig. 3.10 A)8 or free heme plus Fas cross-
linking (which activates the Fas signaling transduction pathway), 
hepatocytes produced large amounts of intracellular free radicals 
(Fig. 3.10 A). This effect was not observed when hepatocytes 
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Figure 3.9. Free heme promotes the pathogenesis of severe sepsis. (A) Survival of Hmox1+/+ 
BALB/c mice subjected to high-grade CLP. Mice received purified rabbit HPX (50mg/kg i.p.; n = 9), 
purified rabbit polyclonal IgG (50 mg/kg i.p.; n = 16), or vehicle (i.p., PBS; n = 7) at 2, 12, 24, and 36 
hours after CLP. (B) Serological markers of organ injury in mice treated as in (A). Measurements were 
made in serum from IgG-treated mice at the time of death (36 hours) and in HPX-treated mice at the 
end of the experiment (day 11). Results shown are the mean ± SD (n=5 to 6 mice per group). (C) 
Representative H&E staining (magnification, x400) in mice treated as in (A). Samples are representative 
of three mice. CV, coronary vessel; G, glomerulus. M, myocardium. Samples are representative results 
of three mice in each group. HPX-treated mice in (B) and (C) were analyzed 11 days after CLP. Control 
IgG-treated mice in (B) and (C) were analyzed 24 to 36 hours after CLP (time of death). *P < 0.05; **P < 
0.01; ***P < 0.001; ns, not significant. 
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were exposed to free heme and oxidizing agents such as 
hydrogen peroxide (H2O2) or peroxynitrite (ONOO−), which are 
sufficient to cause free radical accumulation in hepatocytes (Fig. 
3.10 A). Primary hepatocytes did not undergo programmed cell 
death when exposed to TNF, Fas cross-linking, H2O2, or ONOO− 
(Fig. 3.10 B)8, whereas programmed cell death was readily 
induced in cells treated with free heme first and then TNF, Fas 
cross-linking, H2O2, or ONOO− (Fig. 3.10 B). These observations 
suggest that the redox activity of the heme Fe atom underlies its 
cytotoxicity, presumably by catalyzing the production of free 
radicals through Fenton chemistry12. Consistent with this 
hypothesis, the antioxidant N-acetyl-cysteine (NAC) protected 
hepatocytes from programmed cell death in the presence of free 
heme and TNF, Fas ligand, H2O2, or ONOO− (Fig. 3.10 B). These 
observations reveal that the pathological effects of free heme, 
namely, its ability to synergize with other cytotoxic agonists to 
cause tissue damage, can be extended to a variety of agonists 
other than TNF11, including some previously implicated in the 
pathogenesis of severe sepsis. 
Transduction of hepatocytes with a recombinant 
adenovirus (Rec.Ad.) that expresses HO-1 (Fig. 3.10 D) was 
protective against programmed cell death in the presence of free 
heme and TNF, Fas cross-linking, H2O2, or ONOO−, when 
compared with control hepatocytes transduced with a Rec.Ad. 
that expresses LacZ (Fig. 3.10 C). We have previously shown 
that the cytoprotective effect of HO-1 is associated with inhibition 
of free radical production8, suggesting that HO-1 acts as an 
antioxidant to suppress the cytotoxic effects of free heme8. 
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3.5 Heme triggers HMGB1 release in vitro and in vivo 
We reasoned that the cytotoxic effect of free heme might 
precipitate severe sepsis by eliciting tissue damage per se, as 
well as by promoting the release of high mobility group box 1 
(HMGB1), an endogenous proinflammatory ligand18 involved in 
the pathogenesis of severe sepsis19 and previously linked to HO-
120. In untreated primary hepatocytes, HMGB1 expression was 
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hours). Cell viability was determined by crystal violet staining. (C) Percentage of cell death in 
primary hepatocytes treated as in (A). When indicated (+), hepatocytes were transduced with a 
LacZ- or Hmox1-encoding Rec.Ad. Cell viability was determined as in (B). Data are representative of 
three independent experiments with hepatocytes isolated from different mice. Bars indicate mean ± 
SD of n = 5 to 6 independent samples per group. *P < 0.05; **P < 0.01; ***P < 0.001. 
Figure 3.10. The oxidative effect of free heme sensitizes 
hepatocytes to programmed cell death. (A) Primary BALB/c 
hepatocytes were either left untreated (NT) or exposed to heme (5 
µM, 1 hour) plus mouse recombinant TNF (5 ng/ml, for 16 hours), 
antibody against Fas (0.5 mg/ml, for 4 hours), H2O2 (125 mM, for 8 
hours), or the ONOO− donor SIN-1 (100 mM, for 24 hours). 
Production of free radicals was determined by flow cytometry with 
CM-H2DCFDA. 2nd signal refers to TNF, antibody against Fas, H2O2, 
or ONOO−, as specified for each panel. (B) Percentage of cell  death   
in   primary    hepatocytes treated as in (A). When indicated (+), 
hepatocytes were pretreated with the antioxidant NAC (10 mM, for 4 
hours). Cell viability 
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mainly restricted to the nucleus (Fig. 3.11 A). However, when 
hepatocytes were exposed in vitro to free heme plus TNF, 
HMGB1 was translocated from the nucleus to the cytoplasm (Fig. 
3.11 A) and released extracellularly (Fig. 3.11 B). This was not 
the case when hepatocytes were exposed to either free heme or 
TNF alone (Fig. 3.11, A and B). Extracellular HMGB1 release 
was suppressed by the antioxidant NAC (Fig. 3.11 C), as well as 
by HO-1 overexpression (Fig. 3.11 D). These observations reveal 
that the oxidative effect of free heme promotes HMGB1 release 
from hepatocytes, an effect suppressed by HO-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next, we asked whether HO-1 would prevent HMGB1 
release from damaged tissue in vivo18, as suggested in previous 
studies20. In Hmox1−/− mice subjected to low-grade CLP there 
was translocation of HMGB1 into the cytoplasm, as assessed in 
the liver and kidney (Fig. 3.12 C), whereas translocation was less 
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Figure 3.11. Free heme triggers the release of HMGB1 from hepatocytes in vitro. (A) HMGB1 (red) 
and DNA (blue) in mouse Hepa1-6 hepatocytes exposed to vehicle (Non treated), free heme (40 µM, for 
1 hour), TNF (50 ng/ml, for 3 hours), or heme (40 µM, for 1 hour) plus TNF (50 ng/ml, for 3 hours). 
Magnification, x400. Images are representative of three independent experiments. One nucleus per field 
is outlined (dotted line). (B) HMGB1 was measured by Western immunoblotting of proteins in the 
supernatants of primary mouse (BALB/c) hepatocytes that were exposed to heme (5 µM, for 1 hour) and 
TNF (5 ng/ml, for 16 hours) in culture. A representative result from two independent experiments is 
shown. NS, nonspecific band. (C) HMGB1 was measured by Western immunoblotting of proteins in the 
supernatants of mouse Hepa1-6 hepatocytes exposed to heme and TNF as described in (A). When 
indicated, cells were pretreated with the antioxidant NAC (10 mM; for 4 hours). A representative result 
from two independent experiments is shown. (D) HMGB1 was measured by Western immunoblotting of 
proteins in the supernatants of mouse Hepa1-6 hepatocytes treated with heme and TNF as in (A) and 
either transduced or not transduced with LacZ or Hmox1 Rec.Ad. Blots are representative of two 
independent experiments. 
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pronounced in wild-type (Hmox1+/+) mice (Fig. 3.12 C). This effect 
was associated with the systemic release of HMGB1 into the 
peritoneum and plasma of Hmox1−/− relative to Hmox1+/+ mice 
(Fig. 3.12, A and B). The relative amount of peritoneal or plasma 
IgG was unchanged in Hmox1−/− versus Hmox1+/+ mice (Fig. 
3.12, A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
3.6 HPX neutralizes the cytotoxic effect of free heme 
We next sought to determine whether HPX, which binds 
tightly to heme (Kd <1 pM) in a manner that dampens its pro-
oxidant activity21, can also prevent heme-induced tissue damage 
(Fig. 3.9, A to C)16. The ability of free heme to sensitize 
hepatocytes in vitro such that they produced high amounts of free 
radicals in response to TNF was inhibited when heme was bound 
to HPX (Fig. 3.13 A). Moreover, the ability of free heme to 
sensitize hepatocytes to undergo programmed cell death in 
response to TNF was also inhibited once heme was bound to 
HPX (Fig. 3.13 B). Similar results were obtained with primary 
human hepatocytes in that HPX prevented heme sensitization to 
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Figure 3.12. Free heme triggers the release of 
HMGB1 in vivo  (A and B) HMGB1 and Ig heavy 
chain (IgG) were detected by Western blot in the 
peritoneal cavity (A) or plasma (B) of Hmox1+/+, 
Hmox1+/−, or Hmox1−/− mice 12 hours after low-
grade CLP. Numbers indicate individual animals 
(n=3 per genotype). (C) HMGB1 staining in the liver 
and kidney from Hmox1+/+ and Hmox1−/− mice 24 
hours after CLP. One of three representative 
samples are shown. Samples were counterstained 
with hematoxylin. Magnification, x400. Arrows 
indicate representative nuclei from which HMGB1 
underwent full translocation from the nucleus to the 
cytoplasm and extracellular space. 
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Figure 3.13. HPX suppresses the cytotoxic effect of free heme in vitro. (A) Primary BALB/c 
hepatocytes were left untreated (NT) or exposed to heme (5 µM) or HPX-heme complexes (5 µM, for 1 
hour) and TNF (5 ng/ml, for 16 hours). Production of free radicals was determined by flow cytometry 
with the broad free radical probe CM-H2DCFDA. (B) Primary BALB/c hepatocytes were treated as in (A), 
exposed to heme (5 µM), HPX (5 µM), or heme-HPX complexes (5 µM, for 1 hour) and, when indicated, 
to TNF (5 ng/ml; for 16 hours). Cell viability was determined by crystal violet staining. Results shown are 
the mean ± SD from six samples in one of two independent experiments with hepatocytes pooled from 
three mice. (C) Primary human hepatocytes were exposed to heme (10 µM; 1 hour) or heme-HPX 
complexes (10 µM, 1 hour), and then to TNF (10 ng/ml, 8 hours). Cell viability was determined by crystal 
violet staining. Results shown are the mean ± SD from six samples in one experiment representative of 
four independent experiments. (D) HMGB1 was measured by Western blotting of proteins in the 
supernatants of primary mouse (BALB/c) hepatocytes treated as in (A). Blots are representative of two 
independent experiments. (E) HMGB1 measured by Western blotting in the supernatants of primary 
human hepatocytes treated as in (C). 
programmed cell death in response to TNF (Fig. 3.13 C). 
Accordingly, HPX-bound heme also failed to promote HMGB1 
release from primary mouse hepatocytes in vitro (Fig. 3.13 D). 
Similarly, HPX-bound heme also failed to promote HMGB1 
release from primary human hepatocytes in response to TNF 
(Fig. 3.13 E). The increased molecular weight of the cell-free 
HMGB1 released from primary human hepatocytes is most likely 
attributed to posttranslational HMGB1 modifications, such as 
phosphorylation. Together, these observations suggest that HPX 
suppresses the cytotoxic effects of free heme in both mouse and 
human hepatocytes. 
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3.7 Low HPX serum concentration is associated with organ 
dysfunction and fatal outcome in septic shock patients 
Given that HPX plasma concentration is reduced in mice 
that succumb to severe sepsis (Fig. 3.8 E), we asked whether 
this would also be the case in patients that succumb to septic 
shock22. In a cohort of 52 patients (table 3.1), HPX serum 
concentration within 48 hours of presentation with septic shock 
was positively associated with patient survival time (Fig. 3.14 A). 
That is, patients with lower HPX serum concentrations 
succumbed at earlier time points compared to patients with 
higher HPX serum concentrations (Fig. 3.14 A). This observation 
allowed us to extrapolate the probability of survival/mortality as a 
function of HPX serum concentration (Fig. 3.14 B), in keeping 
with the observation that HPX serum concentration within 48 
hours of septic shock diagnosis was higher in patients that 
survived septic shock compared to nonsurvivors (Fig. 3.14 C). 
Finally, there was an inverse correlation between HPX serum 
concentration and severity of organ dysfunction, as defined by 
the sequential organ failure assessment (SOFA) score23 (table 
3.2). Overall, these observations support the notion that HPX 
serum concentration defines the extent of tissue damage (organ 
dysfunction) and hence the outcome of septic shock in humans. 
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  N=52 % 
Age (years) 69 (51-82) - 
Gender (female/male) 24/28 46/54 
Surgical admission 37 71 
SAPS II score (points) 52.5 (45-60) - 
SOFA score on day 1 (points) 9 (6-11) 17 
Positive microbiological cultures 34 65 
28-day mortality 18 35 
Hospital morality 28 54 
Table 3.1: Characteristics of septic shock patients. Severity of organ 
dysfunction was defined using the Sequential Organ Failure Assessment 
(SOFA) score. Ranges are indicated between brackets. 
 
 
 
Days Survivors Nonsurvivors 
1 -0.33 (p=0.26) -0.41 (p=0.08) 
2 -0.40 (p=0.20) -0.13 (p=0.61) 
3 -0.10 (p=0.75) -0.58 (p=0.048) 
5 -0.63 (p=0.051) -0.93 (p=0.002) 
7 -0.63 (p=0.051) -0.58 (p=0.08) 
Table 3.2: Correlations between HPX serum concentration and SOFA. The 
correlations are based on Spearman coefficient calculated between HPX and 
SOFA at the days indicated. P-values are given in parentheses. 
 
A            B   C 
               
Figure 3.14. HPX levels correlate with the outcome in human septic shock patients. (A) Survival 
time (see Materials and Methods) of patients developing septic shock versus prediction of best-fitted 
model. The solid line refers to the expected median survival time as a function of HPX serum 
concentration at the time of septic shock diagnosis, predicted by the best model for survival time (based 
on lognormal distribution). Gray circles represent individuals that succumbed during hospitalization 
(nonsurvivors). White circles represent individuals that survived septic shock and left the hospital at the 
times indicated. P < 0.05 for the respective effect. (B) Expected mortality probability at day 28, plotted 
as a function of HPX serum concentration at the time of septic shock diagnosis, predicted by the best 
model for survival time (based on lognormal distribution). (C) Box plot representation of HPX serum 
concentration at the time of septic shock diagnosis in a cohort of 52 patients, including survivors (n = 34) 
and nonsurvivors (n=18).Data represent mean [interquartile range (IQR), 25 to 75%]. *P< 0.05. 
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4. DISCUSSION 
  
An infected host has two distinct evolutionarily conserved 
defense strategies that limit disease severity. The best 
characterized of these two strategies relies on the capacity of the 
host immune system to contain and reduce its pathogen load. 
This defense strategy is referred to as host resistance to 
infection6. The other defense strategy acts irrespective of 
pathogen load and relies instead on limiting tissue damage 
caused directly or indirectly by the pathogen and/or by the 
immune response elicited by that pathogen. This defense 
strategy, referred to as host tolerance to infection6, has long been 
recognized in plants5, but only more recently in flies6 and mice24. 
Blood-borne pathogens can cause hemolysis25 and hence 
lead to accumulation of extracellular hemoglobin in circulation. 
Oxidation of cell-free hemoglobin can be highly deleterious to the 
host in at least three ways. First, it can exacerbate 
inflammation26. Second, it can release heme (Figs. 3.3, A and B, 
and 3.8 D)14, a putative source of iron that can promote microbial 
growth27. Third, as shown herein, free heme can be highly 
cytotoxic in the presence of proinflammatory agonists (Fig. 3.10 
B)11, causing irreversible tissue damage and organ failure (Fig. 
3.4, B and C), the hallmarks of severe sepsis2. 
That heme-driven tissue damage can contribute to the 
pathogenesis of severe sepsis is suggested by four independent 
lines of evidence. First, exacerbated mortality of Hmox1−/− mice 
subjected to microbial infection (Fig. 3.1B) correlated with the 
accumulation of free heme in the plasma (Fig. 3.3 B). Second, 
administration of free heme to wild-type (Hmox1+/+) mice 
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subjected to low-grade (nonlethal) microbial infection was 
sufficient to elicit a lethal form of severe sepsis (Fig. 3.4 E). Third, 
free heme accumulated in the plasma of wild-type (Hmox1+/+) 
mice subjected to high-grade (lethal), but not low-grade, 
microbial infection (Fig. 3.8 D). Fourth, sequestration of free 
heme by HPX suppressed the development of severe sepsis in 
wild-type (Hmox1+/+) mice subjected to high-grade microbial 
infection (Fig. 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are a number of cytoprotective mechanisms 
against the deleterious effects of free heme8,11,16,28. These include 
the plasma protein HPX, which binds free heme and neutralizes 
 
Figure 3.15. Role of free heme in the pathogenesis of severe sepsis. The 
pathogenesis of severe sepsis is associated with hemolysis, which involves the release 
of hemoglobin (Hb) from red blood cells (RBC). Oxidation of cell-free Hb leads to the 
release of its prosthetic heme groups. This pathological event can be prevented by the 
acute-phase protein haptoglobin (HPT), whereas free heme can be captured by the 
acute-phase protein HPX. Once the concentration of HPT and/or HPX in serum 
decreases below a certain threshold level, free heme accumulates in plasma and can 
sensitize cells in parenchymal tissues to undergo programmed cell death in response to 
a variety of proinflammatory agonists. This leads to the release of endogenous 
proinflammatory ligands from damaged tissues, for example, HMGB1. Expression of the 
stress-responsive enzyme HO-1 in parenchymal cells affords cytoprotection against free 
heme, thus suppressing tissue damage and ultimately multiple-organ dysfunction/failure. 
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its oxidative (Fig. 3.13 A) and hence cytotoxic (Fig. 3.13, B and 
C) effects16 (Fig. 3.15). As shown, the lethal outcome of severe 
sepsis in mice (Fig. 3.8 E) and septic shock in humans is 
associated with decreased concentration of circulating HPX (Fig. 
3.14 A). Therefore, we reasoned that administration of 
exogenous HPX might be used therapeutically to increase 
tolerance to infection and hence prevent the development of 
severe sepsis in mice, which we found to be the case (Fig. 3.9, A 
to C). It is likely that a similar approach will translate into the 
treatment of severe sepsis in humans, given the observation that 
low concentrations of circulating HPX are associated with septic 
shock lethality in humans as well (Fig. 3.14, A to C). One cannot 
exclude at this point that in addition to preventing the cytotoxic 
effects of free heme, HPX29 might exert anti-inflammatory effects 
that contribute to its protective effect. 
The salutary effect of HPX most probably requires the 
expression of HO-1 to catabolize HPX-bound heme (Fig. 3.15). 
This would explain why, despite the presence of HPX, HO-1–
deficient (Hmox1−/−) mice are highly susceptible to immune-
mediated inflammatory diseases30, including endotoxic shock31 
and polymicrobial infection10 (Fig. 3.1 B), in which lack of 
adequate HPX-bound heme catabolism leads to irreversible 
tissue damage, end-stage organ dysfunction, and eventually to 
death32,33. 
The protective effect of HO-1 against polymicrobial 
infection has previously been attributed to the antimicrobial 
activity of carbon monoxide10, one of the end products of heme 
catabolism carried out by HO-19. This would suggest that HO-1 
affords some level of resistance against polymicrobial infection. 
Two independent lines of evidence support the notion that HO-1 
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also affords tolerance against polymicrobial infection: first, mice 
that can induce the expression of HO-1 (Hmox1+/+) in response to 
polymicrobial infection (Fig. 3.1 A) survive (Fig. 3.1 B) when 
subjected to the same pathogen load (Fig. 3.1 E) that kills 
Hmox1−/− mice (Fig. 3.1 B). Second, Hmox1−/− but not Hmox1+/+ 
mice succumb to death even when challenged with heat-killed 
bacteria (Fig. 3.1 F)31,33. These observations provide mechanistic 
evidence for the proposed protective effect of HO-1 expression in 
the outcome of severe sepsis and septic shock34. 
The mechanism by which HO-1 affords tolerance against 
microbial infections relies to a large extent on its ability to 
suppress the deleterious effect of free heme (Fig. 3.10, A and B) 
produced during the course of infection (Figs. 3.8 D and 3.15). 
This notion is strongly supported by the observation that HO-1 
protected mouse cells from the cytotoxic effects of free heme 
(Fig. 3.10 C), and should prevent irreversible tissue damage, 
multiple organ dysfunction, and host death (Fig. 3.1, C and D). 
Because this protective effect of HO-1 does not interfere with 
pathogen load (Fig. 3.1 E), we conclude that HO-1 promotes, 
whereas extracellular heme compromises, host tolerance to 
polymicrobial infection. 
The findings from the studies reported here potentially 
can be translated into several clinical applications for monitoring 
and treatment of sepsis. In the clinical setting, monitoring the 
patients’ levels of circulating heme and/or HPX might be used to 
predict the likelihood of a fatal outcome in each case of severe 
sepsis (Fig. 3.16 B). In addition, the development of strategies 
that mitigate the deleterious effects of free heme might also be 
used therapeutically to prevent the all-too-common lethal 
outcome of severe sepsis. 
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5. METHODS 
 
Mice and genotyping 
BALB/c, BALB/c.SCID, BALB/c.Hmox1+/−, and 
BALB/c.SCID.Hmox1+/− mice were maintained under specific 
pathogen-free conditions according to the Animal Care 
Committee of the Instituto Gulbenkian de Ciência. All animal 
protocols were approved by the “Direcção Geral de Veterinária” 
of the Portuguese government. BALB/c.Hmox1+/− mice were 
generated originally by S. F. Yet (Pulmonary and Critical Care 
Division, Brigham and Women’s Hospital, Boston, MA) by 
disruption of exon 3 in the Hmox1 locus35. Mice were 
backcrossed 10 times into the BALB/c background. 
Heterozygous (Hmox1+/−) breeding pairs yield ~8% viable and 
otherwise healthy Hmox1-/- mice35. Littermate Hmox1-/+ and 
Hmox1+/+ mice were used as controls. Mice were genotyped by 
PCR. Briefly, a 400–base-pair (bp) PCR product spanning the 5′ 
flanking region of the neomycin complementary DNA (cDNA) in 
the Hmox1 locus was amplified from genomic DNA with the 
following primers: 5′-TCTTGACGAGTTCTTCTGAG-3′ and 5′-
ACGAAGTGACGCCATCTGT-3′ 35. For the endogenous Hmox1 
locus, 5′-GGTGACAGAAGAGGCTAAG-3′ and 5′-
CTGTAACTCCACCTCCAAC-3′ primers were used to amplify a 
456-bp product. PCRs were repeated at least two times before 
experiments were performed and were carried out after 
experiments to confirm genotypes. 
 
Cell culture 
Primary mouse peritoneal leukocytes were obtained by 
peritoneal lavage with ice-cold apyrogen PBS (Sigma). Briefly, 
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leukocytes were washed in PBS and resuspended in RPMI 1640 
Glutamax I (Gibco) supplemented with 5% fetal bovine serum, 
penicillin (50 U/ml), and streptomycin (50 mg/ml) (Life 
Technologies). For cytokine measurements, cells (2.5x104) were 
plated in flat-bottom 96-well microtiter plates (Techno Plastic 
Products AG) (100 µl, 2 hours, 37°C); nonadherent cells were 
removed, and adherent cells, that is, Mø, were activated with 
bacterial LPS (Sigma, Escherichia coli serotype 0127:B8) for 6 or 
24 hours. Bone marrow cells were incubated for 6 days in RPMI 
1640 Glutamax I (Gibco), 10% fetal calf serum, 30% L929 
supernatant [as macrophage colony-stimulating factor (M-CSF) 
source]. The bone marrow-derived macrophages (BMDMs) were 
seeded (16 hours) in six-well plates (3x105 cells per well) in 
RPMI, 3.3% FCS, and 5% L929 supernatant. BMDMs were 
incubated with live Gram-positive (Enterococcus subsp. isolated 
from mouse intestine) or Gram-negative (E. coli DH5a) bacteria 
(8 hours), after which cell culture supernatant was collected and 
centrifuged (5 min, 1200 rpm, 4°C) to remove cells and bacteria 
(5 min, 10.000 rpm, 4°C). Cell-free supernatants were stored at 
−80°C until use. Hepa1-6 cells (C57BL/6 mouse hepatoma; 
American Type Culture Collection) were seeded in DMEM 
(Invitrogen), 10% FCS, penicillin, and streptomycin (20 U/ml, 
Invitrogen). All cells were incubated at 37°C, 95% humidity, and 
5% CO2. 
 
Protoporphyrins 
Heme (iron protoporphyrin; FePPIX; Frontier Scientific) 
and protoporphyrin IX (protoporphyrin IX disodium salt; NaPPIX; 
Frontier Scientific) were dissolved in 0.2 M HCl, and pH was 
adjusted to 7.4 with sterile 0.2 M NaOH. 
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Primary hepatocytes 
Primary mouse hepatocytes were isolated as described36. 
Briefly, livers from naïve BALB/c mice were perfused through the 
portal vein (5 ml/min, 10 min, 37°C) with liver perfusion medium 
(Invitrogen), and the tissue was disrupted. Cells were filtered 
(100 µm), washed (William’s E medium; 4% FCS) (Invitrogen), 
pelleted (100g, 30s, 20°C), and resuspended (William’s E 
medium, 4% FCS). Hepatocytes were isolated in a Percoll 
gradient (1.06/1.08/1.12 g/ml; 750g, 20 min, 20°C) (GE 
Healthcare), resuspended (William’s E medium; 4% FCS), 
centrifuged (2x200g, 10 min, 4°C), resuspended (William’s E 
medium; 4% FCS), and seeded onto gelatin (0.2%)–coated 
plates. The medium was replaced after 4 hours, and experiments 
were performed 24 to 48 hours thereafter. Primary human 
hepatocytes were cultured in hepatocytes culture medium as 
detailed by the supplier (Lonza). 
 
Heme sensitization assays 
Hepatocytes were seeded and exposed to heme (5 mM, 1 
hour) in Hanks’ Balanced Salt Solution (Invitrogen) without serum 
to avoid potential heme scavenging by serum proteins, as 
described8. Subsequently, hepatocytes were washed (PBS) and 
challenged in Dulbecco’s modified Eagle’s medium, 10% FCS 
(Hepa1-6), or 4% FCS (primary hepatocytes), with human 
recombinant TNF (5 to 40 ng/ml, 3 to 16 hours; R&D Systems), 
Fas ligand (Jo2 antibody against CD95, 0.5 mg/ml, 4 hours; BD 
Biosciences), H2O2 (125 mM, 8 hours; Sigma), or 3- 
morpholinosydnonimine (SIN-1; 100 mM, 24 hours; Sigma). Cell 
viability was assessed by crystal violet assay, as described37. 
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Heme (FePPIX; Frontier Scientific) was dissolved in sterile 0.2 M 
NaOH at alkaline pH and adjusted to pH 7.4 with sterile 0.2 M 
HCl. Iron-free protoporphyrin (NaPPIX, Frontier Scientific) was 
dissolved in sterile 0.2 M HCl at acidic pH, and pH was adjusted 
to 7.4 with sterile 0.2 M NaOH. Aliquots were stored at −80°C 
until use. 
 
Cytokines and NO measurements 
TNF, IL-6 and IL-10 were quantified by enzyme-linked 
immunosorbent assay (ELISA) according to the manufacturer’s 
instructions (Becton Dickinson). NO was measured with a Griess 
colorimetric assay38. 
 
CLP 
CLP was performed as described elsewhere39,40. Briefly, 
mice were anesthetized [ketamine (120 mg/kg)/xylazine (16 
mg/kg) (i.p.)]. Under sterile conditions, a 1-cm incision was made 
parallel to the midline, and the cecum was exteriorized and 
ligated (sterile 3-0 Mersilk sutures; Ethicon) immediately distal to 
the ileocecal valve (reducing the lumen by 50 to 60% for low-
grade CLP and 80 to 90% for high-grade CLP). The cecum was 
punctured once with a 23-gauge needle (low-grade CLP) or twice 
with a 21-gauge needle (high-grade CLP) and its content was 
extruded by applying pressure and reinserted into the abdominal 
cavity. The peritoneal wall was sutured with sterile 3-0 Dafilon 
sutures (Braun) and the skin was closed with a surgical staple 
(Autoclip 9 mm; Becton Dickinson). A single dose of saline was 
injected subcutaneously (1 ml per animal) for fluid resuscitation. 
After the surgical procedure, animals were maintained at 37°C 
(30 min) and received antibiotics intraperitoneally 
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(imipenemcilastatin, Tienam, MSD; 0.5 mg per animal) 2 hours 
after the surgical procedure and every 12 hours during 72 hours. 
 
Colony-forming units  
Peritoneal fluid was obtained by peritoneal lavage with 5 
ml of sterile PBS (Sigma). Organs were weighed and 
homogenized under sterile conditions in 0.5 ml of PBS with 
Dounce tissue grinders (Sigma). Serial dilutions of blood, 
peritoneal lavage, and homogenized organs were immediately 
plated on Trypticase Soy Agar II plates supplemented with 5% 
Sheep Blood (Becton Dickinson). CFUs were counted after 24 
hours of incubation at 37°C. 
 
cDNA synthesis and LightCycler analysis 
Total RNA was extracted with RNeasy Protect Mini Kit 
(Qiagen) and reverse-transcribed (SuperScriptII RNase H− 
reverse transcriptase; Invitrogen) with random hexamer primers 
(Invitrogen) as follows: 70°C for 10min, 37°C for 50 min, and 
95°C for 5min (RoboCycler Stratagene). HO-1 primers are 5′-
TCTCAGGGGGTCAGGTC-3′ (forward) and 5′-
GGAGCGGTGTCTGGGATG-3′ (reverse). The reaction was 
carried out with 1 µl of cDNA and 3 pmol of each primer, 2 mM 
MgCl2, and 1X FastStartDNASYBR Green I mix (Roche). The 
thermal cycler program was composed of 1 cycle at 95°C for 
10min, 45 cycles at 95°C for 15s, 58°C for 5s, and 72°C for 16s, 
with transition rates of 20°C/s. PCR products were quantified by 
LightCycler Real-Time quantitative PCR software (Roche). Cycle 
numbers in the log-linear phase were plotted against the 
logarithm of template DNA. External standardization was 
 117 
performed with full-length HO-1 cDNA. Hypoxanthine-guanine 
phosphoribosyl-transferase (HPRT) was used to normalize cDNA 
levels41. 
 
Flow cytometry 
Leukocytes were washed and blocked in calcium- and 
magnesium-free PBS containing 2% FCS (v/v). After incubation 
(30min, 4°C) with fluorochrome-conjugated monoclonal 
antibodies directed against CD11b (clone M1/70), IAd (clone 
AMS-32.1), GR1 (clone RB6-8C5), Ly6G (clone 1A8), CD49b 
(clone DX5), α/β TCR (clone H57-597), or CD19 (clone 1D3) (BD 
Biosciences, Pharmingen), cells were washed twice with PBS 
and 2% FCS (v/v) and acquired in a FACScan or FACSCalibur 
with CellQuest software (BD Biosciences). Dead cells were 
excluded from the analysis with propidium iodide. Analysis was 
done with FlowJo software (Tree Star Inc.). Cellular free radical 
generation was determined by incubating cells (10 mM, 15 min, 
37°C, 95% humidity, 5%CO2) with the broad free radical probe 5-
(and 6)-chloromethyl-2′7′-dichlorodihydrofluoscein diacetate 
acetyl ester (CM-H2DCFDA; Molecular Probes). 
 
Immunofluorescence 
Hepa1-6 cells, seeded and treated (as described above) 
on glass cover slips (Paul Marienfeld GmbH & Co.), were fixed 
(4% paraformaldehyde, 30 min), permeabilized (0.1% Triton X-
100, 20 min), blocked (PBS, 10% goat serum, 20 min), and 
incubated overnight at 4°C with rabbit antibody against human 
HMGB1 (Abcam, ab18256; 0.5 mg/ml) or control rabbit IgG 
(Sigma) in PBS and 10% goat serum. Alexa 568–conjugated 
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goat antibody against rabbit IgG (5 mg/ml; Invitrogen) was used 
as secondary antibody. Nuclear DNA was stained with Hoechst 
33342 (10 mg/ml, PBS, 20 min; Invitrogen), and cells were 
mounted in Vectashield (Vector Laboratories). Images were 
captured with a fluorescence microscope (Leica, DMRA2) 
equipped with UV light and Evolution MP 5.0 Color Camera 
(Media Cybernetics). Images were analyzed with ImageJ 
software (National Institutes of Health). 
 
Histology and immunohistology 
Tissue samples were processed and stained essentially 
as described42. HMGB1 was detected in paraffin-embedded, 
formalin-fixed sections (5 µm) after microwave antigen retrieval 
[0.01 M citrate buffer (pH 6.0) 20 min] with rabbit antibody 
against human HMGB1 (Becton Dickinson, 556528) (0.5 mg/ml, 
4°C, overnight). Rabbit IgG was detected with biotin-conjugated 
donkey antibody against rabbit secondary antiserum (1:1000; 
Jackson Immunoresearch) and streptavidin conjugated 
horseradish peroxidase amplification kit (Vectastain Elite ABCKit, 
Vector Labs). Signal was revealed with 3,3′-diaminobenzidine 
(DAB). Sections were counterstained with Harris hematoxylin. 
Negative controls were performed by omitting the primary 
antibody or with a nonspecific rabbit polyclonal antibody. Images 
were obtained and analyzed as described above. 
 
Serum biochemistry 
Blood was collected in tubes with heparin after cardiac 
puncture, centrifuged (2x5 min, 1600g). AST, BUN, and CPK 
were measured according to the protocols of the International 
Federation of Clinical Chemistry, as described43-45, by 
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spectrophotometric analysis (modular DP; Roche-Hitachi, 
Echevarne Laboratories). Plasma HPX and haptoglobin were 
determined by ELISA (Life Diagnostics). Plasma hemoglobin was 
determined by spectroscopy at a wavelength of 577 nm (l577). 
Total plasma heme was measured with the 3,3′,5,5′ 
tetramethylbenzidine (TMB) peroxidase assay (BD Biosciences) 
at l655. Purified hemoglobin was used as standard for plasma 
hemoglobin and heme measurements. Blood smears were fixed 
in methanol and stained with Giemsa stain, and images were 
obtained and analyzed as described above. 
 
HPX 
Intact apo-HPX was isolated from rabbit serum as 
described46. Purified HPX binds heme as assessed by 
absorbance and circular dichroism spectroscopy of the 
apoprotein or the oxidized and reduced heme-HPX complexes; 
the concentration of the protein and equimolar heme binding 
were quantified with published procedures and extinction 
coefficients47. Neither the apo-HPX nor the heme-HPX complex 
is toxic for cells in vitro even at high concentrations48. Mice 
received purified HPX (50 mg/kg i.p.) at 2, 12, 24, and 36 hours 
after CLP. 
 
Western blotting 
Proteins were prepared and subjected to electrophoresis 
essentially as described before49. For HMGB1 detection in 
peritoneal fluid and in serum, samples were ultrafiltered with 
Centricon 100 columns (Millipore) and precipitated with 
trichloroacetic acid (TCA), washed twice in acetone, dried, 
dissolved in urea (8 M), and added to SDS–polyacrylamide gel 
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electrophoresis (SDS-PAGE) loading buffer. Primary hepatocyte 
and Hepa1-6 culture supernatants were concentrated on 
Vivaspin 500 columns (10-kD molecular mass cutoff; Vivascience 
AG) resulting in up to ~10-fold concentration. HMGB1 was 
detected with polyclonal antibody (Abcam, ab18256; 0.1 mg/ml). 
HO-1 was detected with a rabbit polyclonal antibody against 
human HO-1 (1:2.500; SPA-895, StressGen). Monoclonal 
antibodies were used to detect α-tubulin (T9026, 1:5.000 dilution; 
Sigma) and inducible NO synthase (Becton Dickinson). Primary 
antibodies were detected with horseradish peroxidase–
conjugated donkey antibody against rabbit, goat antibody against 
mouse, or rabbit antibody against mouse IgG secondary 
antibodies (Pierce, Rockford). Peroxidase activity was visualized 
with the SuperSignal chemiluminescent detection kit (Pierce) 
according to the manufacturer’s instructions and stored in the 
form of photoradiographs (BiomaxTMMS, Eastman Kodak) or 
with the Image Station 440CF (Kodak). Digital images were 
obtained with an image scanner equipped with Adobe Photoshop 
software. 
 
Septic shock patients 
We analyzed the plasma concentration of HPX in 52 
patients undergoing septic shock, as defined by the American 
College of Chest Physicians (ACCP)–Society of Critical Care 
Medicine (SCCM) consensus criteria22. Patients were treated 
according to standard recommendations50, including aggressive 
fluid resuscitation, broad-spectrum antibiotic therapy over the first 
24 hours, vasoactive agents, and at least one intravenous dose 
of hydrocortisone. Blood samples were collected on the first, 
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second, third, fifth, and seventh day after septic shock diagnosis. 
Blood was collected on ice between 1000 and 1200 hours with 
an arterial line or a peripheral vein, and plasma was collected by 
centrifugation (800g, 15 min, 4°C), aliquoted, and stored (−70°C) 
until analysis. Organ dysfunction was defined by the SOFA score 
on the basis of daily measurements23. The outcome analyzed 
was 28th-day hospital mortality. The study protocol was 
approved by the institutional review board of each participating 
center (University Hospital of Federal University of Rio de 
Janeiro, Hospital Quinta D’Or, Casa de Saúde São José, Rio de 
Janeiro, Brazil). All patients, or their legal surrogates, gave 
written informed consent before any study-related procedures. 
 
Statistical analysis 
The comparison of two independent samples was 
assessed by the Student’s t test and the Mann-Whitney test for 
Gaussian and non- Gaussian distributed samples, respectively. 
To compare more than two samples, we performed analysis of 
variance (ANOVA) or Kruskal-Wallis tests for Gaussian and non-
Gaussian distributed samples, respectively. Comparison of 
different survival curves for the variously treated animals was 
done by the nonparametric log-rank test. For pairwise 
comparisons, the Bonferroni correction was used to ensure the 
overall significance level. Regression models were applied to 
describe genotype-based data, and statistical significance 
presented throughout the paper refers to additive effects. 
Kolmogorov-Smirnov and Shapiro-Wilk tests were performed to 
assess the normality of the samples under analysis. Regression 
models were applied to describe genotype-based data. In all data 
sets, the following model equation was applied: Y = a + b x 
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genotype + c x heterozygote, where Y denotes the variable under 
analysis, with logarithmic transformation when appropriate; a is 
the baseline referring to the Hmox1−/− mean; b is the mean effect 
of adding a Hmox1+/+ allele in the genotype (additive effect); c is 
the deviation of heterozygote mean from a single additive effect; 
genotype is an explanatory variable denoting the genotype coded 
as 0, 1, and 2 (0, 1, 2 Hmox1+/+ alleles, respectively); and 
Hmox1+/− is the binary variable indicating the heterozygote 
genotype. Model validation was done by a thorough residual 
analysis, which included testing normality of the residuals and 
visual inspection of any trend in the residuals across genotypes. 
Statistical significance refers to additive effects in the regression 
analysis. Kolmogorov-Smirnov and Shapiro-Wilk tests were 
performed to infer whether data could come from normal 
distributions. All statistical tests were done at 5% significance 
level with InStat and R software51. For human data, a survival 
analysis was performed with the package available in the R 
software51. For each patient, survival time was computed by the 
difference between the time of patient inclusion in the intensive 
care unit and the respective closing date of the hospital record. 
Patients that left hospital after treatment were considered as 
right-censored observations for the respective survival time. 
Because the survival time could be approximated by a lognormal 
distribution, several survival regression models based on such 
probability distributions were fitted to the data. HPX was included 
in the models as an explanatory variable with either the first or 
the last time point measure available for a patient. The statistical 
significance of this explanatory variable in the models was 
assessed by the traditional z-score tests. A correlation analysis 
between SOFA score and HPX at different time points was also 
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performed with Spearman’s coefficient. 
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1. ABSTRACT 
 
 Sickle human hemoglobin (Hb) confers a survival 
advantage to individuals living in endemic areas of malaria, the 
disease caused by Plasmodium infection. As demonstrated 
hereby, mice expressing sickle Hb do not succumb to 
experimental cerebral malaria (ECM). This protective effect is 
exerted irrespectively of parasite load, revealing that sickle Hb 
confers host tolerance to Plasmodium infection. Sickle Hb 
induces the expression of heme oxygenase-1 (HO-1) in 
hematopoietic cells, via a mechanism involving the transcription 
factor NF-E2-related factor 2 (Nrf2). Carbon monoxide (CO), a 
byproduct of heme catabolism by HO-1, prevents further 
accumulation of circulating free heme after Plasmodium infection, 
suppressing the pathogenesis of ECM. Moreover, sickle Hb 
inhibits activation and/or expansion of pathogenic CD8+ T cells 
recognizing antigens expressed by Plasmodium, an 
immunoregulatory effect that does not involve Nrf2 and/or HO-1. 
Our findings provide insight into molecular mechanisms via which 
sickle Hb confers host tolerance to severe forms of malaria. 
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2. INTRODUCTION 
 
Several point mutations in the β-chain of human Hb, e.g. 
HbS (β6Glu->Val)1,2 , HbC (β6Glu->Lys)3 and HbE (β26Glu>Lys)4, 
can confer a survival advantage to Plasmodium (P.) infection5. 
When present in the homozygous form, some of these mutations, 
e.g. HbS, become pathologic causing hemolytic anemia, leading 
to accumulation of high levels of cell-free Hb and heme in 
plasma6. Individuals carrying the HbS mutation in the 
heterozygous form, i.e. the A/S sickle cell trait, also accumulate 
low (nonpathologic) levels of heme in plasma7 and are protected 
against malaria1,5,8,9. 
Once released from Hb, a phenomenon favored in the 
case of HbS10, free heme becomes cytotoxic11-13. This deleterious 
effect is countered by the expression of heme oxygenase-1 (HO-
1, encoded by the Hmox1 gene)11,13,14, a stress responsive 
enzyme that catabolizes free heme into biliverdin, iron and 
carbon monoxide (CO)15. HO-1 expression is induced by free 
heme, through a mechanism that involves the ubiquitination-
degradation of Kelch-like ECH-associated protein 1 (Keap1)16, a 
cytoplasmic repressor of the transcription factor NF-E2-related 
factor-2 (Nrf2)17. Upon nuclear translocation, Nrf2 binds to the 
stress-responsive elements in the Hmox1 promoter18, a 
regulatory mechanism that plays a central role in the control of 
Hmox1 expression in response to heme16. 
HO-1 is protective against a wide variety of immune- 
mediated inflammatory diseases19,20 including experimental 
cerebral malaria (ECM)21, a lethal neuroinflammatory syndrome 
that develops in P. berghei ANKA infected C57BL/6 mice and 
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that mimics some of the pathologic features of human cerebral 
malaria (CM)22. This protective effect is mediated by CO, which 
binds cell-free Hb and inhibits its oxidation, thus preventing heme 
release from oxidized Hb10 and hence the pathogenesis of 
ECM21. Given that expression of HO-123,24 and production of 
CO25 are induced in individuals carrying the HbS mutation we 
hypothesized that this might explain why individuals carrying the 
A/S sickle cell trait have a survival advantage against 
malaria2,8,26. We provide evidence demonstrating that this is the 
case. 
 
3. RESULTS 
 
 
3.1 Sickle Hb Confers a Survival Advantage against Malaria 
in Mice 
Inoculation of C57BL/6 mice (Hbwt) with P. berghei ANKA 
infected red blood cells (RBC) led within 6 to 12 days to the 
development of clinical signs of ECM (Figure 4.1 A). Incidence of 
ECM was significantly reduced in hemizygous C57BL/6 HbSAD 
mice (Figure 4.1 A) expressing a β-chain of human Hb carrying 
the β6Glu->Val (HbS) mutation as well as two additional 
mutations, β23Ala->Ile (Antilles23I) and β121Asp->Gln (D-
Punjab121Q), known to enhance HbS polymerization in humans 
and mice27. Naive HbSAD mice present a very mild sickle cell 
syndrome, which does not lead to anemia28 (Table 4.1) similar to 
the asymptomatic human A/S sickle cell trait that affords 
protection against malaria1,8,9. HbSAD mice that did not develop 
ECM, succumbed 20-25 days postinfection from 
hyperparasitemia-induced anemia (data not shown), a condition 
unrelated to ECM29. 
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When infected with P. berghei ANKA, C57BL/6.Sv/129 
HbA/a mice expressing normal human Hb as well as endogenous 
mouse Hb30 developed clinical signs of ECM and succumbed 6 to 
12 days after infection (Figure 4.1 G). Littermate control 
C57BL/6.Sv/129 Hba/a mice, expressing only the endogenous 
mouse Hb developed ECM but with lower incidence, as 
compared to HbA/a mice (Figure 4.1 G). This suggests that normal 
human Hb might promote, rather than prevent, the pathogenesis 
of ECM in C57BL/6.Sv/129 mice. While the reason for this is not 
clear, it is possible that human Hb alters mouse RBC physiology 
in a manner that would promote the development of ECM. 
However, this effect becomes negligible as C57BL/6.Sv/129 mice 
are backcrossed into the C57BL/6 genetic background (Figure 
4.1 J), in which ECM incidence is higher than 95% (Figure 4.1 A). 
Given that HbSAD suppresses the pathogenesis of ECM in 
C57BL/6 mice and that the deleterious effect of normal human 
Hb becomes negligible under this genetic background, it is 
reasonable to infer that the protective effect of HbSAD is 
attributable to the mutations in the human β-globin chain rather 
than to human Hb per se. 
HbSAD mice that did not succumb within 6–12 days 
postinfection also did not develop the pathologic hallmarks of 
ECM, including blood brain barrier (BBB) disruption (Figure 4.1 
B), perivascular RBC accumulation in brain (Figure 4.1 B) and 
brain edema (Figure 4.1 C). These pathologic features were 
present in Hbwt (Figures 4.1 B and C) and HbA/a mice, i.e. brain 
edema (Figure 4.1 H). Given that BBB disruption and brain 
edema occur in P. berghei ANKA infected C57BL/6 mice via a 
CD8+ T cell-dependent mechanism29,31, we asked whether the 
 132 
 
 
G   H           I 
 
J         K  
 
 
Figure 4.1. HbSAD Prevents ECM Onset. (A) Survival of P. berghei ANKA infected Hbwt (n = 91) and 
HbSAD (n = 76) mice (10 independent experiments with survival advantage p < 0.05). Grey shading: 
expected time of ECM. (B) Representative H&E stained microvessel in the BBB of infected Hbwt and 
HbSAD mice, at ECM onset in Hbwt mice (n = 3/group). EC: endothelial cell; PVC: perivascular 
compartment; GL: glia limitans (dotted line); RBC: red blood cells; iRBC: infected RBC. Magnification: 
100x. (C) Mean brain edema in naïve versus infected Hbwt and HbSAD mice ± standard deviation 
(n=4/group), at the time of ECM onset in Hbwt mice. ns: not significant. (D) Brain leukocyte sequestration 
in naïve versus infected Hbwt and HbSAD mice, at the time of ECM onset in Hbwt mice. Dots represent 
single mice (n = 4 -14/ group). Red lines represent mean values. nd: not determined. (E) Mean 
percentage of infected RBC in Hbwt and HbSAD mice ± standard deviation. Same mice as in (A). (F) 
Mean number of infected RBC in Hbwt (n=7) and HbSAD (n=9) mice ± standard deviation at the time of 
ECM onset in Hbwt mice. (G) Survival of P. berghei ANKA infected HbA/a (n=15) and littermate control 
Hba/a (n=19) mice (3 independent experiments with survival advantage P<0.05). (H) Brain edema was 
measured by Evans blue (EB) accumulation in brains ± standard deviation (n=3-4/group), at the time of 
ECM onset in HbA/a mice. (I) Mean percentage of infected RBC ± standard deviation, same mice as in 
(G). Notice that the HbA/a and Hba/a mice used in these experiments are in a mixed C57BL/6.SV129 
genetic background, produced by breeding HbA/a mice. (J) Survival of P. berghei ANKA infected Hba/a 
mice under different genetic backgrounds, i.e. Hba/a N1 (n=19), Hba/a N2 (n=7) and Hba/a C57BL/6 (n=15) 
mice (data pooled from 4 independent experiments). (K) Mean percentage of infected RBC in the same 
mice as in (J). Grey shading indicates expected time of ECM. Notice that expression of a nonmutated β-
chain of human Hb in the HbA/a mice does not protect against ECM, as compared to littermate control 
Hba/a mice. This supports the notion that protection of HbSAD mice against ECM is afforded by the 
mutations of β-chain of human Hb and not by the β-chain of human Hb itself. 
protective effect of HbSAD against ECM was associated with 
 133 
inhibition of CD8+ T cell sequestration in the brain. The number of  
CD45high leukocytes and CD8+ T cells, including granzyme B-
positive (GrB+) CD8+ T cells, was reduced in P. berghei ANKA 
infected HbSAD, as compared to Hbwt mice at ECM onset (Figure 
4.1 D). When infected with P. berghei ANKA, Hbwt mice also 
developed severe lung injury and a mild form of liver injury 
(Figure 4.2) with no apparent injury to the kidneys or to the heart 
(data not shown). The extent of lung and liver injury was reduced 
in P. berghei ANKA infected HbSAD versus Hbwt mice (Figure 4.2). 
 
3.2 Sickle Hb Confers Tolerance to Plasmodium Infection in 
Mice 
Protection of HbSAD mice against ECM was not associated 
with reduction of pathogen load, as assessed by the percentage 
of infected RBC, i.e., parasitemia (Figure 4.1 E) as well as by the 
number of circulating infected RBC (Figure 4.1 F) versus control 
Hbwt (Figures 4.1 E and F) or HbA/a mice (Figures 4.1 I K). While 
the protective effect of the human sickle cell trait against malaria 
has been associated with decreased pathogen load2,8,26, there 
are several instances where this does not appear to be the 
case32-34, which is in keeping with the observation that HbSAD 
confers protection against ECM without interfering with pathogen 
load. These observations suggest that mutations in the β-chain of 
human Hb, such as those in HbSAD can afford tolerance to 
Plasmodium infection, a host defense strategy that limits disease 
severity by preventing tissue damage, without targeting the 
pathogen. This contrasts to resistance to infection, the well-
recognized host defense strategy that limits disease severity by 
decreasing pathogen load35,36. 
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Parasite sequestration was similar in Hbwt, 
HbSADHmox1+/+, and HbSADHmox1+/- mice, as assessed using a 
transgenic luciferase-P. berghei ANKA strain (Figure 4.3). This 
supports further the notion that induction of HO-1 by sickle Hb 
confers host tolerance to Plasmodium infection. 
 
3.3 Sickle Hb Induces the Expression of HO-1 that Confers 
Tolerance to Plasmodium Infection 
Humans and rodents carrying the HbS mutation express 
high levels of HO-1 in the hematopoietic compartment23,24. 
Consistent with this, naive HbSAD mice express high levels of 
Hmox1 mRNA in bone marrow and peripheral blood cells, as 
 
 
Figure 4.2. HbSAD Affords Protection Against Lung and Liver Injury Via a Mechanism Involving 
HO-1 and Nrf2. Paraffin sections stained with standard hematoxylin/eosin staining. Naïve Hbwt, HbSAD, 
HbSADHmox1+/- and HbSADNrf2+/- mice exhibit normal lungs and livers that were indistinguishable from 
each other. Infection with P. berghei ANKA in Hbwt mice was associated with the development of 
interstitial pneumonia and RBC extravasation as well as iron deposits, prominent in the liver. The latter 
can also be seen in P. berghei ANKA infected HbSAD mice, albeit to a lesser extent. Lungs of P. berghei 
ANKA infected HbSAD were only mildly affected, as compared to those of Hbwt mice. The protective effect 
of HbSAD was lost in HbSADHmox1+/- and HbSADNrf2+/- mice. That is, HbSADHmox1+/- and HbSADNrf2+/- 
showed massive pneumonia as well as iron deposits in the liver when infected with P. berghei ANKA. 
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compared to naïve Hbwt mice (Figure 4.4 A).  Naive  HbSAD  mice  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
also expressed higher levels of Hmox1 mRNA in the kidneys 
(Figure 4.4 G), which is consistent with the chronic development 
of kidney injury in these mice, revealed clinically upon aging37. 
HbSAD mice expressed similar levels of Hmox1 mRNA in the liver, 
heart, lung and spleen (Figure 4.4 G), as compared to Hbwt mice. 
HbA/a mice expressed similar levels of Hmox1 mRNA in the bone 
marrow and peripheral blood versus littermate control Hba/a mice 
(Figure 4.4 I), demonstrating that expression of a βS related 
variant but not a normal β-globin chain is required to induce 
Hmox1 expression. 
Given that HO-1 is protective against severe forms of 
malaria in mice12,21, we asked whether its induction in HbSAD mice 
(Figure 4.4 A) is required to suppress the development of ECM 
A 
 
B 
 
C 
 
 
 
Figure 4.3. Neither HbSAD 
or HO-1 Regulate 
Plasmodium 
Sequestration. (A) Mean 
ratio of Luciferase activity in 
different organs from 
HbwtHmox1+/+, 
HbSADHmox1+/+ and 
HbSADHmox1+/- mice ± 
standard deviation 
(n=9/group), at day 7 
postinfection with 
Luciferase-transgenic P. 
berghei ANKA. Pooled from 
3 independent experiments 
with similar results 
(exposure time 15 sec). (B) 
Visualization of Luciferase-
transgenic P. berghei ANKA 
sequestration in the same 
mice as in (A) (exposure 
time 15 sec). (C) 
Visualization of Luciferase-
transgenic P. berghei ANKA 
sequestration in the brains 
of the same mice as in (A) 
(exposure time 2 min.). 
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(Figure 4.1 A). Deletion of one Hmox1 allele (Hmox1+/-) reduced 
Hmox1 mRNA expression in bone marrow and whole blood 
leukocytes of HbSAD mice (Figure 4.4 H), without causing overt 
postnatal lethality (Table 4.2 A). When challenged by P. berghei 
ANKA infection, HbSADHmox1+/- mice succumbed to ECM (Figure 
4.4 B), with concomitant development of BBB disruption (Figure 
4.4 C), brain edema (Figure 4.4 D) and sequestration of CD45high 
leukocytes (data not shown), CD8+ T cells and activated 
GrB+CD8+ T cells in the brain (Figure 4.4 E). 
The protective effect of HbSAD against lung and liver injury, 
associated with P. berghei ANKA infection, was lost in 
HbSADHmox1+/- mice (Figure 4.2). This was not associated with 
increased parasite load (Figure 4.4 F). 
Pharmacologic inhibition of HO activity by zinc 
protoporphyrin IX (ZnPPIX) (Figures 4.5 A and B), increased 
ECM incidence in HbSAD mice versus vehicle-treated controls 
(Figure 4.5 C). This effect was not associated with modulation of 
parasitemia (Figure 4.5 D), suggesting that heme catabolism by 
HO-1 confers tolerance to Plasmodium infection in HbSAD mice. 
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Figure 4.4. HO-1 Mediates the Protective Effect of HbSAD Against 
ECM (A) Mean ratio of Hmox1 versus hypoxanthine-guanine 
phosphoribosyltransferase (Hprt) mRNA molecules in naïve Hbwt and 
HbSAD mice ± standard deviation (n=4/group). (B) Survival of P. berghei 
ANKA infected HbwtHmox1+/+ (n=19), HbSADHmox1+/+ (n =13), 
HbwtHmox1+/- (n =15) and HbSADHmox1+/- (n = 15) mice (three 
independent experiments; survival advantage p<0.05). Grey shading: 
expected time of ECM. (C) Representative H&E stained micro-vessel in 
the brain of infected HbSADHmox1+/+ and HbSADHmox1+/- mice, at ECM 
onset in HbSADHmox1+/- mice (n=3/group). EC: endothelial cells; PVC: 
perivascular compartment; GL: glia limitans (dotted line); RBC: red blood 
cells. Magnification: 100x. (D) Mean brain edema in naïve versus infected 
HbSADHmox1+/+ and HbSADHmox1+/- mice, at ECM onset in HbSADHmox1+/-  
 mice ±  standard deviation (n=3-4/group). (E) CD8+ T cells and activated GrB+CD8+ T cells in brains of 
naïve versus infected HbSADHmox1+/+ and HbSADHmox1+/- mice, at the time of ECM onset in HbSADHmox1+/- 
mice. Dots represent single mice (n = 4–5/group). Red lines represent mean values. nd: not determined. 
(F) Mean percentage of infected RBC (parasitemia) in the same mice as in (B). (G) Mean ratio of Hmox1 
versus hypoxanthine-guanine phosphoribosyltransferase (Hprt) mRNA molecules in different organs of 
naïve Hbwt and HbSAD mice ± standard deviation (n=4/group), (H) bone marrow and peripheral blood 
leukocytes of naïve HbSADHmox1+/+ and HbSADHmox1+/- mice ± standard deviation (n=4). (I) bone marrow 
and peripheral blood leukocytes of naïve HbA/a and Hba/a mice ± standard deviation (n=4) Notice in (I) the 
lack of up-regulation of Hmox1 mRNA expression in HbA/a versus Hba/a mice. Notice in (H) the significant 
decrease in the levels of Hmox1 mRNA expression in HbSAD mice with only one (Hmox1+/-) versus two 
(Hmox1+/+) functional Hmox1 alleles. 
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3.4 Induction of HO-1 by Sickle Hb Inhibits the Production Of 
Chemokines Involved in the Pathogenesis of ECM 
Several chemokines can contribute to the pathogenesis of 
ECM and presumably to that of human CM22,29,38. Expression of 
mRNA encoding Ccl2 (Mcp-1), Ccl3 (MIP1α), Ccl5 (Rantes), and 
Cxcl10 (Ip-10) were decreased in the brain of HbSAD mice that did 
not develop ECM versus Hbwt mice that succumbed to ECM 
(Figure 4.6 A). This inhibitory effect involved HO-1, since 
expression of mRNA encoding these chemokines was increased 
in the brain of infected HbSADHmox1+/- versus HbSADHmox1+/+ 
(Figure 4.6 A). The involvement of CXCL10/IP-10 in the 
pathogenesis of ECM38 suggests that its inhibition might 
contribute functionally to the protective effect of HbSAD against 
A   B 
 
C   D 
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Figure 4.5. Pharmacologic Inhibition 
of HO Activity Negates the Protective 
Effect of Sickle Hb Against ECM. HO 
activity was measured in (A) liver and 
(B) spleen of naïve or P. berghei ANKA 
infected Hbwt mice receiving the HO 
enzymatic inhibitor ZnPPIX (mg/kg bw, 
every 12 hours from day 2 pre-infection 
to day 7 postinfection) or vehicle (-). 
Results are shown as mean percentage 
of HO enzymatic activity (pmol 
bilirubin/mg protein/h) ± standard 
deviation (n=5 mice/group). (C) Survival 
of P. berghei ANKA infected HbSAD mice 
receiving vehicle (n=8) or ZnPPIX 
(5mg/kg bw) as in (A) and (B) (n=8). 
Vehicle-treated P. berghei ANKA 
infected Hbwt mice were used as controls 
(n=8). Results shown were pooled from 2 
independent experiments with similar 
results. (D) Mean percentage of infected 
RBC (parasitemia) in infected HbSAD mice 
receiving vehicle (n=8) or ZnPPIX (n=8) 
and in vehicle-treated Hbwt mice (n=8) ± 
standard deviation. (E) Survival of P. 
berghei ANKA infected HbSAD mice 
receiving ZnPPIX as in (A) and (B) and 
exposed to air (n=8) or CO (250 ppm, 4-
7 days postinfection) (n=8). Results 
shown were pooled from 2 independent 
experiments with similar results. (F) 
Mean percentage of infected RBC 
(parasitemia) in the same mice as (E). 
Grey shadings in panels (C) and (E) 
indicate the expected time of ECM. 
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ECM. Expression of mRNAs encoding other chemokines, such 
as Cxcl11 (Ip-9) or the chemokine receptors Ccr2 and Cxcr3 was 
also inhibited by HbSAD but in a manner that was not impaired in 
HbSADHmox1+/- versus HbSADHmox1+/+ mice (Figure 4.6 B). This 
suggests that the inhibitory effect of HbSAD over the expression of 
these genes, probably does not involve HO-1. Expression of 
mRNA encoding the chemokine Ccl19 (MIP-3β) and the 
chemokines receptor Ccr7 was not modulated by HbSAD and/or 
did not involve HO-1 (Figure 4.6 C). This was also the case for 
several other genes previously involved or not in the 
pathogenesis of ECM (Figure 4.6 D to G). Of note is the HO-1 
independent marked suppression of cytokines and molecules 
mainly produced by innate immune cells such as NOS2, IL-1β, 
IL-6 and TNF, as well as perforin, FasL, GrB, IFNγ and  CTLA4, 
markers of CD4+ and CD8+ T cell activation and/or effector 
function. This finding suggests that HbSAD exerts 
immunosuppressive effects that are independent of HO-1 
expression. 
 
3.5 Sickle Hb Confers Tolerance to Plasmodium Infection via 
HO-1 Expression in Hematopoietic Cells 
We performed syngenic bone marrow transplants from 
HbSADHmox1+/+ or HbSADHmox1+/- mice into lethally irradiated 
HbwtHmox1+/+ or HbwtHmox1+/- mice to generate chimeric HbSAD 
mice in which one Hmox1 allele is deleted in the hematopoietic 
(HbSADHmox1+/-HbwtHmox1+/+) or nonhematopoietic 
(HbSADHmox1+/+HbwtHmox1+/-) compartment. Chimeric HbSAD 
mice carrying two functional Hmox1 alleles in the hematopoietic 
and in the nonhematopoietic compartments (HbSADHmox1+/+ 
 140 
HbwtHmox1+/+) did not succumb to ECM (Figure 4.7 A) or develop 
brain edema (Figure 4.7 B) in response to P. berghei ANKA 
infection. Control chimeric mice in which the bone marrow of 
HbwtHmox1+/+ mice was transferred into lethally irradiated 
HbSADHmox1+/+ mice, develop ECM (Figure 4.7 A) and brain 
edema (Figure 4.7 B), confirming that cells derived from the 
hematopoietic compartment confer the protective effect of HbSAD. 
Chimeric HbSAD mice carrying a single functional Hmox1 allele in 
hematopoietic cells (HbSADHmox1+/-HbwtHmox1+/+) succumbed 
to ECM (Figure 4.7 A), developing brain edema (Figure 4.7 B). 
The reverse was not true in that deletion of a single Hmox1 allele 
in nonhematopoietic cells (HbSADHmox1+/+HbwtHmox1+/-) did not 
impair the protective effect of HbSAD against ECM (Figure 4.7 A), 
confirmed by lack of brain edema (Figure 4.7 B). Similar results 
were obtained when transferring bone marrows from     
HbSADHmox1+/+ or   HbSADHmox1+/- mice into HbSADHmox1+/+ or 
HbSADHmox1+/- mice (Figure 4.7 D to F). Lethality after day 12 
postinfection (Figure 4.7 A) was most probably due to the 
development of a  ‘‘composite disease’’ in which high levels of 
parasitemia (>20%) synergize with sickle human Hb to cause 
death, without overt clinical or pathological signs of ECM. These 
observations reveal that the protective effect of HbSAD requires 
the induction of HO-1 expression in hematopoietic cells, 
consistent with the observed induction of HO-1 expression in 
blood and bone marrow cells of naïve HbSAD mice (Figure 4.4 A). 
The protective effect of HO-1 expression in the hematopoietic 
compartment was not associated with modulation of pathogen 
load (Figure 4.7 C and F), confirming that HO-1 affords tolerance 
to Plasmodium infection. 
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Figure S6. HbSAD Inhibits Neuroinflammation, Related to Figure 3
Quantification of mRNA encoding (a) cytokines, (b) molecules expressed by leukocyte, (c) co-stimulatorymolecules expressed by antigen presenting cells and (d)
diverse set of molecules, in the brains of naı̈ve (-) versus berghei ANKA-infected infected (+) mice carrying one (-) or two (+) functional Hmox1 alleles and ex-
pressing (+) HbSAD or not (-). Results are shown as mean ± standard deviation (n=4-8/group), analyzed at the time of ECM onset. Notice that inhibition of pro-
inflammatory gene expression in P. berghei ANKA-infected HbSAD versus Hbwt mice is similar whether the HbSAD mice have one (-) or two (+) functional Hmox1
alleles. This suggests that HbSAD can exert protective effects independently of HO-1.
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Figure 4.6. HbSAD Inhibits Proinflammatory Molecules Expression in the Brain. (A, B and C) 
Quantification of mRNA encoding chemokines and chemokine receptors in the brains of naïve (-) and P. 
berghei ANKA infected (+) mice carrying one (-) or two (+) functional Hmox1 alleles and expressing (+) 
HbSAD or not (-). Results are shown as mean fold induction over naïve HbwtHmox1+/+ mice ± standard 
deviation (n = 4-8/group), analyzed at ECM onset in Hbwt or HbSADHmox1+/- control groups. (A) Genes 
inhibited by HbSAD under the control of HO-1. (B) Genes inhibited by HbSAD, presumably not under the 
control of HO-1. (C) Genes not regulated by HbSAD.  (D) cytokines, (E) molecules expressed by 
leukocytes, (F and G) co-stimulatory molecules, T cell effector molecules, signaling molecules. Notice 
that inhibition of proinflammatory gene expression in P. berghei ANKA infected HbSAD versus Hbwt mice 
is similar whether the HbSAD mice have one (-) or two (+) functional Hmox1 alleles. *p < 0.05; **p < 0.01; 
ns P > 0.05. 
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3.6 Sickle Hb Inhibits the Activation/Expansion of CD8+ T 
Cells Recognizing Antigens Expressed by Plasmodium 
The number of splenic CD8+ T cells recognizing 
specifically a MHC I-restricted epitope derived from glycoprotein 
B (gB498-505) of herpes simplex virus-1 expressed by transgenic P. 
berghei ANKA39 was reduced in HbSAD versus Hbwt mice, as 
assessed five days after infection (Figure 4.8 A and C). The 
number of splenic GrB+CD8+ T cells was also reduced in HbSAD 
versus Hbwt mice five days after infection (Figure 4.8 B and D). 
This reveals that HbSAD prevents overt expansion of pathogenic 
 
D             E                  F 
 
 
 
Figure 4.7. The Protective Effect of Sickle Hb Against ECM Involves the Expression of HO-1 in 
Hematopoietic Cells (A) Survival of P. berghei ANKA infected chimeric mice resulting from the 
adoptive transfer of bone marrow from HbSADHmox1+/+ mice into HbwtHmox1+/+ recipients (n = 6); from 
HbwtHmox1+/+ mice into HbSADHmox1+/+ recipients (n = 5); from HbSADHmox1+/+ mice into HbwtHmox1+/- 
recipients (n = 8) and from HbSADHmox1+/- into HbwtHmox1+/+ recipients (n = 7). Recipients were lethally 
irradiated before the adoptive transfer. Grey shading indicates expected time of ECM. Pooled from four 
independent experiments. (B) Mean brain edema ± standard deviation (n = 3/group) in chimeric mice, 
produced as in (A). (C) Mean percentage of infected RBC in chimeric mice ± standard deviation, same 
mice as in (A). (D) Survival of P. berghei ANKA infected chimeric HbSAD mice resulting from the adoptive 
transfer of bone marrows from HbSADHmox1+/+ mice into HbSADHmox1+/+ recipients (n=6); from 
HbSADHmox1+/+ mice into HbSADHmox1+/- recipients (n=7) and from HbSADHmox1+/- mice into 
HbSADHmox1+/+ recipients (n=8). Results shown were pooled from 5 independent experiments. (E) Brain 
edema was measured by Evans blue (EB) accumulation in brains of chimeric mice, produced as in (D). 
Results are shown as mean ± standard deviation (n=3/group). (F) Mean percentage of infected RBC in 
chimeric mice, produced as in (D). Results are shown as mean ± standard deviation. Same mice as in 
(D). 
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CD8+ T cells, an effect that should contribute to the protective 
effect of HbSAD against ECM31,39. We then asked whether this 
immunoregulatory effect of HbSAD involved the expression of HO-
1. The number of gB498-505-specific CD8+ T cells and GrB+CD8+ T 
cells was not different in the spleen of HbSADHmox1+/- versus 
HbSADHmox1+/+ mice five days after infection (Figures 4.8 A to D). 
This suggests that HbSAD controls the activation and/or expansion 
of splenic CD8+ T cells, via a mechanism that probably does not 
involve HO-1. 
 
3.7 Sickle Hb Induces HO-1 Expression via a Mechanism 
Involving Nrf2 
Given that Nrf2 plays a central role in the transcriptional 
regulation of HO-1 expression17 we asked whether induction of 
HO-1 expression in whole blood leukocytes of naïve HbSAD mice 
(Figure 4.4 A) involved this transcription factor. Deletion of one 
Nrf2 allele in HbSAD mice (HbSADNrf2+/-) was sufficient to reduce 
the level of Hmox1 mRNA expression in whole blood leukocytes, 
to those of naïve HbwtNrf2+/+ mice  (Figure 4.9 A).   This suggests 
that sickle Hb induces Hmox1 transcription and expression via a 
mechanism involving Nrf2. Incidence of ECM increased 
significantly in P. berghei ANKA infected HbSADNrf2+/- versus 
HbSADNrf2+/+ mice (Figure 4.9 B), confirmed by the development 
of brain edema (Figure 4.9 C). A similar effect was observed in a 
limited number of HbSAD mice in which both Nrf2 alleles were 
functionally deleted, i.e. HbSADNrf2-/- mice (n=5; 20% survival). It 
should be noted that deletion of both Nrf2 alleles in HbSAD mice 
lead to overt postnatal lethality (Table 4.2 B). Loss of protection 
against ECM in HbSADNrf2+/- versus HbSADNrf2+/+ mice was not 
associated with a regain of CD8+ T cell activation and/or 
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expansion in the spleen, as assessed five days after infection 
(Figure 4.10 A to D). 
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Figure 4.8. The Immunoregulatory Effect of Sickle Hb Does not Depend on Expression of HO-1. 
(A) Number of splenic CD8+ T cells specific for gB498-505 in HbwtHmox1+/+, HbSADHmox1+/+ and 
HbSADHmox1+/- naïve mice or 5 days after P. berghei ANKA infection. (B) Number of splenic CD8+GrB+ T 
in the same mice as in (A). Circles in (A) and (B) represent single mice and red lines mean values (n=10 
and n=16 in naïve and infected groups, respectively), data pooled from 4 independent experiments with 
similar results. (C) Representative flow cytometry dot plots of CD8+ T cells specific for the P. berghei 
ANKA encoded MHC I-restricted epitope derived from glycoprotein B of herpes simplex virus-1 (gB498-
505) in the spleen of HbwtHmox1+/+, HbSADHmox1+/+ and HbSADHmox1+/+ mice not infected or 5 days after 
P. berghei ANKA infection (D) Representative flow cytometry dot plots of CD8+GrB+ T cells, in the 
spleen of HbwtHmox1+/+, HbSADHmox1+/+ and HbSADHmox1+/+ mice not infected or 5 days after P. berghei 
ANKA infection. Numbers in gray indicate the percentage of cells inside the gates. 
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This suggests that the immunoregulatory effect of HbSAD 
probably does not involve Nrf2 (Figure 4.10 A to D), which is 
consistent with the observation that this effect also does not 
seem to involve HO-1, a gene regulated by HbSAD via Nrf2. 
 
 
 
 
 
 
 
 
 
 
 
 
The protective effect of HbSAD against lung and liver injury 
associated to P. berghei ANKA infection was lost in HbSADNrf2+/- 
versus HbSADNrf2+/+ mice (Figure 4.2). This was not associated 
with increased parasite load in HbSADNrf2+/- versus HbSADNrf2+/+ 
mice (Figure 4.9 D), which is consistent with the notion that 
induction of HO-1 expression by Nrf2 confers tolerance to 
Plasmodium infection. 
 
3.8 Sickle Hb Confers Tolerance to Plasmodium Infection via 
a Mechanism Involving CO Produced through Heme 
Catabolism by HO-1 
Consistent with similar observations in individuals 
carrying the HbS mutation in the homozygous6 or heterozygous7 
form, naïve HbSAD mice had higher concentration of free heme in 
A             B           C   
 
D 
 
Figure 4.9. Sickle Human Hb Prevents the Onset of ECM Via 
the Induction of HO-1 Expression by Nrf2. (A) Mean ratio of 
Hmox1 versus hypoxanthineguanine phosphoribosyltransferase 
(Hprt) mRNA molecules in peripheral blood mononuclear cells of 
naïve HbwtNrf2+/+, HbwtNrf2+/-, HbSADNrf2+/+ and HbSADNrf2+/- mice 
± standard deviation (n=6–8/group). (B) Survival of P. berghei 
ANKA infected HbwtNrf2+/+ (n=6), HbwtNrf2+/- (n=13), HbSADNrf2+/+ 
(n=10) and HbSADNrf2+/- (n=14) mice, three independent 
experiments. Grey shading indicates expected time of ECM. (C) 
Brain edema was measured by Evans blue (EB) accumulation in 
brains of infected HbwtNrf2+/+, HbwtNrf2+/-, HbSADNrf2+/+ and 
HbSADNrf2+/- mice, at the time of ECM onset. Mean ± standard 
deviation (n=4-5/group). (D) Mean percentage of infected RBC 
(parasitemia) ± standard deviation, same mice as in (B). 
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plasma, as compared to age-matched control naïve Hbwt mice 
(Figure 4.11 A). Herein, free heme is defined as heme molecules 
not contained within the heme pockets of hemoglobin. When pre-
exposed in vitro to low levels of free heme cells are protected 
against a subsequent heme challenge11. We asked whether free 
heme would exert a similar protective effect in vivo. 
Administration of free heme to Hbwt mice prior to P. berghei 
ANKA infection suppressed ECM incidence, as compared to 
vehicle-treated Hbwt mice (Figure 4.11 B). 
The protective effect of heme was dose-dependent, with 
higher dosage leading to (1) increased HO-1 expression in whole 
blood cells (Figure 4.13 A) and spleen (Figure 4.13 B) and to a 
lesser extent in the bone marrow (Figure 4.13 C) and (2) 
suppression of ECM (Figure 4.13 D). This protective effect was 
not associated with modulation of parasitemia (Figure 4.13 D), 
suggesting that low concentration of free heme in the plasma of 
naïve HbSAD mice (Figure 4.11 A) can confer tolerance to 
Plasmodium infection. 
We asked whether accumulation of low levels of free 
heme in HbSAD contributes to the immunoregulatory effect exerted 
by HbSAD on CD8+ T cells (Figures 4.8 A to D). Administration of 
free heme to Hbwt mice, prior to infection with transgenic P. 
berghei ANKA expressing gB498-505, reduced the number of 
splenic gB498-505-specific CD8+ T cells (Figures 4.14 A and C) as 
well as GrB+CD8+ T cells, as compared to vehicle treated Hbwt 
mice five days after infection (Figures 4.14 B and D). This 
supports further the notion that the protective effect of HbSAD 
against ECM is mediated, to a large extent, via the accumulation 
of low levels of circulating free heme.  
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Plasma free heme concentration increased significantly 
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Figure 4.10. The Immunoregulatory Effect of Sickle Hb Does not Depend on Nrf2. (A) Number of 
CD8+ T cells specific for the P. berghei ANKA-encoded MHC I restricted epitope derived from 
glycoprotein B of herpes simplex virus-1 (gB498-505), in the spleen of HbwtNrf2+/+, HbSADNrf2+/+ and 
HbSADNrf2+/- mice not-infected (naïve) or 5 days after P. berghei ANKA infection. (B) Number of splenic 
CD8+GrB+ T cells in the same mice as in (A). (C) Representative flow cytometry dot plots of splenic 
CD8+ T cells recognizing the gB498-505 epitope in the same mice as in (A). (D) Representative flow 
cytometry dot plots of splenic CD8+GrB+ T cells in the same mice as in (A). Circles in (A) and (B) 
represent single mice and red lines mean values (n=4 and n=10 in noninfected and infected groups, 
respectively), pooled from 2 independent experiments with similar results. Numbers in gray (C) and (D) 
indicate the percentage of cells inside the gates. 
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following P. berghei ANKA infection in Hbwt mice (Figure 4.11 A), 
an effect we have previously shown to contribute in a critical 
manner to the pathogenesis of ECM14,21. Albeit less pronounced 
this increase was also observed in HbSAD mice (Figure 4.11 A). 
When challenged with free heme after infection, HbSAD 
succumbed to ECM (Figure 4.11 C), confirmed by the occurrence 
of brain edema (Figure 4.11 D). This reveals that free heme has 
a dual effect in the control of ECM onset, being protective when 
present at slightly above normal concentration before infection 
(Figure 4.11 B) while highly pathogenic when present at higher 
levels after infection (Figure 4.11 C). Free heme did not interfere 
with pathogen load (Figures 4.13 E and F), revealing that when 
present at slightly above normal concentration before infection 
free heme promotes tolerance to malaria, while impairing 
tolerance to malaria when present at higher concentrations after 
infection. Heme administration at the same dosage and schedule 
to naïve Hbwt or HbSAD mice did not result in lethality (data not 
shown). When applied via inhalation to wild type mice, CO 
suppresses the pathogenesis of ECM via a mechanism that 
relies on the inhibition of heme release from Hb21. We asked 
whether the protective effect of HbSAD against ECM was mediated 
via this mechanism. Inhaled CO suppressed the incidence of 
ECM in HbSADHmox1+/- mice (Figure 4.11 E), confirmed by the 
lack of brain edema (Figure 4.11 F). A similar protective effect 
was observed when CO was applied to P. berghei infected HbSAD 
mice treated with the enzymatic HO inhibitor ZnPPIX (Figures 4.5 
E and F). 
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CO did not modulate parasitemia (Figures 4.12 B and C). 
 
 
Figure 4.11. HbSAD Inhibits Free Heme Accumulation Via the Production of CO. (A) Mean plasma 
free heme concentration in naïve versus P. berghei ANKA infected Hbwt and HbSAD mice at ECM onset 
in Hbwt mice ± standard deviation (n=4–15/group). (B) Survival of infected Hbwt mice receiving vehicle 
(n=25) or heme (35–40 mg/kg, every 48 hr, day 2 preinfection to 4 postinfection) (n=17). Pooled from 
four independent experiments, with similar results. (C) Survival of infected HbSAD mice receiving vehicle 
(n=8) or heme (20 mg/kg, every 12 hr, day 4–7 postinfection) (n=8). Pooled from two independent 
experiments, with similar results. (D) Mean brain edema in HbSAD mice treated as in (C) at ECM onset in 
heme-treated HbSAD mice ± standard deviation (n=4/group). (E) Survival of infected HbSADHmox1+/- mice 
exposed to air (n=8) or CO (250 ppm, days 4-7 post infection) (n=12). Pooled from three independent 
experiments, with similar results. (F) Mean brain edema in HbSADHmox1+/- mice treated as in (E), at 
ECM onset in air-treated mice ± standard deviation (n=3–4/group). (G) Mean free heme in plasma of 
HbSADHmox1+/- mice treated as in (E) ± standard deviation (n=4–6/group). (H) Survival of infected 
HbSADHmox1+/- mice exposed to CO (250ppm; days 4–7 postinfection) and receiving vehicle (n=8) or 
heme (20 mg/kg, every 12 hr, days 4–7 postinfection) (n=8). Pooled from two independent experiments, 
with similar results. (I) Mean brain edema in HbSADHmox1+/- mice treated as in (H), at ECM onset in 
heme-treated mice ± standard deviation (n=3–4/group). Grey shading in (B, C, E, and H) indicates 
expected time of ECM. 
 150 
Instead, its protective effect was associated with reduction of 
plasma free heme concentration, below that of naïve 
HbSADHmox1+/- mice (Figure 4.11 G). Administration of free heme 
to infected HbSADHmox1+/- mice abrogated the protective effect of 
CO, restoring ECM incidence (Figure 4.11 H), confirmed by brain 
edema (Figure 4.11 I). Heme was not toxic when administered at 
the same dosage and schedule to naïve HbSADHmox1+/- mice 
receiving CO, i.e. 0% mortality. These observations demonstrate 
that sickle Hb suppresses the onset of ECM via the induction of 
HO-1 and the production of CO, which inhibits the accumulation 
of free heme thus affording tolerance to Plasmodium infection 
(Figure 4.15). 
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Figure 4.12. CO and Heme do not Affect Parasitemias in Infected HbSAD and HbSADHmox1+/- Mice  
(A) Mean percentage of P. berghei ANKA infected RBC (parasitemia) in HbSAD mice receiving vehicle 
(n=8) or heme (days 4-7 postinfection, 30 mg/kg bw, every 12 h; n=8) ± standard deviation. (B) Mean 
percentage of P. berghei ANKA infected RBC (parasitemia) in infected HbSADHmox1+/- mice exposed to 
air (n=8) or CO (250 ppm, days 4-7 postinfection; n=12) ± standard deviation. (C) Mean percentage of 
P. berghei ANKA infected RBC (parasitemia) in infected HbSADHmox1+/- mice exposed to CO (250 ppm, 
days 4-7 postinfection) and receiving vehicle or heme (days 4-7 postinfection, 25 mg/kg bw, every 12 h; 
n=8) ± standard deviation. 
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Figure 4.13. Heme Regulates HO-1 Expression and Confers Tolerance to Plasmodium Infection Via 
CO. Hmox1 mRNA was measured by qRT-PCR in the (A) whole blood (B) spleen and (C) bone marrow of 
Hbwt mice 12 hours after receiving heme at the dosage indicated (mg/kg bw; i.p.). Circles represent single 
mice and red lines mean values (n=4-5/group), (D) Survival and (E) mean percentage ± standard deviation 
of P. berghei ANKA infected RBC (parasitemia) in Hbwt mice receiving vehicle (n=15) or heme (mg/kg bw, 
every 48h, from day 2 pre-infection to 4 postinfection; n=9-10/group). Results shown were pooled from 
three independent experiments, with similar results.  
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4. DISCUSSION  
 
The protective effect of sickle human Hb against malaria 
is thought to rely on the reduction of parasite load2,8,26, implying 
that sickle human Hb affords resistance35,36 to Plasmodium 
infection. Consistent with this notion, sickle human Hb decreases 
RBC permissiveness to Plasmodium invasion and growth40,41 
while increasing phagocytosis of infected RBC, as assessed ex 
vivo42. Whether these effects account for the protective effect of 
sickle human Hb in vivo remained to be established. We used a 
well-established mouse model of malaria allowing for genetic 
manipulation of the host, to test in vivo the relative contribution of 
host specific genes to the protective effect of sickle Hb against 
A                    B 
                     
C    D 
  
Figure 4.14. Heme Administration Mimics the Immunoregulatory Effect of HbSAD. (A) Number of 
CD8+ T cells specific for the P. berghei ANKA-encoded MHC I-restricted epitope derived from 
glycoprotein B of herpes simplex virus-1 (gB498-505), in the spleen of naïve or infected with P. berghei 
ANKA Hbwt mice (5 days postinfection). Hbwt received (+) or not (-) heme (35 mg/kg, i.p., every 48h, from 
day 2 pre-infection to 4 postinfection). (B) Number of splenic CD8+GrB+ T cells in the same mice as in 
(A). (C) Representative flow cytometry dot plots of splenic CD8+ T cells recognizing the gB498-505 epitope 
in the same mice as in (A). (D) Representative flow cytometry dot plots of splenic CD8+GrB+ T cells in 
the same mice as in (C). Circles in (A) and (B) represent single mice and red lines mean values (n=6-
8/group), pooled from 2 independent experiments with similar results. Numbers in gray (C and D) 
indicate the percentage of cells inside the gates. 
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Plasmodium infection. For technical and ethical reasons these 
studies can only be performed in rodent models of malaria. 
As demonstrated hereby, sickle Hb affords protection 
against Plasmodium infection in mice (Figure 4.1 A and Figure 
4.4), a finding consistent with previous reports using different 
mouse and Plasmodium strains43,44. This survival advantage 
occurs irrespectively of parasite load (Figures 4.1 E and 1F) and 
is not associated with modulation of parasite sequestering in 
different organs (Figure 4.3), revealing that sickle human Hb 
confers tolerance35,36 to Plasmodium infection. This is consistent 
with our recent observation that heme catabolism by HO-1 also 
suppresses development of multiple organ dysfunction 
associated with the pathogenesis of severe sepsis in mice45, a 
lethal outcome of polymicrobial infection that resembles, in some 
aspects, severe malaria46. Since the survival advantage 
conferred by HbS against malaria in human populations can 
occur without overt decrease of parasite load32-34, tolerance to 
Plasmodium infection might also operate in individuals 
expressing sickle Hb. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. Protective Effect of Sickle Hb against ECM. Release of Hb from sickle RBC leads to 
chronic accumulation of cell-free Hb and release of its heme prosthetic groups. Free heme induces HO-
1 expression in bone marrow (BM) and white blood (WB) cells, via a mechanism involving Nrf2. Heme 
catabolism by HO-1 produces CO that prevents (STOP I) further heme release from the cell-free Hb 
after Plasmodium infection, suppressing the pathogenesis of ECM. Moreover, sickle human Hb exerts 
an immunoregulatory effect that appears to act independently of Nrf2 and/or HO-1 and that inhibits 
(STOP II) cytotoxic GrB+CD8+ T cells (TC) activation and expansion. APC: Antigen presenting cell. 
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We provide evidence for the existence of a specific 
molecular mechanism via which sickle human Hb confers 
tolerance to Plasmodium infection. When expressed at 
nonpathological levels in mice, sickle Hb leads to the 
accumulation of low concentrations of free heme in plasma 
(Figure 4.11 A). The same is true for individuals carrying the 
sickle cell trait7, which affords protection against malaria1,5,8,9. 
Presumably, this is due to the higher rate of heme release from 
sickle versus normal human Hb10. In the absence of overt 
inflammation, free heme induces HO-1 expression without 
causing cytotoxicity11,13. Presumably, this explains how sickle 
human Hb induces the expression of HO-1 in human24 and 
mouse (Figure 4.4 A) peripheral blood mononuclear cells as well 
as in human endothelial cells47,48. Expression of HO-1 prevents 
the cytotoxic effects of free heme11,13, hence limiting the 
pathological outcome of sickle cell anemia in mice23. 
The mechanism via which sickle Hb induces the 
expression of HO-1 in vivo involves Nrf2 (Figure 4.9 A), a 
transcription factor previously shown to regulate Hmox1 
expression16,17. Induction of HO-1 via Nrf2 affords protection 
against malaria in HbSAD mice expressing sickle Hb (Figure 4.4 A 
and B, Figure 4.9 A and B). This protective effect occurs 
irrespectively of parasite load (Figure 4.4 F and Figure 4.9 D) or 
parasite sequestration in different organs (Figure 4.3), revealing 
that sickle human Hb affords tolerance to Plasmodium infection 
via the Nrf2/HO-1 system. 
The protective effect of HO-1 against sickle cell anemia23 
and against malaria is mediated by the same end product of 
heme catabolism, namely CO (Figures 4.11 E and F). This 
gasotransmitter inhibits Hb oxidation and subsequently heme 
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release from Hb10 (Figure 4.11 G), thus preventing free heme 
from participating in the pathogenesis of ECM (Figures 4.11 H 
and I)21 (Figure 4.15). However, CO might have additional 
protective effects that contribute to prevent the lethal outcome of 
Plasmodium infection14. 
Other end-products of heme catabolism by HO-1, such as 
labile iron, might also contribute to the protective effect conferred 
by sickle Hb against malaria. While cytotoxic per se, labile iron 
induces the expression of ferritin H chain (FtH)49,50, which confers 
cytoprotection against free heme in vitro11.  
The pathogenesis of ECM relies on a ‘‘multiple hit’’ 
system in which free heme synergizes with other cytotoxic 
agonists, e.g. pathogenic CD8+ T cells, to trigger disease 
onset14,21. While sickle Hb suppresses both, accumulation of 
pathogenic free heme (Figure 4.11 A) and activation and/or 
expansion of pathogenic CD8+ T cells (Figure 4.8), it appears to 
do so via different mechanisms. Namely, it inhibits the 
accumulation of free heme after infection, via the HO-1/CO 
system (Figures 4.11 A and G) while restraining the activation 
and/or expansion of pathogenic CD8+ T cells (Figure 4.8), via a 
mechanism that does not seem to involve HO-1 (Figure 4.8) or 
Nrf2 (Figure 4.10). This latter effect is in keeping with the likely 
immunoregulatory basis of the protective effect of sickle cell trait 
against severe malaria in human populations51. While the 
immunoregulatory effect of sickle Hb appears to be driven by free 
heme (Figure 4.14) its molecular mechanism acts via a signal 
transduction pathway that remains to be established and that 
might target antigen presenting cells, e.g. dendritic cells, and/or 
CD8+ T cells. 
It is possible that chronic hemolysis, associated with 
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oxidation of cell-free Hb and production of circulating free heme, 
acts as a general protective mechanism against severe forms of 
malaria in human populations. This would contribute to explain 
the survival advantage conferred by a variety of RBC mutations 
against P. falciparum infection. In keeping with this notion, many 
of these RBC mutations can induce hemolysis (spontaneously or 
upon oxidative challenge) associated with the accumulation of 
circulating free heme7. Some of these also afford protection 
against CM as illustrated for HbC3,26, glucose 6 phosphate 
dihydrogenase (G6PD) deficiency in males52, β or α-thalassemia 
that confer protection mainly against severe anemia caused by P. 
falciparum infection26 as well as other RBC cytoskeleton or 
membrane protein defects5. The notion that chronic hemolysis 
might be protective per se against severe forms of malaria is 
strongly supported by the observation that heme administration 
to naïve mice, is sufficient per se to elicit a protective response 
(Figure 4.11 B and Figure 4.14), relying, presumably on the 
induction of the Nrf2/ HO-1 system. This is however, difficult to 
prove because the same Nrf2/HO-1 system provides protection 
against the pathological outcome of some of these RBC 
mutations, as demonstrated for sickle cell disease23. 
In conclusion, we suggest that induction of the Nrf2/HO-1 
system associated with sickle cell trait and probably with other 
often clinically silent genetic RBC defects might provide a general 
protective mechanism against Plasmodium infection in human 
populations. We propose that modulation of the Nrf2/HO-1 
system might be used therapeutically to treat severe forms of 
malaria and in particular CM. 
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5. Tables 
 
Table 4.1. Hematological parameters of HbWTHmox1+/+ 
HbSADHmox1+/+, HbSADHmox1+/+ mice. 
 Non-infected 
  Hbwt HbSAD Hmox1+/+ HbSAD Hmox1+/- 
RBC (106/ml) 8.24±0.4 8.04±0.3 8.06±0.3 
Hb (g/dl) 12.7±0.7 12.3±0.8 12.2±0.5 
Hemtocrit (%) 34.2±1.9 32.0±1.4 32.1±1.0 
MCV (fl) 41.5±1.3 39.9±0.8 39.8±0.9 
MCHC (%) 37.1±1.0 38.5±2.1 38.1±1.1 
Leukocytes (x103/µl) 9.03±3.5 13.85±2.4 12.27±3.8 
Neutrophils (x103/µl) 1.81±1.3 2.06±0.9 2.76±1.6 
Lymphocytes (x103/µl) 6.0±1.6 10.81±1.5 12.01±3.37 
Monocytes (x103/µl) 0.96±0.4 1.14±0.4 1.33±0.06 
Eosinophils (x103/µl) 0.27±0.27 0.24±0.22 0.36±0.34 
Basophils/µl 76.3±91.2 55.0±86.2 13.8±38.9 
Platelets (x103/µl) 0.47±0.18 0.56±0.1 0.80±0.09 
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Table 4.2. Increased mortality in HbSAD mice carrying two deleted 
alleles of Hmox1 and Nrf2 
 
A 
HbSAD Hmox1+/- x HbWTHmox1+/- 
HbSADHmox1+/+ HbSADHmox1+/- HbSADHmox1-/- 
N=148 N=320 N=1 
10.9% 23.56% 0.07% 
HbWTHmox1+/+ HbWTHmox1+/- HbWTHmox1-/- 
N=293 N=575 N=21 
21.28% 42.34% 1.55% 
     Note: HbSADHmox1-/- vs HbWTHmox1-/-: p<0.00001 
 
B 
HbSADNrf2+/- x HbWTNrf2+/- 
HbSADNrf2+/+ HbSADNrf2+/- HbSADNrf2-/- 
N=58 N=93 N=7 
9.93% 15.92% 1.2% 
HbWTNrf2+/+ HbWTNrf2+/- HbWTNrf2-/- 
N=99 N=247 N=80 
16.95% 43.29% 13.7% 
       Note: HbSADNrf2-/- vs HbWTNrf2-/- : p<0.00001 
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6. METHODS 
 
Mice 
C57BL/6 Hmox1+/- mice were provided by Shaw-Fang Yet 
(Brigham and Women’s Hospital, Boston)53. C57BL/6 Nrf2-/- mice 
were obtained from the RIKEN BioResource Center (Koyadai, 
Tsukuba, Ibaraki, Japan)54. C57BL/6 HbSAD mice (expressing 
19% HbSAD, i.e. aH2β2SAD) were provided originally by Annie Henri 
(INSERM U733 IUH Hôpital Saint-Louis, Paris)27. The transgenic 
HbSAD mice used in this study are hemizygotes for a cluster of 
human genes including one copy the Hb β SAD gene and two 
copies of α gene28. The insertion site of this cluster in the mouse 
genome was not determined. The human α globin chains 
represent about 50% of the total α chain content, while the β 
SAD chain is only 19% of the total β chains. These human chains 
are not expressed in addition to the mouse globin chains but at 
their expense. The ratio of α/β globin chain synthesis remains 
normal. The relative excess in human α globin chains (compared 
to the β SAD chains) form functional human α/β mouse hybrid 
Hb. The Hb content in RBC remains normal (Table 1). The 
various blood counts are in the normal range (Table 1). However, 
SAD RBC exhibit a slight dehydration, which revealed by an 
increase in the intracellular Hb concentration (MCHC) (Table 1). 
This is expected from the presence of HbSAD (loss of 3 negative 
charges and an increased isoelectric charge). This modest 
modification is also seen in HbC heterozygote state in human 
and it plays a role in the S/C syndrome when associated with the 
S determinant in compound heterozygote. While hemizygous 
HbSAD can develop typical complications of sickle cell disease, 
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e.g. generalized congestion and microvascular occlusions, 
occasionally with thrombosis and infarctions of lung, kidneys, 
penis and myocardium these occur only when HbSAD mice are 
exposed to hypoxia or upon extensive aging, i.e. 38-75 weeks28. 
HbSAD neonates exhibit transient anemia at delivery, related to 
hemolysis caused by HbSAD polymerization, most probably due to 
transient hypoxia associated with late fetal development and 
delivery. Hb values in HbSAD mice return to normal levels shortly 
after weaning27. HbSAD mice used in the experiments described 
hereby were under the age of 18 weeks presenting no overt 
hematological changes (Table 1) or complications of sickle cell 
disease. HbSADHmox1+/- and HbSADNrf2+/- mice were generated 
from HbSADHmox1+/- x Hbwt Hmox1+/- or HbSADNrf2+/- x HbwtNrf2+/- 
breeding, respectively (Table 2). C57BL/6.Sv129 HbA/A mice, a 
knock-in mouse model expressing exclusively human Hb without 
the endogenous mouse Hb were provided originally by Tim 
Townes (University of Alabama at Birmingham, USA)30. HbA/A 
mice present normal RBC morphology and hematologic 
parameters30. Breeding of the HbA/A with C57BL/6 Hbwt mice (or 
C57BL/6 Hba/a) resulted in the production of HbA/a mice, 
expressing only one copy of the human Hb chains (HbA) and one 
copy of the endogenous mouse Hb chains (Hba). Interbreeding of 
HbA/a mice produced, among other genotypes, HbA/a mice and 
littermate control Hba/a mice expressing only the endogenous 
alleles of the mouse Hb chains. Both genotypes, i.e. HbA/a and 
Hba/a mice, presented regular Hb levels, 11.0 ± 0.5 and 12.1 ± 
0.9 (g/dl), respectively; hematocrit, 40.1 ± 2.5 and 41.8 ± 2.6 (%), 
respectively and RBC counts, 8.6 ± 0.5 and 8.3 ± 0.6 (x106/mL), 
respectively, but decreased levels of Mean Cell Hemoglobin 
content (MCHC), 27.5 ± 2.0 and 28.8 ± 1.4 (g/dl), respectively. 
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Mice were genotyped by PCR (Hmox1 and Nrf2) and isoelectric 
focusing (Hb), as described elsewhere21,27. Experimental 
protocols were approved by the ‘‘Instituto Gulbenkian de Ciência 
animal care committee’’ and by the ‘‘Direcção Geral de 
Veterenária (DGV)’’ of the Portuguese Ministry of Agriculture, 
Rural Development and Fisheries (License 018831-2010-09-03). 
 
Bone Marrow Chimeras 
Bone Marrow chimeras were generated in Hmox1+/+, 
Hmox1+/- mice expressing or not the HbSAD allele (8-10 weeks). 
Mice (recipients) were lethally irradiated (900 rad, 2.35 minutes, 
137Cs source) (Gammacell 2000, Mølsgaard Medical, Denmark) 
and reconstituted 4 hours thereafter with 106 total bone marrow 
cells from Hmox1+/+, Hmox1+/- expressing or not the HbSAD allele 
(6 weeks). Chimerism was assessed 8-10 weeks thereafter by 
RT-PCR, as described12. Flow cytometry was used to assess 
percent and total number of circulating cells in reconstituted mice 
as compared to control nonchimeric mice. 
 
Parasites, Infection, and Disease Assessment 
Mice were infected by intraperitoneal (i.p.) inoculation of 
105 RBCs infected with (GFP)-P. berghei ANKA21, GFP-
Luciferase P. berghei ANKA (MR4-866) or a (GFP)-P. berghei 
transgenic parasite expressing different MHC II and MHC I 
restricted epitopes including the MHC I-restricted epitope derived 
from glycoprotein B of herpes simplex virus-1 (gB498-505)39, 
provided originally by William R. Heath (Walter and Eliza Hall, 
Melbourne, Victoria, Australia). Drug-resistant P. berghei ANKA 
transfectants were selected using Pyrimethamine (10 mg/ml in 
drinking water). Parasitemias were determined by flow 
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cytometry21. Infected mice were monitored twice daily for clinical 
symptoms of ECM including hemi- or paraplegia, head deviation, 
tendency to roll-over on stimulation, ataxia and convulsions. All 
experiments were performed in mice sacrificed under CO2 and 
perfused with PBS, at the time of ECM in control mice. 
 
Visualization and Quantification of Luciferase Activity P. 
berghei ANKA Infected Mice 
Luciferase activity was visualized by imaging of dissected 
tissues using an electron multiplying-charge-coupled device (EM-
CCD) photon-counting camera (ImagEM, Hamamatsu). Mice 
received d-Luciferin (i.p.) in PBS (100 mg/kg of body weight; 
Promega) at day 7 postinfection, at the time of ECM onset. Mice 
were sacrificed and perfused with PBS 5 min thereafter. Organs 
were dissected, placed in a Petri dish and exposed (5–120s). 
Imaging quantification was performed with ImageJ software and 
is expressed arbitrary units per mg of tissue. 
 
Protoporphyrins 
Iron-protoporphyrin IX (FePPIX; heme) and zinc-
protoporphyrin IX (ZnPPIX) were dissolved in 0.2 M NaOH, 
neutralized (pH 7.4) with 0.2 M HCl and administered (i.p.), as 
described21. 
 
HO-1 Activity 
Spleen and liver were harvested and snap frozen in liquid 
nitrogen. Tissue samples were homogenized in 3mL of 
homogenizing buffer (200 mM KH2PO4, 135 mM KCl, 0.1 mM 
EDTA, [pH 7.4]), and sonicated at 4ºC. The supernatant was 
transferred to ultracentrifuge tubes and 5mL of homogenizing 
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buffer was added, followed by an ultracentrifugation (100.000g, 
4ºC, 1h, Beckman L7-35 Ultracentrifuge, 70 Ti rotor). The 
microsomal pellet was resuspended in 320 ml of HO activity 
buffer (100 mM KH2PO4, 2 mM MgCl2, [pH 7.4]). Samples were 
sonicated again, centrifuged and the supernatant was used to 
determine HO activity using rat liver cytosol (as a source of 
biliverdin reductase, 2 mg/assay), hemin (20 mM), glucose 6-
phosphate (2 mM), glucose 6-phosphate dehydrogenase (0.2 
U/reaction) and NADPH (0.8 mM) (400 µl 37ºC, 1 hr). Bilirubin 
was extracted (1 ml of chloroform; vortexing 3x for 10 sec.). After 
centrifugation optical densities at λ=464 nm and λ=530 nm of the 
organic phase were determined and HO activity was calculated 
as pmol bilirubin formed/mg of tissue/hour. 
 
CO treatment 
Mice were placed in a gastight 60 L capacity chamber 
and exposed continuously between days 4-7 postinfection to CO 
at a flow rate of ~12 L/min (final concentration of 250 parts per 
million; ppm), as described21,55. CO concentration was monitored 
using a CO analyzer (Interscan Corporation, Chatsworth). 
 
Histology 
Brains were harvested, when clinical signs of ECM were 
noticed in control mice. Tissue was fixed in buffered 4% (vol/vol) 
paraformaldehyde and histological analysis was performed on 
perfusion-fixed tissues. 
  
BBB Permeability 
Mice were injected intravenously (i.v.) with 0.1 ml of 2% 
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Evans Blue (Sigma) when clinical symptoms of ECM were 
noticed in control mice. Mice were sacrificed 1h thereafter. Brains 
were weighted and placed in formamide (Merck) (37ºC, 48h) to 
extract Evans Blue dye. Absorbance was measured at λ=620 nm 
(Spectronic Unicam, Heλios β). Evans Blue concentration was 
calculated from a standard curve of Evans Blue and is expressed 
as mg of Evans Blue per g of brain tissue21. 
 
Analyzes of splenic CD8+ T cell activation 
Single cell suspensions were obtained from spleen of 
naïve mice or five days after infection with a transgenic P. 
berghei ANKA strain encoding the MHC I-restricted epitope 
derived from the glycoprotein B of herpes simplex virus-1 (gB498-
505)39. For intracellular granzyme B staining splenocytes (1x106) 
were re-stimulated in vitro (5 hours, 37ºC) with 100ng/ml of 
phorbol 12-myristate 13-acetate (Sigma), 500ng/ml Ionomycin 
(Calbiochem) in the presence of 10mg/ml brefeldin A (Epicenter 
Technologies). Fc receptors were blocked using anti-FcγIII/II 
(2.4G2) receptor antibody (produced in house) and cells were 
stained with anti-CD8 antibody (YTS169.4 clone, produced in 
house). Cells were fixed (2% paraformaldehyde in PBS, 30 min, 
RT) and permeabilized (0,5% saponin in PBS 2% FCS, 10 min, 
RT) prior to the addition of anti-granzyme B antibody (16G6 
clone, eBioscience) in 0,5% saponin in PBS 2% FCS (30 min, 
RT). For the analyzes of CD8+ T cells recognizing the MHC I-
restricted epitope gB498-505 (SSIEFARL) from glycoprotein B of 
herpes simplex virus-1, splenocytes (2x106) were stained with R-
phycoerythrin-conjugated H-2Kb-gB498–505 pentamer (ProImmune) 
according to manufacturer instructions prior to staining with anti-
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CD19 (MB19-1, eBioscience) and anti-CD8 antibodies. H-2Kb-
gB498–505 pentamer positive cells were determined as CD19-
CD8+H-2Kb-gB498–505+. Data were acquired using FACSCalibur 
(BD Bioscience) and CyAn ADP (Dako Cytomation) and 
analyzed using FlowJo software (Tree Star Inc.). Dead cells were 
excluded from analysis based on propidium iodide staining. 
 
Leukocyte Brain Infiltration 
Leukocytes were isolated from the brain of P. berghei 
ANKA infected mice when clinical symptoms of ECM were 
detectable in control groups. Mice were perfused with PBS in 
toto, brains were collected, homogenized, digested (30 min, 
37ºC) in Hanks-balanced salt solution (HBSS; Life Technologies) 
supplemented with 0.2 mg/ml collagenase VIII (Sigma-Aldrich), 
strained (100 µm) (Becton Dickinson) and centrifuged (1200 g; 
10 min). Brain leukocyte infiltration was quantified by flow 
cytometry21. 
 
Quantitative Real-Time Reverse Transcription PCR 
Mice were sacrificed at the day of ECM onset in Hbwt 
mice. RNA was isolated from brain, liver, kidney, heart, bone 
marrow, spleen and lungs using Trizol Reagent (Invitrogen, Life 
technologies) and RNeasy Plus Mini Kit (Quiagen), according to 
manufacturers recommendation. RNeasy Protect Animal Blood 
Kit (Quiagen) was used for the extraction of RNA from whole 
blood. cDNA was synthesized as described21. Hmox1 mRNA was 
quantified by qRT-PCR (Roche System) as described21. TaqMan 
Gene Signature Mouse Immune Array (Applied Biosystems) was 
used to quantify all other mRNAs (7900HT ABI system), 
according to manufacturers´ recommendations. 
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Serum Biochemistry 
Blood was collected in heparinized tubes by cardiac 
puncture, centrifuged (2x5min, 1600g). Hematograms were 
measured by focused flow technology (Hemavet Multispecies 
Hematology System, HV950FS, Drew Scientific Inc., CDVET 
Lab, Centro Diagnóstico Veterinário, Lisboa, Portugal). Plasma 
Hb was determined by spectroscopy at λ=577. Total plasma 
heme was measured using the 3,3´, 5,5´ tetramethylbenzidine 
(TMB) peroxidase assay (BD Biosciences), at λ=655 nm. Purified 
Hb was used as standard for plasma Hb and heme 
measurements. 
 
Statistical Analysis 
Nonparametric Mann-Whitney U test was used to assess 
statistical significance between averages in different samples in 
which n<5. In samples with n=5 or n>5 the unpaired Student’s t-
test for unequal variances was used. Normal distributions were 
confirmed using the Kolmogorov-Smirnov test. Significant 
differences in survival were evaluated by the generation of 
Kaplan-Meier plots and by performing log-rank analysis for all 
experiments in which survival was assessed as an end-point. 
Statistical analysis for the progeny-expected ratios was 
performed using Pearson’s chi-squared tests. *P<0.05 or 
**P<0.01 were considered statistically significant. 
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Chapter 5: General Discussion 
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An inexorable side effect of immune responses is the 
generation of immune-mediated tissue damage. The very same 
mechanisms used by innate and adaptive immune cells to control 
infectious agents also affect host cells, leading to varying 
degrees of immunopathology. An immune response able to 
control the deleterious effects of pathogen overgrowth and, at the 
same time, preserve host tissue integrity could be regarded as 
the perfect immune response. Nonetheless, tissues should not 
be seen as passive bystanders as immunopathology ensues, as 
they can and do engage genetic programs devoted to dealing 
with harmful insults by augmenting tissue resilience to immune-
mediated damage. In this thesis data supporting a role for the 
immune system and tissues in avoiding immunopathology is 
presented. First, it is demonstrated that DC efficiently expand 
TREG, a major cell population involved in preventing 
immunopathology (see chapter 2). Second, it is demonstrated 
that HO-1 expression affords protection against development of 
severe sepsis by decreasing overall tissue damage (see chapter 
3).  Third, it is demonstrated that protection conferred by HbSAD 
against ECM development in mice depends on a composite 
effect of increased expression of HO-1, and on an 
immunoregulatory effect leading to diminished immune activation 
(see chapter 4). 
The importance of TREG in maintaining immune tolerance 
and avoiding autoimmunity has long been known6. Importantly, 
TREG also play a fundamental role in controlling immunopathology 
associated with immune responses against non-self antigens, 
such as allografts358 and infectious agents359. These findings 
imply that a pool of non-self antigen-specific TREG is present in 
the naïve host and/or that naïve CD4+ T cells become TREG upon 
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encounter with foreign antigen. Herein we provide evidence that 
the TREG pool specific for non-self antigens, namely alloantigens, 
can be expanded in vitro when in contact with DC regardless of 
DC activation state (see chapter 2). Most importantly, TREG 
expanded in such conditions are able to suppress T cell 
proliferation in vitro and immunopathology in vivo360. 
The capacity of DC to stimulate TREG cells expansion 
during an immune response might be determinant in preventing 
immunopathology by maintaining an ideal ratio between effector 
T cells and TREG, allowing the immune system to act towards the 
elimination of the harmful insult while, at the same time, 
preventing immunopathology. It is possible that the expansion of 
these two T cell compartments follows different kinetics allowing 
for a powerful initial T cell response, followed by a wave of 
regulation provided by expanded TREG. The possibility of TREG 
expansion by DCs uncovers a mechanism via which the immune 
system might control the development of immunopathology 
through interactions among its own cells, regardless of the tissue 
being affected. 
On the opposite extreme of the control of 
immunopathology via interactions solely among immune cells, is 
the notion that tissues being damaged can modulate their 
capacity to withstand injury. Genes involved in limiting 
immunopathology by increasing tissue resilience to damage are 
often called cytoprotective genes, and Hmox1 is thought to be a 
prototypic gene involved in preventing immunopathology via this 
mechanism (see chapter 1, section 2). Herein, data providing 
evidence that Hmox1 expression has salutary effects on the 
development of severe sepsis serves as an example of such a 
mechanism. 
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By controlling heme levels, Hmox1 expression prevents 
tissue damage caused by the concerted cytotoxic action of heme 
and inflammatory agonists such as those elicited by CLP (see 
chapter 3). The absence of apparent excessive immune 
activation or increased bacterial load in Hmox1-/- mice 
undergoing CLP, suggest that lethality observed in these animals 
derives from an inability of organs to sustain normal function 
under severe inflammatory conditions. Most probably, organ 
dysfunction occurs as a result of massive cell death induced by 
high heme levels in conjunction with proinflammatory agonists 
(see chapter 3). Furthermore, the salutary effect of hemopexin 
administration to Hmox1+/+ mice undergoing severe CLP, as a 
mean to scavenge heme from circulation, strongly supports the 
notion that heme triggers widespread tissue damage ultimately 
leading to death. 
These findings evoke the concept of tolerance to infection 
as the mechanism via which Hmox1 expression limits death 
caused by disproportionate immunopathology (see chapter 1, 
section 1.3 and chapter 3). Notwithstanding the findings that 
Hmox1-/- mice present increased organ dysfunction leading 
ultimately to death, and the fact that scavenging heme from 
circulation by hemopexin administration protects Hmox1+/+ from 
death after severe CLP, the conclusion that tolerance to infection 
is involved in these phenotypes requires a more stringent 
analysis. The reasons for this are discussed below.  
 The conclusion that Hmox1 confers tolerance to infection 
can only be taken if one accepts that the uninfected health status 
(uHS, as defined in chapter 1, section 1.3) of naïve Hmox1+/+ and 
Hmox1-/- mice is equal (see figure 5.1 A), an assumption that is 
challenged by several lines of evidence. First, Hmox1-/- mice 
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present severe splenomegaly208,242 and increased white blood 
cell counts208, suggesting that these animals are under a 
constitutive inflammatory state, a notion further supported by the 
finding that monocytes/macrophages in liver and kidney of naïve 
Hmox1-/- express TNF constitutively222. Second, Hmox1-/- present 
progressive wasting disease and anemia208. Third, progressive 
oxidative damage of organs affected by CLP is observed in naïve 
Hmox1-/- mice, as evidenced by increased protein carbonylation 
and lipid peroxidation in liver and kidneys208 with concomitantly 
increased serum ferritin levels, a finding indicative of liver 
damage189. Fourth, naive Hmox1-/- mice develop inflammatory 
infiltration in the liver239. Fifth, heme administration to naïve 
Hmox1+/+ causes profound kidney damage (see chapter 3, figure 
4B) that, per se, lowers the uninfected health status (uHS) of the 
host subjected to CLP. Therefore, it is possible that the direct 
comparison between Hmox1+/+ versus Hmox1-/- mice disregards 
differences in the uninfected health status. This oversight might 
lead to an inaccurate measurement of tolerance to infection (see 
figure 5.1 B). It remains as a possibility that differences in uHS 
occur concomitantly with differences in tolerance to infection. In 
this scenario, Hmox1-/- animals would present both lower uHS and 
decreased tolerance to infection (see figure 5.1 C). Further 
studies will be necessary to determine whether this is the case. 
To obtain a better assessment of tolerance to infection 
and what is the role played by Hmox1 in this process, it would be 
fundamental to use mice where Hmox1 could be deleted shortly 
before infection, thus avoiding the deleterious effects of 
prolonged lack of Hmox1 expression. This could be easily 
achieved with available tools, namely by making use of mice 
where the Hmox1 gene has been flanked by loxP-sites crossed 
 176 
with mice carrying a transgene that would lead to Cre-
recombinase expression and activity upon exogenous stimulus. 
In fact, mice with myeloid-specific ablation of Hmox1 show no 
signs of the pathologies associated with total Hmox1 deletion239, 
further supporting the notion that the use of strategies where 
Hmox1 deletion is controlled might be extremely informative in 
the study of its role in tolerance to infection. 
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More likely than not, in cases where hosts are at risk of 
developing immunopathology, mechanisms involved in 
constraining immune responses and mechanisms involved in 
increasing tissue protection will be used concomitantly. The 
concerted action of both mechanisms seems to work at its best in 
the case of protection against ECM conferred by HbSAD (see 
chapter 4). In HbWT animals ECM development seems to rely on 
     
 
 
Figure 5.1.Three scenarios for tolerance to 
infection in Hmox1+/+ vs Hmox1-/- mice. (A) uHS is 
equal in Hmox1+/+ and Hmox1-/- mice and the 
accentuated decrease in Hmox1-/- health upon 
infection is an effect of decreased tolerance to 
infection alone. (B) uHS differs in Hmox1+/+ and 
Hmox1-/- mice, with tolerance to infection being equal. 
In this case, the apparently sharp decrease in host 
health observed in Hmox1-/- as compared to Hmox1+/+ 
mice reflects only the lower uHS of the former and not 
differences in tolerance to infection. (C) Both uHS and 
tolerance to infection differs in Hmox1+/+ and Hmox1-/- 
mice. In this case, the abrupt decrease in host health 
observed in Hmox1-/- mice derives from a composite 
effect of lower uHS and lower tolerance to infection. 
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a “two hit system”, one being the increased heme levels 
associated with Plasmodium infection, the other being CD8+ T 
cell-mediated cytotoxicity. Most importantly, these “two hit” seem 
to be controlled by distinct mechanisms. This is revealed by the 
fact that HbSAD animals lacking one functional Hmox1 or Nrf2 
allele lose the protection associated with HbSAD expression by 
regaining increased levels of heme in circulation, while 
maintaining low levels of CD8+ T cell activation (see chapter 4). 
Nonetheless, it is important to note that this observation might be 
related to a gene dosage effect. In fact, the immunomodulatory 
effect of HbSAD might be lost in the complete absence of Hmox1 
or Nrf2 expression. Unfortunately, the experimental system used 
herein does not allow for such analysis to be done (see chapter 
4). 
The expression of HbSAD limits the increase in circulating 
heme levels upon Plasmodium infection by a mechanism that 
involves increased expression of Hmox1 via Nrf2 activation. The 
occurrence of chronic hemolysis in HbSAD mice presumably leads 
to high levels of Hmox1 expression via the action of the Nrf2 
transcription factor. That, in turn, avoids pathological levels of 
heme to accumulate upon Plasmodium infection. Furthermore, 
increased HO-1 expression and heme catabolism will 
presumably lead to increased CO production that can act to 
avoid unlocking of heme from hemoproteins thus limiting heme 
release. Interestingly, disruption of one allele of Hmox1 or Nrf2 
abrogates the protection conferred by HbSAD, by impairing the 
capacity of these animals to control heme levels upon 
Plasmodium infection. Notably, disruption of one allele of Hmox1 
or Nrf2 did not affect CD8+ T cell activation impairment in mice 
carrying HbSAD. This finding indicates that ablation of one Hmox1 
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or Nrf2 allele is not sufficient to revert the decreased CD8+ T cell 
activation phenotype. As noted before, it is possible that a 
complete ablation of Hmox1 or Nrf2 would revert the effect of 
HbSAD on CD8+ T cell activation. Nonetheless, alternative 
explanations for the immunomodulatory effect of HbSAD are 
discussed below. 
Data obtained from mRNA expression analysis in the 
brains of HbWT, HbSAD and HbSADHmxo1+/- mice, at the time of 
ECM onset, suggests that innate immune activation is 
suppressed in HbSAD and HbSADHmxo1+/- mice (see chapter 4, 
figure 6). mRNA encoding IL-1β, IL-6, TNF, CD40 and inducible 
nitric oxide synthase (NOS2) enzyme, are all downregulated in 
the brains of HbSAD and HbSADHmxo1+/- mice as compared to the 
levels observed in HbWT animals. These findings suggest that 
HbSAD induces a broad modulation of innate and adaptive 
immunity that is not reverted in the absence of one functional 
Hmox1 allele. Since data indicating impaired innate immune 
activation derives from mRNA obtained from brains of animals 
undergoing ECM, it becomes difficult to determine whether this is 
cause or consequence of diminished CD8+ T cell activation. 
However, given the pivotal role of innate immune cells in initiating 
adaptive immune responses, the hypothesis that protection 
conferred by HbSAD against ECM relies primarily on innate 
immune suppression leading to defective adaptive immune 
activation will be discussed in further detail. 
HbSAD mice have been reported to constitutively express 
higher levels of erythropoietin (EPO) than WT animals. The 
elevated EPO levels in HbSAD mice could, per se, account for the 
immunosuppression observed in these animals. It has been 
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recently demonstrated that macrophages and DC express EPO 
receptor361. Furthermore, binding of EPO to EPO receptor inhibits 
macrophage production of the proinflammatory cytokines TNF, 
IL-6, IL-12p70 and IL-23, an effect linked to suppressed NF-κB 
activation upon TLR stimulation and Salmonella infection361. 
Importantly, EPO signaling exacerbated Salmonella infection 
while controlling colitis, demonstrating the functional relevance of 
this pathway in restraining immune responses361. 
Deregulation of iron homeostasis during 
hemoglobinopathies, with consequent alterations in intracellular 
iron pool, might be a general mechanism implicated in the 
protection afforded by different kinds of hemoglobinopathies to 
Plasmodium infection. Regulation of iron homeostasis is a 
systemic response orchestrated in great part by hepcidin, and 
hemoglobinopathies have been linked to decreased levels of 
hepcidin in humans and mice362-365. HbSAD mice are likely to 
present low hepcidin levels. In support of this notion is the 
observation that HbSAD mice present increased EPO production, 
increased erythropoiesis, and hemolysys367,368, three conditions 
associated with lower levels of hepcidin255,366,369. Low hepcidin 
leads to increased levels of FPN expression on cells, with 
consequent depletion of intracellular iron pool. Of note, innate 
immune cells, specially macrophages, but also DC370, have been 
reported to express FPN and, therefore, are subjected to 
intracellular iron content regulation by hepcidin. 
The effect of low intracellular iron in cells of the immune 
system has been extensively reported283,371. Macrophages 
obtained from animals in which the Hfe gene has been disrupted, 
leading to abnormally low hepcidin expression, produce lower 
 180 
levels of pro-inflammatory cytokines in response to PAMP 
stimulation as compared to wild type animals, an effect due to 
increased FPN expression in macrophages and consequent 
intracellular iron depletion286. These effects can be attributed to at 
least two different molecular mechanisms: a) inhibition of 
cytokine translation286 and b) inhibition of TLR signaling285. Since 
the development of adaptive immunity is normally preceded by a 
strong activation of the innate immune system, it is possible that 
decreased intracellular iron levels might impair the ability of 
innate immune cells to induce a full-blown adaptive immune 
response. Therefore, the diminished CD8+ T cell activation 
observed in mice carrying HbSAD might be a consequence of the 
diminished hepcidin levels, leading to lower intracellular iron on 
innate immune cells. Importantly, the immunomodulatory effect of 
low intracellular iron would fine-tune the immune response 
against Plasmodium, allowing parasitemia control while limiting 
immunopathology. 
In fact, expansion and acquisition of effector functions by 
short-lived effector CD8+ T cells, has been reported to rely on a 
strong inflammatory response during the activation phase81. 
Therefore, the failure of CD8+ T cells in HbSAD mice to achieve 
complete expansion and effector differentiation is consistent with 
the hypothesis of a less inflammatory milieu during their 
activation. Curiously, the observation that a milder inflammatory 
environment favors formation of memory CD8+ T cells372, brings 
about the hypothesis that besides partially dampening 
detrimental CD8+ T cell response, HbSAD might increase 
generation of memory CD8+ T cells which could provide long-
term protection against subsequent Plasmodium infections.  
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Indeed, the mechanism described above would predict 
that in the bone marrow chimeras analyzed (see chapter 4, 
Figure 7), diminished CD8+ T cell activation should be observed 
whenever HbSAD or HbSADHmox1+/- bone marrow cells were 
transferred. The presence of HbSAD bone marrow would lead to 
decreased hepcidin production, as a consequence of increased 
EPO levels, erythropoiesis, and hemolysis, associated with the 
presence of HbSAD carrying RBC. In this setting, animals 
receiving HbSADHmox1+/- bone marrow cells would succumb to 
ECM due solely to the limited capacity of their bone marrow-
derived cells to catabolize heme.  
Furthermore, a less inflammatory state, generated by 
control of innate immunity activation in HbSAD mice, could provide 
a more favorable environment for TREG expansion (see chapter 
2). Inducing TREG expansion during ECM can prevent disease, via 
a mechanism that rely on Foxp3+ cells-mediated control of T cell 
activation354. Therefore, the less inflammatory environment 
generated in HbSAD mice upon Plasmodium infection, could lead 
not only to the generation of non-pathological CD8+ T cell 
response, but also to an increase in the TREG compartment, 
adding a further layer of protection against ECM development 
(see figure 5.2).  
Of note, African children with sickle-cell anemia present 
higher risk of developing bacteraemia373, an observation 
consistent with impairment in mounting protective immune 
responses. Furthermore, although some controversy exists in the 
literature374, African children with iron deficiency, a condition 
leading to diminished hepcidin expression, presented lower 
incidence of clinical malaria375,376, while iron supplementation has 
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been associated with increased incidence of severe malaria377 
378,379.  
Heme administration during specific periods of time also 
leads to marked suppression of CD8+ T cell activation (see 
chapter 4, Figure 13). However, the mechanisms responsible for 
this effect remain obscure, since there is no data indicating 
whether it is dependent or not on the HO-1/Nrf2 system. 
Nonetheless, it is possible that, contrary to what might occur in 
HbSAD mice, after heme injection the sharp increase in iron 
concentration leads to a burst in hepcidin production culminating 
in FPN degradation and a transient decrease in inflammatory 
cytokine production. In fact, an acute increase in body iron 
concentration leads to a decreased inflammatory response upon 
LPS challenge. This effect is dependent on hepcidin and 
JAK2/STAT3 induced upregulation of SOCS3 transcription287. 
Therefore, it is plausible that chronic decreased hepcidin 
production and acute increased hepcidin production direct 
inflammatory responses towards the same outcome, that is, 
decreased innate immune activation leading to reduced adaptive 
immune response. 
While speculative at this point, the link between 
deregulated iron homeostasis in HbSAD mice and the observed 
suppression of CD8+ T cell response in these animals is a 
mechanism worth exploring in the effort to determine the 
molecular basis underlying HbSAD-mediated immunoregulation. 
Importantly, hepcidin-dependent regulation of immune responses 
might also occur in other hemoglobinopathies where hemolysis 
occurs, leading to protection against the development of severe 
forms of malaria. Indeed, the role of hepcidin in protecting 
against Plasmodium infection has begun to be addressed. It has 
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recently been reported that hepcidin is responsible for blocking 
secondary Plasmodium infection, in a host with an ongoing 
Plasmodium infection. This blockade occurs by inhibition of 
Plasmodium growth during the liver stage of infection380. This 
data suggests that hepcidin might play a role in resistance 
against Plasmodium infection in the liver stage of the disease. 
Furthermore, the possibility of manipulating iron homeostasis in 
humans by using iron-chelating therapy or iron supplementation 
might open new therapeutical possibilities for controlling 
immunopathology mediated by Plasmodium infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 5.2. Model for hepcidin control of immunopathology in HbSAD mice. HbWT mice, present 
hepcidin levels that prevent high expression of ferroportin, which in turn maintains the level of 
intracelular iron in innate immune cells in a normal range. In HbSAD mice, low hepcidin levels sustain 
high expression of ferroportin, leading to low intracellular iron levels in innate immune cells. Upon 
Plasmodium infection differences in intracellular iron content in innate immune cells determine the 
magnitude of the innate immune responses that, in turn, determines whether the adaptive immune 
response will or not be pathological. HbWT mice present an exacerbated innate immune response 
leading to an adaptive immune response that is capable of controlling parasitemia, but that also causes 
immunopathology. On the other hand, HbSAD mice present a more controlled innate immune activation, 
leading to an adaptive immune response that is still capable of controlling parasitemia, but that does 
not cause immunopathology. In the model presented herein, intracellular iron levels, by controling 
innate immune activation, determines whether a pathological adaptive immune response is generated 
or not. 
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In the present thesis data exploring two different 
strategies employed by hosts to decrease the deleterious effects 
of immunopathology have been analyzed. Namely, mechanisms 
via which the damaging potential of the immune system is 
restrained, by TREG expansion (see chapter 2) and decreased 
CD8+ T cell response (see chapter 4), and mechanisms via which 
tissue resilience to immune-mediated damage is increased, by 
reducing heme availability under highly inflammatory conditions 
(see chapter 3 and 4), have been addressed. The body of work 
presented here suggests that by altering either or both 
mechanisms it is possible to shift disease outcome towards a 
more favorable result to the host. Furthermore, it highlights the 
complexity of mechanisms involved in the pathological outcomes 
of immune-mediated inflammatory diseases and opens new 
possibilities in the quest for therapies targeting disorders where 
the main deleterious effects are consequence of 
immunopathology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 185 
References 
 
 
1. Buckley, R.H. Molecular defects in human severe combined immunodeficiency 
and approaches to immune reconstitution. Annu Rev Immunol 22, 625-655 
(2004). 
2. Conley, M.E., et al. Primary B cell immunodeficiencies: comparisons and 
contrasts. Annu Rev Immunol 27, 199-227 (2009). 
3. Glocker, E.O., et al. A homozygous CARD9 mutation in a family with 
susceptibility to fungal infections. N Engl J Med 361, 1727-1735 (2009). 
4. Hugot, J.P., et al. Association of NOD2 leucine-rich repeat variants with 
susceptibility to Crohn's disease. Nature 411, 599-603 (2001). 
5. Ogura, Y., et al. A frameshift mutation in NOD2 associated with susceptibility to 
Crohn's disease. Nature 411, 603-606 (2001). 
6. Sakaguchi, S. Naturally arising CD4+ regulatory t cells for immunologic self-
tolerance and negative control of immune responses. Annu Rev Immunol 22, 
531-562 (2004). 
7. Saenz, S.A., Noti, M. & Artis, D. Innate immune cell populations function as 
initiators and effectors in Th2 cytokine responses. Trends Immunol 31, 407-413 
(2010). 
8. Chu, C.C., Di Meglio, P. & Nestle, F.O. Harnessing dendritic cells in 
inflammatory skin diseases. Semin Immunol 23, 28-41 (2011). 
9. Ryu, J.H., Kim, C.H. & Yoon, J.H. Innate immune responses of the airway 
epithelium. Mol Cells 30, 173-183 (2010). 
10. Cerf-Bensussan, N. & Gaboriau-Routhiau, V. The immune system and the gut 
microbiota: friends or foes? Nat Rev Immunol 10, 735-744 (2010). 
11. Smith, P.D., et al. Intestinal macrophages and response to microbial 
encroachment. Mucosal Immunol 4, 31-42 (2011). 
12. Medzhitov, R. Recognition of microorganisms and activation of the immune 
response. Nature 449, 819-826 (2007). 
13. Qu, Y., Franchi, L., Nunez, G. & Dubyak, G.R. Nonclassical IL-1 beta secretion 
stimulated by P2X7 receptors is dependent on inflammasome activation and 
correlated with exosome release in murine macrophages. J Immunol 179, 1913-
1925 (2007). 
14. Gasse, P., et al. Uric acid is a danger signal activating NALP3 inflammasome in 
lung injury inflammation and fibrosis. Am J Respir Crit Care Med 179, 903-913 
(2009). 
15. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated 
uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 
(2006). 
16. Ather, J.L., et al. Serum Amyloid A Activates the NLRP3 Inflammasome and 
Promotes Th17 Allergic Asthma in Mice. J Immunol 187, 64-73 (2011). 
17. Halle, A., et al. The NALP3 inflammasome is involved in the innate immune 
response to amyloid-beta. Nat Immunol 9, 857-865 (2008). 
18. Tian, J., et al. Toll-like receptor 9-dependent activation by DNA-containing 
immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8, 487-
496 (2007). 
19. Yanai, H., et al. HMGB proteins function as universal sentinels for nucleic-acid-
mediated innate immune responses. Nature 462, 99-103 (2009). 
20. Ganguly, D., et al. Self-RNA-antimicrobial peptide complexes activate human 
dendritic cells through TLR7 and TLR8. J Exp Med 206, 1983-1994 (2009). 
21. Lande, R., et al. Plasmacytoid dendritic cells sense self-DNA coupled with 
antimicrobial peptide. Nature 449, 564-569 (2007). 
22. Scaffidi, P., Misteli, T. & Bianchi, M.E. Release of chromatin protein HMGB1 by 
necrotic cells triggers inflammation. Nature 418, 191-195 (2002). 
23. Kawai, T. & Akira, S. Toll-like Receptors and Their Crosstalk with Other Innate 
Receptors in Infection and Immunity. Immunity 34, 637-650 (2011). 
24. Elinav, E., Strowig, T., Henao-Mejia, J. & Flavell, R.A. Regulation of the 
Antimicrobial Response by NLR Proteins. Immunity 34, 665-679 (2011). 
 186 
25. Loo, Y.M. & Gale, M., Jr. Immune Signaling by RIG-I-like Receptors. Immunity 
34, 680-692 (2011). 
26. Osorio, F. & Reis, E.S.C. Myeloid C-type Lectin Receptors in Pathogen 
Recognition and Host Defense. Immunity 34, 651-664 (2011). 
27. Nish, S. & Medzhitov, R. Host defense pathways: role of redundancy and 
compensation in infectious disease phenotypes. Immunity 34, 629-636 (2011). 
28. Tamura, T., Yanai, H., Savitsky, D. & Taniguchi, T. The IRF family transcription 
factors in immunity and oncogenesis. Annu Rev Immunol 26, 535-584 (2008). 
29. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 
140, 805-820 (2010). 
30. Fitzgerald, K.A., et al. Mal (MyD88-adapter-like) is required for Toll-like 
receptor-4 signal transduction. Nature 413, 78-83 (2001). 
31. Horng, T., Barton, G.M. & Medzhitov, R. TIRAP: an adapter molecule in the Toll 
signaling pathway. Nat Immunol 2, 835-841 (2001). 
32. Horng, T., Barton, G.M., Flavell, R.A. & Medzhitov, R. The adaptor molecule 
TIRAP provides signalling specificity for Toll-like receptors. Nature 420, 329-
333 (2002). 
33. Yamamoto, M., et al. TRAM is specifically involved in the Toll-like receptor 4-
mediated MyD88-independent signaling pathway. Nat Immunol 4, 1144-1150 
(2003). 
34. Meyer-Wentrup, F., et al. Targeting DCIR on human plasmacytoid dendritic 
cells results in antigen presentation and inhibits IFN-alpha production. Blood 
111, 4245-4253 (2008). 
35. Meyer-Wentrup, F., et al. DCIR is endocytosed into human dendritic cells and 
inhibits TLR8-mediated cytokine production. J Leukoc Biol 85, 518-525 (2009). 
36. Fujikado, N., et al. Dcir deficiency causes development of autoimmune 
diseases in mice due to excess expansion of dendritic cells. Nat Med 14, 176-
180 (2008). 
37. LeibundGut-Landmann, S., et al. Syk- and CARD9-dependent coupling of 
innate immunity to the induction of T helper cells that produce interleukin 17. 
Nat Immunol 8, 630-638 (2007). 
38. Robinson, M.J., et al. Dectin-2 is a Syk-coupled pattern recognition receptor 
crucial for Th17 responses to fungal infection. J Exp Med 206, 2037-2051 
(2009). 
39. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010). 
40. Petrilli, V., et al. Activation of the NALP3 inflammasome is triggered by low 
intracellular potassium concentration. Cell Death Differ 14, 1583-1589 (2007). 
41. Tattoli, I., et al. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-
kappaB and JNK pathways by inducing reactive oxygen species production. 
EMBO Rep 9, 293-300 (2008). 
42. Cruz, C.M., et al. ATP activates a reactive oxygen species-dependent oxidative 
stress response and secretion of proinflammatory cytokines in macrophages. J 
Biol Chem 282, 2871-2879 (2007). 
43. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-
interacting protein links oxidative stress to inflammasome activation. Nat 
Immunol 11, 136-140 (2010). 
44. Hornung, V., et al. Silica crystals and aluminum salts activate the NALP3 
inflammasome through phagosomal destabilization. Nat Immunol 9, 847-856 
(2008). 
45. Kobayashi, K., et al. IRAK-M is a negative regulator of Toll-like receptor 
signaling. Cell 110, 191-202 (2002). 
46. Seki, M., et al. Critical role of IL-1 receptor-associated kinase-M in regulating 
chemokine-dependent deleterious inflammation in murine influenza pneumonia. 
J Immunol 184, 1410-1418 (2010). 
47. Su, J., Xie, Q., Wilson, I. & Li, L. Differential regulation and role of interleukin-1 
receptor associated kinase-M in innate immunity signaling. Cell Signal 19, 
1596-1601 (2007). 
48. Coornaert, B., Carpentier, I. & Beyaert, R. A20: central gatekeeper in 
inflammation and immunity. J Biol Chem 284, 8217-8221 (2009). 
 187 
49. Opipari, A.W., Jr., Hu, H.M., Yabkowitz, R. & Dixit, V.M. The A20 zinc finger 
protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 267, 
12424-12427 (1992). 
50. Lee, E.G., et al. Failure to regulate TNF-induced NF-kappaB and cell death 
responses in A20-deficient mice. Science 289, 2350-2354 (2000). 
51. Boone, D.L., et al. The ubiquitin-modifying enzyme A20 is required for 
termination of Toll-like receptor responses. Nat Immunol 5, 1052-1060 (2004). 
52. Turer, E.E., et al. Homeostatic MyD88-dependent signals cause lethal 
inflamMation in the absence of A20. J Exp Med 205, 451-464 (2008). 
53. Hitotsumatsu, O., et al. The ubiquitin-editing enzyme A20 restricts nucleotide-
binding oligomerization domain containing 2-triggered signals. Immunity 28, 
381-390 (2008). 
54. Lin, R., et al. Negative regulation of the retinoic acid-inducible gene I-induced 
antiviral state by the ubiquitin-editing protein A20. J Biol Chem 281, 2095-2103 
(2006). 
55. Kayagaki, N., et al. DUBA: a deubiquitinase that regulates type I interferon 
production. Science 318, 1628-1632 (2007). 
56. Trompouki, E., et al. CYLD is a deubiquitinating enzyme that negatively 
regulates NF-kappaB activation by TNFR family members. Nature 424, 793-796 
(2003). 
57. Kovalenko, A., et al. The tumour suppressor CYLD negatively regulates NF-
kappaB signalling by deubiquitination. Nature 424, 801-805 (2003). 
58. Matsushita, K., et al. Zc3h12a is an RNase essential for controlling immune 
responses by regulating mRNA decay. Nature 458, 1185-1190 (2009). 
59. O'Neill, L.A., Sheedy, F.J. & McCoy, C.E. MicroRNAs: the fine-tuners of Toll-
like receptor signalling. Nat Rev Immunol 11, 163-175 (2011). 
60. Rothlin, C.V., Ghosh, S., Zuniga, E.I., Oldstone, M.B. & Lemke, G. TAM 
receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 
1124-1136 (2007). 
61. Lu, Q. & Lemke, G. Homeostatic regulation of the immune system by receptor 
tyrosine kinases of the Tyro 3 family. Science 293, 306-311 (2001). 
62. Kim, K.D., et al. Adaptive immune cells temper initial innate responses. Nat 
Med 13, 1248-1252 (2007). 
63. Guarda, G., et al. T cells dampen innate immune responses through inhibition 
of NLRP1 and NLRP3 inflammasomes. Nature 460, 269-273 (2009). 
64. Kim, J.M., Rasmussen, J.P. & Rudensky, A.Y. Regulatory T cells prevent 
catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 8, 191-
197 (2007). 
65. Soares, M.P., Marguti, I., Cunha, A. & Larsen, R. Immunoregulatory effects of 
HO-1: how does it work? Curr Opin Pharmacol 9, 482-489 (2009). 
66. Steinman, R.M. & Cohn, Z.A. Identification of a novel cell type in peripheral 
lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp 
Med 137, 1142-1162 (1973). 
67. Steinman, R.M. & Cohn, Z.A. Identification of a novel cell type in peripheral 
lymphoid organs of mice. II. Functional properties in vitro. J Exp Med 139, 380-
397 (1974). 
68. Steinman, R.M., Lustig, D.S. & Cohn, Z.A. Identification of a novel cell type in 
peripheral lymphoid organs of mice. 3. Functional properties in vivo. J Exp Med 
139, 1431-1445 (1974). 
69. Steinman, R.M., Adams, J.C. & Cohn, Z.A. Identification of a novel cell type in 
peripheral lymphoid organs of mice. IV. Identification and distribution in mouse 
spleen. J Exp Med 141, 804-820 (1975). 
70. Steinman, R.M. & Witmer, M.D. Lymphoid dendritic cells are potent stimulators 
of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci U S A 75, 
5132-5136 (1978). 
71. Jung, S., et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of 
CD8+ T cells by exogenous cell-associated antigens. Immunity 17, 211-220 
(2002). 
72. Tian, T., Woodworth, J., Skold, M. & Behar, S.M. In vivo depletion of CD11c+ 
cells delays the CD4+ T cell response to Mycobacterium tuberculosis and 
exacerbates the outcome of infection. J Immunol 175, 3268-3272 (2005). 
 188 
73. Liu, C.H., et al. Cutting edge: dendritic cells are essential for in vivo IL-12 
production and development of resistance against Toxoplasma gondii infection 
in mice. J Immunol 177, 31-35 (2006). 
74. Zaft, T., Sapoznikov, A., Krauthgamer, R., Littman, D.R. & Jung, S. CD11chigh 
dendritic cell ablation impairs lymphopenia-driven proliferation of naive and 
memory CD8+ T cells. J Immunol 175, 6428-6435 (2005). 
75. Probst, H.C. & van den Broek, M. Priming of CTLs by lymphocytic 
choriomeningitis virus depends on dendritic cells. J Immunol 174, 3920-3924 
(2005). 
76. van Rijt, L.S., et al. In vivo depletion of lung CD11c+ dendritic cells during 
allergen challenge abrogates the characteristic features of asthma. J Exp Med 
201, 981-991 (2005). 
77. Zammit, D.J., Cauley, L.S., Pham, Q.M. & Lefrancois, L. Dendritic cells 
maximize the memory CD8 T cell response to infection. Immunity 22, 561-570 
(2005). 
78. Sporri, R. & Reis e Sousa, C. Inflammatory mediators are insufficient for full 
dendritic cell activation and promote expansion of CD4+ T cell populations 
lacking helper function. Nat Immunol 6, 163-170 (2005). 
79. Reis e Sousa, C. Dendritic cells in a mature age. Nat Rev Immunol 6, 476-483 
(2006). 
80. Zhu, J., Yamane, H. & Paul, W.E. Differentiation of effector CD4 T cell 
populations (*). Annu Rev Immunol 28, 445-489 (2010). 
81. Williams, M.A. & Bevan, M.J. Effector and memory CTL differentiation. Annu 
Rev Immunol 25, 171-192 (2007). 
82. Bonasio, R., et al. Clonal deletion of thymocytes by circulating dendritic cells 
homing to the thymus. Nat Immunol 7, 1092-1100 (2006). 
83. Ohnmacht, C., et al. Constitutive ablation of dendritic cells breaks self-tolerance 
of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 206, 
549-559 (2009). 
84. Hawiger, D., et al. Dendritic cells induce peripheral T cell unresponsiveness 
under steady state conditions in vivo. J Exp Med 194, 769-779 (2001). 
85. Liu, K., et al. Immune tolerance after delivery of dying cells to dendritic cells in 
situ. J Exp Med 196, 1091-1097 (2002). 
86. Bonifaz, L., et al. Efficient targeting of protein antigen to the dendritic cell 
receptor DEC-205 in the steady state leads to antigen presentation on major 
histocompatibility complex class I products and peripheral CD8+ T cell 
tolerance. J Exp Med 196, 1627-1638 (2002). 
87. Carreno, B.M. & Collins, M. The B7 family of ligands and its receptors: new 
pathways for costimulation and inhibition of immune responses. Annu Rev 
Immunol 20, 29-53 (2002). 
88. Lenschow, D.J., Walunas, T.L. & Bluestone, J.A. CD28/B7 system of T cell 
costimulation. Annu Rev Immunol 14, 233-258 (1996). 
89. Tan, J.T., Whitmire, J.K., Ahmed, R., Pearson, T.C. & Larsen, C.P. 4-1BB 
ligand, a member of the TNF family, is important for the generation of antiviral 
CD8 T cell responses. J Immunol 163, 4859-4868 (1999). 
90. Kwon, B.S., et al. Immune responses in 4-1BB (CD137)-deficient mice. J 
Immunol 168, 5483-5490 (2002). 
91. Hendriks, J., et al. CD27 is required for generation and long-term maintenance 
of T cell immunity. Nat Immunol 1, 433-440 (2000). 
92. Keller, A.M., Schildknecht, A., Xiao, Y., van den Broek, M. & Borst, J. 
Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks 
CD8+ T cell tolerance and permits effective immunity. Immunity 29, 934-946 
(2008). 
93. Soares, H., et al. A subset of dendritic cells induces CD4+ T cells to produce 
IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. 
J Exp Med 204, 1095-1106 (2007). 
94. Ito, T., et al. TSLP-activated dendritic cells induce an inflammatory T helper 
type 2 cell response through OX40 ligand. J Exp Med 202, 1213-1223 (2005). 
95. Hsieh, C.S., et al. Development of TH1 CD4+ T cells through IL-12 produced by 
Listeria-induced macrophages. Science 260, 547-549 (1993). 
 189 
96. Le Gros, G., Ben-Sasson, S.Z., Seder, R., Finkelman, F.D. & Paul, W.E. 
Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-
4 are required for in vitro generation of IL-4-producing cells. J Exp Med 172, 
921-929 (1990). 
97. Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M. & Stockinger, B. 
TGFbeta in the context of an inflammatory cytokine milieu supports de novo 
differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006). 
98. Zhou, L., et al. IL-6 programs T(H)-17 cell differentiation by promoting 
sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8, 967-
974 (2007). 
99. Wei, G., et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity 
and plasticity in lineage fate determination of differentiating CD4+ T cells. 
Immunity 30, 155-167 (2009). 
100. Reis e Sousa, C., et al. In vivo microbial stimulation induces rapid CD40 ligand-
independent production of interleukin 12 by dendritic cells and their 
redistribution to T cell areas. J Exp Med 186, 1819-1829 (1997). 
101. Perrigoue, J.G., et al. MHC class II-dependent basophil-CD4+ T cell 
interactions promote T(H)2 cytokine-dependent immunity. Nat Immunol 10, 697-
705 (2009). 
102. Saenz, S.A., et al. IL25 elicits a multipotent progenitor cell population that 
promotes T(H)2 cytokine responses. Nature 464, 1362-1366. 
103. Neill, D.R., et al. Nuocytes represent a new innate effector leukocyte that 
mediates type-2 immunity. Nature 464, 1367-1370. 
104. Croft, M., Carter, L., Swain, S.L. & Dutton, R.W. Generation of polarized 
antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 
and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180, 
1715-1728 (1994). 
105. Sad, S., Marcotte, R. & Mosmann, T.R. Cytokine-induced differentiation of 
precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 
cytokines. Immunity 2, 271-279 (1995). 
106. Huber, M., et al. A Th17-like developmental process leads to CD8(+) Tc17 cells 
with reduced cytotoxic activity. Eur J Immunol 39, 1716-1725 (2009). 
107. Ciric, B., El-behi, M., Cabrera, R., Zhang, G.X. & Rostami, A. IL-23 drives 
pathogenic IL-17-producing CD8+ T cells. J Immunol 182, 5296-5305 (2009). 
108. Joshi, N.S., et al. Inflammation directs memory precursor and short-lived 
effector CD8(+) T cell fates via the graded expression of T-bet transcription 
factor. Immunity 27, 281-295 (2007). 
109. Badovinac, V.P., Porter, B.B. & Harty, J.T. CD8+ T cell contraction is controlled 
by early inflammation. Nat Immunol 5, 809-817 (2004). 
110. Curtsinger, J.M., Lins, D.C. & Mescher, M.F. Signal 3 determines tolerance 
versus full activation of naive CD8 T cells: dissociating proliferation and 
development of effector function. J Exp Med 197, 1141-1151 (2003). 
111. Curtsinger, J.M., et al. Inflammatory cytokines provide a third signal for 
activation of naive CD4+ and CD8+ T cells. J Immunol 162, 3256-3262 (1999). 
112. Curtsinger, J.M., Valenzuela, J.O., Agarwal, P., Lins, D. & Mescher, M.F. Type I 
IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and 
differentiation. J Immunol 174, 4465-4469 (2005). 
113. Kolumam, G.A., Thomas, S., Thompson, L.J., Sprent, J. & Murali-Krishna, K. 
Type I interferons act directly on CD8 T cells to allow clonal expansion and 
memory formation in response to viral infection. J Exp Med 202, 637-650 
(2005). 
114. Le Bon, A., et al. Direct stimulation of T cells by type I IFN enhances the CD8+ 
T cell response during cross-priming. J Immunol 176, 4682-4689 (2006). 
115. Pearce, E.L. & Shen, H. Generation of CD8 T cell memory is regulated by IL-
12. J Immunol 179, 2074-2081 (2007). 
116. Allard, E.L., et al. Overexpression of IL-21 promotes massive CD8+ memory T 
cell accumulation. Eur J Immunol 37, 3069-3077 (2007). 
117. Elsaesser, H., Sauer, K. & Brooks, D.G. IL-21 is required to control chronic viral 
infection. Science 324, 1569-1572 (2009). 
118. Frohlich, A., et al. IL-21R on T cells is critical for sustained functionality and 
control of chronic viral infection. Science 324, 1576-1580 (2009). 
 190 
119. Yi, J.S., Du, M. & Zajac, A.J. A vital role for interleukin-21 in the control of a 
chronic viral infection. Science 324, 1572-1576 (2009). 
120. Rao, R.R., Li, Q., Odunsi, K. & Shrikant, P.A. The mTOR kinase determines 
effector versus memory CD8+ T cell fate by regulating the expression of 
transcription factors T-bet and Eomesodermin. Immunity 32, 67-78 (2010). 
121. Intlekofer, A.M., et al. Effector and memory CD8+ T cell fate coupled by T-bet 
and eomesodermin. Nat Immunol 6, 1236-1244 (2005). 
122. Banerjee, A., et al. Cutting edge: The transcription factor eomesodermin 
enables CD8+ T cells to compete for the memory cell niche. J Immunol 185, 
4988-4992 (2010). 
123. Bennett, S.R., et al. Help for cytotoxic-T-cell responses is mediated by CD40 
signalling. Nature 393, 478-480 (1998). 
124. Ridge, J.P., Di Rosa, F. & Matzinger, P. A conditioned dendritic cell can be a 
temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-
478 (1998). 
125. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R. & Melief, C.J. 
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L 
interactions. Nature 393, 480-483 (1998). 
126. Rahemtulla, A., et al. Normal development and function of CD8+ cells but 
markedly decreased helper cell activity in mice lacking CD4. Nature 353, 180-
184 (1991). 
127. Buller, R.M., Holmes, K.L., Hugin, A., Frederickson, T.N. & Morse, H.C., 3rd. 
Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper 
cells. Nature 328, 77-79 (1987). 
128. Janssen, E.M., et al. CD4+ T cells are required for secondary expansion and 
memory in CD8+ T lymphocytes. Nature 421, 852-856 (2003). 
129. Shedlock, D.J. & Shen, H. Requirement for CD4 T cell help in generating 
functional CD8 T cell memory. Science 300, 337-339 (2003). 
130. Sun, J.C. & Bevan, M.J. Defective CD8 T cell memory following acute infection 
without CD4 T cell help. Science 300, 339-342 (2003). 
131. Carvalho, L.H., et al. IL-4-secreting CD4+ T cells are crucial to the development 
of CD8+ T-cell responses against malaria liver stages. Nat Med 8, 166-170 
(2002). 
132. Yanez, D.M., Manning, D.D., Cooley, A.J., Weidanz, W.P. & van der Heyde, 
H.C. Participation of lymphocyte subpopulations in the pathogenesis of 
experimental murine cerebral malaria. J Immunol 157, 1620-1624 (1996). 
133. Hermsen, C., van de Wiel, T., Mommers, E., Sauerwein, R. & Eling, W. 
Depletion of CD4+ or CD8+ T-cells prevents Plasmodium berghei induced 
cerebral malaria in end-stage disease. Parasitology 114 ( Pt 1), 7-12 (1997). 
134. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-
tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains 
(CD25). Breakdown of a single mechanism of self-tolerance causes various 
autoimmune diseases. J Immunol 155, 1151-1164 (1995). 
135. Itoh, M., et al. Thymus and autoimmunity: production of CD25+CD4+ naturally 
anergic and suppressive T cells as a key function of the thymus in maintaining 
immunologic self-tolerance. J Immunol 162, 5317-5326 (1999). 
136. Brunkow, M.E., et al. Disruption of a new forkhead/winged-helix protein, scurfin, 
results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 
27, 68-73 (2001). 
137. Wildin, R.S., et al. X-linked neonatal diabetes mellitus, enteropathy and 
endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 
27, 18-20 (2001). 
138. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development 
by the transcription factor Foxp3. Science 299, 1057-1061 (2003). 
139. Fontenot, J.D., Gavin, M.A. & Rudensky, A.Y. Foxp3 programs the 
development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 
330-336 (2003). 
140. Tadokoro, C.E., et al. Regulatory T cells inhibit stable contacts between CD4+ 
T cells and dendritic cells in vivo. J Exp Med 203, 505-511 (2006). 
141. Tang, Q., et al. Visualizing regulatory T cell control of autoimmune responses in 
nonobese diabetic mice. Nat Immunol 7, 83-92 (2006). 
 191 
142. Zhang, X., Izikson, L., Liu, L. & Weiner, H.L. Activation of CD25(+)CD4(+) 
regulatory T cells by oral antigen administration. J Immunol 167, 4245-4253 
(2001). 
143. Levings, M.K., et al. Human CD25+CD4+ T suppressor cell clones produce 
transforming growth factor beta, but not interleukin 10, and are distinct from 
type 1 T regulatory cells. J Exp Med 196, 1335-1346 (2002). 
144. Maloy, K.J., et al. CD4+CD25+ T(R) cells suppress innate immune pathology 
through cytokine-dependent mechanisms. J Exp Med 197, 111-119 (2003). 
145. Rubtsov, Y.P., et al. Regulatory T cell-derived interleukin-10 limits inflammation 
at environmental interfaces. Immunity 28, 546-558 (2008). 
146. Read, S., et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells 
abrogates their function in vivo. J Immunol 177, 4376-4383 (2006). 
147. Tang, Q., et al. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ 
regulatory T cell function. Eur J Immunol 34, 2996-3005 (2004). 
148. Robertson, S.J. & Hasenkrug, K.J. The role of virus-induced regulatory T cells 
in immunopathology. Springer Semin Immunopathol 28, 51-62 (2006). 
149. Demengeot, J., Zelenay, S., Moraes-Fontes, M.F., Caramalho, I. & Coutinho, A. 
Regulatory T cells in microbial infection. Springer Semin Immunopathol 28, 41-
50 (2006). 
150. Wohlfert, E. & Belkaid, Y. Role of endogenous and induced regulatory T cells 
during infections. J Clin Immunol 28, 707-715 (2008). 
151. Belkaid, Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev 
Immunol 7, 875-888 (2007). 
152. Chen, W., et al. Conversion of peripheral CD4+CD25- naive T cells to 
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor 
Foxp3. J Exp Med 198, 1875-1886 (2003). 
153. Fu, S., et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - 
precursors. Am J Transplant 4, 1614-1627 (2004). 
154. Wakkach, A., et al. Characterization of dendritic cells that induce tolerance and 
T regulatory 1 cell differentiation in vivo. Immunity 18, 605-617 (2003). 
155. Awasthi, A., et al. A dominant function for interleukin 27 in generating 
interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8, 1380-1389 
(2007). 
156. Ochando, J.C., et al. Alloantigen-presenting plasmacytoid dendritic cells 
mediate tolerance to vascularized grafts. Nat Immunol 7, 652-662 (2006). 
157. Yamazaki, S., et al. Direct expansion of functional CD25+ CD4+ regulatory T 
cells by antigen-processing dendritic cells. J Exp Med 198, 235-247 (2003). 
158. Tarbell, K.V., Yamazaki, S., Olson, K., Toy, P. & Steinman, R.M. CD25+ CD4+ 
T cells, expanded with dendritic cells presenting a single autoantigenic peptide, 
suppress autoimmune diabetes. J Exp Med 199, 1467-1477 (2004). 
159. Kretschmer, K., et al. Inducing and expanding regulatory T cell populations by 
foreign antigen. Nat Immunol 6, 1219-1227 (2005). 
160. Hawiger, D., Wan, Y.Y., Eynon, E.E. & Flavell, R.A. The transcription cofactor 
Hopx is required for regulatory T cell function in dendritic cell-mediated 
peripheral T cell unresponsiveness. Nat Immunol 11, 962-968 (2010). 
161. Mucida, D., et al. Reciprocal TH17 and regulatory T cell differentiation mediated 
by retinoic acid. Science 317, 256-260 (2007). 
162. Sun, C.M., et al. Small intestine lamina propria dendritic cells promote de novo 
generation of Foxp3 T reg cells via retinoic acid. J Exp Med 204, 1775-1785 
(2007). 
163. Coombes, J.L., et al. A functionally specialized population of mucosal CD103+ 
DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-
dependent mechanism. J Exp Med 204, 1757-1764 (2007). 
164. Haribhai, D., et al. A requisite role for induced regulatory T cells in tolerance 
based on expanding antigen receptor diversity. Immunity 35, 109-122 (2011). 
165. Zheng, Y., et al. Regulatory T-cell suppressor program co-opts transcription 
factor IRF4 to control T(H)2 responses. Nature 458, 351-356 (2009). 
166. Chaudhry, A., et al. CD4+ regulatory T cells control TH17 responses in a Stat3-
dependent manner. Science 326, 986-991 (2009). 
 192 
167. Koch, M.A., et al. The transcription factor T-bet controls regulatory T cell 
homeostasis and function during type 1 inflammation. Nat Immunol 10, 595-602 
(2009). 
168. Liu, K., et al. In vivo analysis of dendritic cell development and homeostasis. 
Science 324, 392-397 (2009). 
169. Darrasse-Jeze, G., et al. Feedback control of regulatory T cell homeostasis by 
dendritic cells in vivo. J Exp Med 206, 1853-1862 (2009). 
170. Raberg, L., Graham, A.L. & Read, A.F. Decomposing health: tolerance and 
resistance to parasites in animals. Philos Trans R Soc Lond B Biol Sci 364, 37-
49 (2009). 
171. Schneider, D.S. & Ayres, J.S. Two ways to survive infection: what resistance 
and tolerance can teach us about treating infectious diseases. Nat Rev 
Immunol 8, 889-895 (2008). 
172. Simms, E.L. Defining tolerance as a norm of reaction. Evol Ecol 14, 563-570 
(2001). 
173. Stowe, K.A., Marquis, R.J., Hochwender, C.G. & Simms, E.L. The evolutionary 
ecology of tolerance to consumer damage. Annu Rev Ecol Syst 31, 565-595 
(2000). 
174. Raberg, L., Sim, D. & Read, A.F. Disentangling genetic variation for resistance 
and tolerance to infectious diseases in animals. Science 318, 812-814 (2007). 
175. Ayres, J.S. & Schneider, D.S. A signaling protease required for melanization in 
Drosophila affects resistance and tolerance of infections. PLoS Biol 6, 2764-
2773 (2008). 
176. Gazzinelli, R.T., et al. In the absence of endogenous IL-10, mice acutely 
infected with Toxoplasma gondii succumb to a lethal immune response 
dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-
gamma and TNF-alpha. J Immunol 157, 798-805 (1996). 
177. Holscher, C., et al. Tumor necrosis factor alpha-mediated toxic shock in 
Trypanosoma cruzi-infected interleukin 10-deficient mice. Infect Immun 68, 
4075-4083 (2000). 
178. Pamplona, A., et al. Heme oxygenase-1 and carbon monoxide suppress the 
pathogenesis of experimental cerebral malaria. Nat Med 13, 703-710 (2007). 
179. Seixas, E., et al. Heme oxygenase-1 affords protection against noncerebral 
forms of severe malaria. Proc Natl Acad Sci U S A 106, 15837-15842 (2009). 
180. Vossenkamper, A., et al. Both IL-12 and IL-18 contribute to small intestinal Th1-
type immunopathology following oral infection with Toxoplasma gondii, but IL-
12 is dominant over IL-18 in parasite control. Eur J Immunol 34, 3197-3207 
(2004). 
181. Chen, S.T., et al. CLEC5A is critical for dengue-virus-induced lethal disease. 
Nature 453, 672-676 (2008). 
182. Ritter, M., et al. Schistosoma mansoni triggers Dectin-2, which activates the 
Nlrp3 inflammasome and alters adaptive immune responses. Proc Natl Acad 
Sci U S A 107, 20459-20464. 
183. Carlsson, F., et al. Host-detrimental role of Esx-1-mediated inflammasome 
activation in mycobacterial infection. PLoS Pathog 6, e1000895. 
184. Hayashi, S., et al. Characterization of rat heme oxygenase-3 gene. Implication 
of processed pseudogenes derived from heme oxygenase-2 gene. Gene 336, 
241-250 (2004). 
185. Otterbein, L.E., Soares, M.P., Yamashita, K. & Bach, F.H. Heme oxygenase-1: 
unleashing the protective properties of heme. Trends Immunol 24, 449-455 
(2003). 
186. Soares, M.P. & Bach, F.H. Heme oxygenase-1: from biology to therapeutic 
potential. Trends Mol Med 15, 50-58 (2009). 
187. Fenton, H.J.H. Oxidation of tartaric acid in presence of iron. J. Chem. Soc. 
Trans. 65, 899-910 (1894). 
188. Gozzelino, R., Jeney, V. & Soares, M.P. Mechanisms of cell protection by heme 
oxygenase-1. Annu Rev Pharmacol Toxicol 50, 323-354 (2010). 
189. Ganz, T. & Nemeth, E. Regulation of iron acquisition and iron distribution in 
mammals. Biochim Biophys Acta 1763, 690-699 (2006). 
190. Brouard, S., et al. Carbon monoxide generated by heme oxygenase 1 
suppresses endothelial cell apoptosis. J Exp Med 192, 1015-1026 (2000). 
 193 
191. Otterbein, L.E., et al. Carbon monoxide has anti-inflammatory effects involving 
the mitogen-activated protein kinase pathway. Nat Med 6, 422-428 (2000). 
192. Silva, G., Cunha, A., Gregoire, I.P., Seldon, M.P. & Soares, M.P. The 
antiapoptotic effect of heme oxygenase-1 in endothelial cells involves the 
degradation of p38 alpha MAPK isoform. J Immunol 177, 1894-1903 (2006). 
193. Zuckerbraun, B.S., et al. Carbon monoxide signals via inhibition of cytochrome 
c oxidase and generation of mitochondrial reactive oxygen species. FASEB J 
21, 1099-1106 (2007). 
194. Ferreira, A., Balla, J., Jeney, V., Balla, G. & Soares, M.P. A central role for free 
heme in the pathogenesis of severe malaria: the missing link? J Mol Med (Berl) 
86, 1097-1111 (2008). 
195. Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N. & Ames, B.N. 
Bilirubin is an antioxidant of possible physiological importance. Science 235, 
1043-1046 (1987). 
196. Reiter, T.A., Pang, B., Dedon, P. & Demple, B. Resistance to nitric oxide-
induced necrosis in heme oxygenase-1 overexpressing pulmonary epithelial 
cells associated with decreased lipid peroxidation. J Biol Chem 281, 36603-
36612 (2006). 
197. Dore, S., et al. Bilirubin, formed by activation of heme oxygenase-2, protects 
neurons against oxidative stress injury. Proc Natl Acad Sci U S A 96, 2445-
2450 (1999). 
198. Balla, G., et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J 
Biol Chem 267, 18148-18153 (1992). 
199. Pham, C.G., et al. Ferritin heavy chain upregulation by NF-kappaB inhibits 
TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119, 
529-542 (2004). 
200. Alam, J. & Cook, J.L. How many transcription factors does it take to turn on the 
heme oxygenase-1 gene? Am J Respir Cell Mol Biol 36, 166-174 (2007). 
201. Sykiotis, G.P. & Bohmann, D. Stress-activated cap'n'collar transcription factors 
in aging and human disease. Sci Signal 3, re3 (2010). 
202. Kensler, T.W., Wakabayashi, N. & Biswal, S. Cell survival responses to 
environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol 
Toxicol 47, 89-116 (2007). 
203. Akamatsu, Y., et al. Heme oxygenase-1-derived carbon monoxide protects 
hearts from transplant associated ischemia reperfusion injury. FASEB J 18, 
771-772 (2004). 
204. Soares, M.P., et al. Expression of heme oxygenase-1 can determine cardiac 
xenograft survival. Nat Med 4, 1073-1077 (1998). 
205. Otterbein, L.E., et al. Carbon monoxide suppresses arteriosclerotic lesions 
associated with chronic graft rejection and with balloon injury. Nat Med 9, 183-
190 (2003). 
206. Chora, A.A., et al. Heme oxygenase-1 and carbon monoxide suppress 
autoimmune neuroinflammation. J Clin Invest 117, 438-447 (2007). 
207. Larsen, R., et al. A central role for free heme in the pathogenesis of severe 
sepsis. Sci Transl Med 2, 51ra71 (2010). 
208. Poss, K.D. & Tonegawa, S. Heme oxygenase 1 is required for mammalian iron 
reutilization. Proc Natl Acad Sci U S A 94, 10919-10924 (1997). 
209. Poss, K.D. & Tonegawa, S. Reduced stress defense in heme oxygenase 1-
deficient cells. Proc Natl Acad Sci U S A 94, 10925-10930 (1997). 
210. Yachie, A., et al. Oxidative stress causes enhanced endothelial cell injury in 
human heme oxygenase-1 deficiency. J Clin Invest 103, 129-135 (1999). 
211. Figueiredo, R.T., et al. Characterization of heme as activator of Toll-like 
receptor 4. J Biol Chem 282, 20221-20229 (2007). 
212. Porto, B.N., et al. Heme induces neutrophil migration and reactive oxygen 
species generation through signaling pathways characteristic of chemotactic 
receptors. J Biol Chem 282, 24430-24436 (2007). 
213. Monteiro, A.P., et al. Leukotriene B4 mediates neutrophil migration induced by 
heme. J Immunol 186, 6562-6567 (2011). 
214. Lee, T.S. & Chau, L.Y. Heme oxygenase-1 mediates the anti-inflammatory 
effect of interleukin-10 in mice. Nat Med 8, 240-246 (2002). 
 194 
215. Lee, T.S., Tsai, H.L. & Chau, L.Y. Induction of heme oxygenase-1 expression in 
murine macrophages is essential for the anti-inflammatory effect of low dose 
15-deoxy-Delta 12,14-prostaglandin J2. J Biol Chem 278, 19325-19330 (2003). 
216. Kapturczak, M.H., et al. Heme oxygenase-1 modulates early inflammatory 
responses: evidence from the heme oxygenase-1-deficient mouse. Am J Pathol 
165, 1045-1053 (2004). 
217. Graca-Souza, A.V., Arruda, M.A., de Freitas, M.S., Barja-Fidalgo, C. & Oliveira, 
P.L. Neutrophil activation by heme: implications for inflammatory processes. 
Blood 99, 4160-4165 (2002). 
218. Wiesel, P., et al. Exacerbation of chronic renovascular hypertension and acute 
renal failure in heme oxygenase-1-deficient mice. Circ Res 88, 1088-1094 
(2001). 
219. Taille, C., et al. Induction of heme oxygenase-1 inhibits NAD(P)H oxidase 
activity by down-regulating cytochrome b558 expression via the reduction of 
heme availability. J Biol Chem 279, 28681-28688 (2004). 
220. Li, X., Schwacha, M.G., Chaudry, I.H. & Choudhry, M.A. Heme oxygenase-1 
protects against neutrophil-mediated intestinal damage by down-regulation of 
neutrophil p47phox and p67phox activity and O2- production in a two-hit model 
of alcohol intoxication and burn injury. J Immunol 180, 6933-6940 (2008). 
221. Wang, X.M., Kim, H.P., Nakahira, K., Ryter, S.W. & Choi, A.M. The heme 
oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by 
regulating the interaction of TLR4 with caveolin-1. J Immunol 182, 3809-3818 
(2009). 
222. Nakahira, K., et al. Carbon monoxide differentially inhibits TLR signaling 
pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J Exp 
Med 203, 2377-2389 (2006). 
223. Chin, B.Y., et al. Hypoxia-inducible factor 1alpha stabilization by carbon 
monoxide results in cytoprotective preconditioning. Proc Natl Acad Sci U S A 
104, 5109-5114 (2007). 
224. Bilban, M., et al. Carbon monoxide orchestrates a protective response through 
PPARgamma. Immunity 24, 601-610 (2006). 
225. Morse, D., et al. Suppression of inflammatory cytokine production by carbon 
monoxide involves the JNK pathway and AP-1. J Biol Chem 278, 36993-36998 
(2003). 
226. Mashreghi, M.F., et al. Inhibition of dendritic cell maturation and function is 
independent of heme oxygenase 1 but requires the activation of STAT3. J 
Immunol 180, 7919-7930 (2008). 
227. Nolte, M.A., Leibundgut-Landmann, S., Joffre, O. & Reis e Sousa, C. Dendritic 
cell quiescence during systemic inflammation driven by LPS stimulation of 
radioresistant cells in vivo. J Exp Med 204, 1487-1501 (2007). 
228. Chauveau, C., et al. Heme oxygenase-1 expression inhibits dendritic cell 
maturation and proinflammatory function but conserves IL-10 expression. Blood 
106, 1694-1702 (2005). 
229. Remy, S., et al. Carbon monoxide inhibits TLR-induced dendritic cell 
immunogenicity. J Immunol 182, 1877-1884 (2009). 
230. Liu, Y., et al. Bilirubin possesses powerful immunomodulatory activity and 
suppresses experimental autoimmune encephalomyelitis. J Immunol 181, 1887-
1897 (2008). 
231. Pae, H.O., et al. Carbon monoxide produced by heme oxygenase-1 suppresses 
T cell proliferation via inhibition of IL-2 production. J Immunol 172, 4744-4751 
(2004). 
232. Song, R., et al. Carbon monoxide promotes Fas/CD95-induced apoptosis in 
Jurkat cells. J Biol Chem 279, 44327-44334 (2004). 
233. McDaid, J., et al. Heme oxygenase-1 modulates the allo-immune response by 
promoting activation-induced cell death of T cells. FASEB J 19, 458-460 (2005). 
234. Yamashita, K., et al. Heme oxygenase-1 is essential for and promotes tolerance 
to transplanted organs. FASEB J 20, 776-778 (2006). 
235. Yamashita, K., et al. Biliverdin, a natural product of heme catabolism, induces 
tolerance to cardiac allografts. FASEB J 18, 765-767 (2004). 
 195 
236. Phelan, D., Winter, G.M., Rogers, W.J., Lam, J.C. & Denison, M.S. Activation of 
the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch 
Biochem Biophys 357, 155-163 (1998). 
237. Quintana, F.J., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl 
hydrocarbon receptor. Nature 453, 65-71 (2008). 
238. Veldhoen, M., et al. The aryl hydrocarbon receptor links TH17-cell-mediated 
autoimmunity to environmental toxins. Nature 453, 106-109 (2008). 
239. Tzima, S., Victoratos, P., Kranidioti, K., Alexiou, M. & Kollias, G. Myeloid heme 
oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-
beta production. J Exp Med 206, 1167-1179 (2009). 
240. Brusko, T.M., Wasserfall, C.H., Agarwal, A., Kapturczak, M.H. & Atkinson, M.A. 
An integral role for heme oxygenase-1 and carbon monoxide in maintaining 
peripheral tolerance by CD4+CD25+ regulatory T cells. J Immunol 174, 5181-
5186 (2005). 
241. Pae, H.O., Oh, G.S., Choi, B.M., Chae, S.C. & Chung, H.T. Differential 
expressions of heme oxygenase-1 gene in CD25- and CD25+ subsets of 
human CD4+ T cells. Biochem Biophys Res Commun 306, 701-705 (2003). 
242. Zelenay, S., Chora, A., Soares, M.P. & Demengeot, J. Heme oxygenase-1 is 
not required for mouse regulatory T cell development and function. Int Immunol 
19, 11-18 (2007). 
243. Choi, B.M., Pae, H.O., Jeong, Y.R., Kim, Y.M. & Chung, H.T. Critical role of 
heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem Biophys 
Res Commun 327, 1066-1071 (2005). 
244. George, J.F., et al. Suppression by CD4+CD25+ regulatory T cells is dependent 
on expression of heme oxygenase-1 in antigen-presenting cells. Am J Pathol 
173, 154-160 (2008). 
245. Watanabe-Matsui, M., et al. Heme regulates B-cell differentiation, antibody 
class switch, and heme oxygenase-1 expression in B cells as a ligand of Bach2. 
Blood 117, 5438-5448 (2011). 
246. Shi, Y., Evans, J.E. & Rock, K.L. Molecular identification of a danger signal that 
alerts the immune system to dying cells. Nature 425, 516-521 (2003). 
247. Kono, H. & Rock, K.L. How dying cells alert the immune system to danger. Nat 
Rev Immunol 8, 279-289 (2008). 
248. Matzinger, P. Tolerance, danger, and the extended family. Annu Rev Immunol 
12, 991-1045 (1994). 
249. Wiesel, P., et al. Endotoxin-induced mortality is related to increased oxidative 
stress and end-organ dysfunction, not refractory hypotension, in heme 
oxygenase-1-deficient mice. Circulation 102, 3015-3022 (2000). 
250. Kim, H.P., Ryter, S.W. & Choi, A.M. CO as a cellular signaling molecule. Annu 
Rev Pharmacol Toxicol 46, 411-449 (2006). 
251. Takamiya, R., et al. High-mobility group box 1 contributes to lethality of 
endotoxemia in heme oxygenase-1-deficient mice. Am J Respir Cell Mol Biol 
41, 129-135 (2009). 
252. Gong, Q., et al. Heme oxygenase-1 upregulation significantly inhibits TNF-alpha 
and Hmgb1 releasing and attenuates lipopolysaccharide-induced acute lung 
injury in mice. Int Immunopharmacol 8, 792-798 (2008). 
253. Wang, H., et al. HMG-1 as a late mediator of endotoxin lethality in mice. 
Science 285, 248-251 (1999). 
254. Nairz, M., Schroll, A., Sonnweber, T. & Weiss, G. The struggle for iron - a metal 
at the host-pathogen interface. Cell Microbiol 12, 1691-1702 (2010). 
255. Andrews, N.C. Forging a field: the golden age of iron biology. Blood 112, 219-
230 (2008). 
256. Andrews, N.C. & Schmidt, P.J. Iron homeostasis. Annu Rev Physiol 69, 69-85 
(2007). 
257. Hentze, M.W., et al. Identification of the iron-responsive element for the 
translational regulation of human ferritin mRNA. Science 238, 1570-1573 
(1987). 
258. Casey, J.L., Koeller, D.M., Ramin, V.C., Klausner, R.D. & Harford, J.B. Iron 
regulation of transferrin receptor mRNA levels requires iron-responsive 
elements and a rapid turnover determinant in the 3' untranslated region of the 
mRNA. EMBO J 8, 3693-3699 (1989). 
 196 
259. Leipuviene, R. & Theil, E.C. The family of iron responsive RNA structures 
regulated by changes in cellular iron and oxygen. Cell Mol Life Sci 64, 2945-
2955 (2007). 
260. Ilyin, G., et al. Comparative analysis of mouse hepcidin 1 and 2 genes: 
evidence for different patterns of expression and co-inducibility during iron 
overload. FEBS Lett 542, 22-26 (2003). 
261. Peyssonnaux, C., et al. TLR4-dependent hepcidin expression by myeloid cells 
in response to bacterial pathogens. Blood 107, 3727-3732 (2006). 
262. Ganz, T. & Nemeth, E. Hepcidin and disorders of iron metabolism. Annu Rev 
Med 62, 347-360 (2011). 
263. Pietrangelo, A. Hepcidin in human iron disorders: therapeutic implications. J 
Hepatol 54, 173-181 (2011). 
264. Viatte, L., et al. Deregulation of proteins involved in iron metabolism in hepcidin-
deficient mice. Blood 105, 4861-4864 (2005). 
265. Nicolas, G., et al. Lack of hepcidin gene expression and severe tissue iron 
overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl 
Acad Sci U S A 98, 8780-8785 (2001). 
266. Nicolas, G., et al. Severe iron deficiency anemia in transgenic mice expressing 
liver hepcidin. Proc Natl Acad Sci U S A 99, 4596-4601 (2002). 
267. Roy, C.N., et al. Hepcidin antimicrobial peptide transgenic mice exhibit features 
of the anemia of inflammation. Blood 109, 4038-4044 (2007). 
268. Ehrlich, R. & Lemonnier, F.A. HFE--a novel nonclassical class I molecule that is 
involved in iron metabolism. Immunity 13, 585-588 (2000). 
269. Babitt, J.L., et al. Bone morphogenetic protein signaling by hemojuvelin 
regulates hepcidin expression. Nat Genet 38, 531-539 (2006). 
270. Wang, R.H., et al. A role of SMAD4 in iron metabolism through the positive 
regulation of hepcidin expression. Cell Metab 2, 399-409 (2005). 
271. Nemeth, E., et al. IL-6 mediates hypoferremia of inflammation by inducing the 
synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113, 1271-1276 
(2004). 
272. Verga Falzacappa, M.V., et al. STAT3 mediates hepatic hepcidin expression 
and its inflammatory stimulation. Blood 109, 353-358 (2007). 
273. Pietrangelo, A., et al. STAT3 is required for IL-6-gp130-dependent activation of 
hepcidin in vivo. Gastroenterology 132, 294-300 (2007). 
274. Wrighting, D.M. & Andrews, N.C. Interleukin-6 induces hepcidin expression 
through STAT3. Blood 108, 3204-3209 (2006). 
275. Schaible, U.E. & Kaufmann, S.H. Iron and microbial infection. Nat Rev Microbiol 
2, 946-953 (2004). 
276. Nemeth, E., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin 
and inducing its internalization. Science 306, 2090-2093 (2004). 
277. Levy, J.E., Jin, O., Fujiwara, Y., Kuo, F. & Andrews, N.C. Transferrin receptor is 
necessary for development of erythrocytes and the nervous system. Nat Genet 
21, 396-399 (1999). 
278. Ned, R.M., Swat, W. & Andrews, N.C. Transferrin receptor 1 is differentially 
required in lymphocyte development. Blood 102, 3711-3718 (2003). 
279. Seldon, M.P., et al. Heme oxygenase-1 inhibits the expression of adhesion 
molecules associated with endothelial cell activation via inhibition of NF-kappaB 
RelA phosphorylation at serine 276. J Immunol 179, 7840-7851 (2007). 
280. Soares, M.P., et al. Heme oxygenase-1 modulates the expression of adhesion 
molecules associated with endothelial cell activation. J Immunol 172, 3553-
3563 (2004). 
281. Xiong, S., et al. Signaling role of intracellular iron in NF-kappaB activation. J 
Biol Chem 278, 17646-17654 (2003). 
282. She, H., et al. Iron activates NF-kappaB in Kupffer cells. Am J Physiol 
Gastrointest Liver Physiol 283, G719-726 (2002). 
283. Wang, L. & Cherayil, B.J. Ironing out the wrinkles in host defense: interactions 
between iron homeostasis and innate immunity. J Innate Immun 1, 455-464 
(2009). 
284. Bubici, C., Papa, S., Pham, C.G., Zazzeroni, F. & Franzoso, G. NF-kappaB and 
JNK: an intricate affair. Cell Cycle 3, 1524-1529 (2004). 
 197 
285. Wang, L., et al. Selective modulation of TLR4-activated inflammatory responses 
by altered iron homeostasis in mice. J Clin Invest 119, 3322-3328 (2009). 
286. Wang, L., et al. Attenuated inflammatory responses in hemochromatosis reveal 
a role for iron in the regulation of macrophage cytokine translation. J Immunol 
181, 2723-2731 (2008). 
287. De Domenico, I., et al. Hepcidin mediates transcriptional changes that modulate 
acute cytokine-induced inflammatory responses in mice. J Clin Invest 120, 
2395-2405 (2010). 
288. Kemp, J.D., et al. Inhibition of lymphocyte activation with anti-transferrin 
receptor Mabs: a comparison of three reagents and further studies of their 
range of effects and mechanism of action. Cell Immunol 122, 218-230 (1989). 
289. Bone, R.C., et al. Definitions for sepsis and organ failure and guidelines for the 
use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference 
Committee. American College of Chest Physicians/Society of Critical Care 
Medicine. Chest 101, 1644-1655 (1992). 
290. Angus, D.C., et al. Epidemiology of severe sepsis in the United States: analysis 
of incidence, outcome, and associated costs of care. Crit Care Med 29, 1303-
1310 (2001). 
291. Martin, G.S., Mannino, D.M., Eaton, S. & Moss, M. The epidemiology of sepsis 
in the United States from 1979 through 2000. N Engl J Med 348, 1546-1554 
(2003). 
292. Martin, G., et al. The international PROGRESS registry of patients with severe 
sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care 13, 
R103 (2009). 
293. Thomas, L. Germs. N Engl J Med 287, 553-555 (1972). 
294. Dejager, L., Pinheiro, I., Dejonckheere, E. & Libert, C. Cecal ligation and 
puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol 
19, 198-208 (2011). 
295. Stearns-Kurosawa, D.J., Osuchowski, M.F., Valentine, C., Kurosawa, S. & 
Remick, D.G. The pathogenesis of sepsis. Annu Rev Pathol 6, 19-48 (2011). 
296. Rittirsch, D., Flierl, M.A. & Ward, P.A. Harmful molecular mechanisms in sepsis. 
Nat Rev Immunol 8, 776-787 (2008). 
297. Sutterwala, F.S., et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and 
adaptive immunity through its regulation of caspase-1. Immunity 24, 317-327 
(2006). 
298. Weighardt, H., et al. Cutting edge: myeloid differentiation factor 88 deficiency 
improves resistance against sepsis caused by polymicrobial infection. J 
Immunol 169, 2823-2827 (2002). 
299. Alves-Filho, J.C., de Freitas, A., Russo, M. & Cunha, F.Q. Toll-like receptor 4 
signaling leads to neutrophil migration impairment in polymicrobial sepsis. Crit 
Care Med 34, 461-470 (2006). 
300. Plitas, G., Burt, B.M., Nguyen, H.M., Bamboat, Z.M. & DeMatteo, R.P. Toll-like 
receptor 9 inhibition reduces mortality in polymicrobial sepsis. J Exp Med 205, 
1277-1283 (2008). 
301. Czermak, B.J., et al. Protective effects of C5a blockade in sepsis. Nat Med 5, 
788-792 (1999). 
302. Rittirsch, D., et al. Functional roles for C5a receptors in sepsis. Nat Med 14, 
551-557 (2008). 
303. Secher, T., et al. Crucial role of TNF receptors 1 and 2 in the control of 
polymicrobial sepsis. J Immunol 182, 7855-7864 (2009). 
304. Calandra, T., et al. Protection from septic shock by neutralization of 
macrophage migration inhibitory factor. Nat Med 6, 164-170 (2000). 
305. Ness, T.L., et al. CCR1 and CC chemokine ligand 5 interactions exacerbate 
innate immune responses during sepsis. J Immunol 173, 6938-6948 (2004). 
306. Matsukawa, A., et al. Absence of CC chemokine receptor 8 enhances innate 
immunity during septic peritonitis. FASEB J 20, 302-304 (2006). 
307. Ness, T.L., Hogaboam, C.M., Strieter, R.M. & Kunkel, S.L. Immunomodulatory 
role of CXCR2 during experimental septic peritonitis. J Immunol 171, 3775-
3784 (2003). 
308. Muenzer, J.T., et al. Characterization and modulation of the 
immunosuppressive phase of sepsis. Infect Immun 78, 1582-1592 (2011). 
 198 
309. Hotchkiss, R.S. & Nicholson, D.W. Apoptosis and caspases regulate death and 
inflammation in sepsis. Nat Rev Immunol 6, 813-822 (2006). 
310. Tinsley, K.W., et al. Sepsis induces apoptosis and profound depletion of splenic 
interdigitating and follicular dendritic cells. J Immunol 171, 909-914 (2003). 
311. Inoue, S., et al. IL-15 prevents apoptosis, reverses innate and adaptive immune 
dysfunction, and improves survival in sepsis. J Immunol 184, 1401-1409 (2010). 
312. Delano, M.J., et al. Sepsis induces early alterations in innate immunity that 
impact mortality to secondary infection. J Immunol 186, 195-202. 
313. Nascimento, D.C., et al. Role of regulatory T cells in long-term immune 
dysfunction associated with severe sepsis. Crit Care Med 38, 1718-1725. 
314. Overhaus, M., et al. Biliverdin protects against polymicrobial sepsis by 
modulating inflammatory mediators. Am J Physiol Gastrointest Liver Physiol 
290, G695-703 (2006). 
315. Chung, S.W., Liu, X., Macias, A.A., Baron, R.M. & Perrella, M.A. Heme 
oxygenase-1-derived carbon monoxide enhances the host defense response to 
microbial sepsis in mice. J Clin Invest 118, 239-247 (2008). 
316. Gardella, S., et al. The nuclear protein HMGB1 is secreted by monocytes via a 
non-classical, vesicle-mediated secretory pathway. EMBO Rep 3, 995-1001 
(2002). 
317. Yang, H., et al. Reversing established sepsis with antagonists of endogenous 
high-mobility group box 1. Proc Natl Acad Sci U S A 101, 296-301 (2004). 
318. Haldar, K., Murphy, S.C., Milner, D.A. & Taylor, T.E. Malaria: mechanisms of 
erythrocytic infection and pathological correlates of severe disease. Annu Rev 
Pathol 2, 217-249 (2007). 
319. Clark, I.A., Alleva, L.M., Mills, A.C. & Cowden, W.B. Pathogenesis of malaria 
and clinically similar conditions. Clin Microbiol Rev 17, 509-539, table of 
contents (2004). 
320. Clark, I.A. & Cowden, W.B. The pathophysiology of falciparum malaria. 
Pharmacol Ther 99, 221-260 (2003). 
321. Idro, R., Jenkins, N.E. & Newton, C.R. Pathogenesis, clinical features, and 
neurological outcome of cerebral malaria. Lancet Neurol 4, 827-840 (2005). 
322. Idro, R., Marsh, K., John, C.C. & Newton, C.R. Cerebral malaria: mechanisms 
of brain injury and strategies for improved neurocognitive outcome. Pediatr Res 
68, 267-274 (2010). 
323. Haldane, J.B.S. The rate of mutation of human genes. Hereditas 35, 267-273 
(1949). 
324. Lopez, C., Saravia, C., Gomez, A., Hoebeke, J. & Patarroyo, M.A. Mechanisms 
of genetically-based resistance to malaria. Gene 467, 1-12 (2010). 
325. Williams, T.N. Human red blood cell polymorphisms and malaria. Curr Opin 
Microbiol 9, 388-394 (2006). 
326. Mockenhaupt, F.P., et al. Alpha(+)-thalassemia protects African children from 
severe malaria. Blood 104, 2003-2006 (2004). 
327. Williams, T.N., et al. Sickle cell trait and the risk of Plasmodium falciparum 
malaria and other childhood diseases. J Infect Dis 192, 178-186 (2005). 
328. Mockenhaupt, F.P., et al. Hemoglobin C and resistance to severe malaria in 
Ghanaian children. J Infect Dis 190, 1006-1009 (2004). 
329. Hutagalung, R., et al. Influence of hemoglobin E trait on the severity of 
Falciparum malaria. J Infect Dis 179, 283-286 (1999). 
330. Ayi, K., Turrini, F., Piga, A. & Arese, P. Enhanced phagocytosis of ring-
parasitized mutant erythrocytes: a common mechanism that may explain 
protection against falciparum malaria in sickle trait and beta-thalassemia trait. 
Blood 104, 3364-3371 (2004). 
331. Cabrera, G., et al. The sickle cell trait is associated with enhanced 
immunoglobulin G antibody responses to Plasmodium falciparum variant 
surface antigens. J Infect Dis 191, 1631-1638 (2005). 
332. Fairhurst, R.M., et al. Abnormal display of PfEMP-1 on erythrocytes carrying 
haemoglobin C may protect against malaria. Nature 435, 1117-1121 (2005). 
333. Fairhurst, R.M., Fujioka, H., Hayton, K., Collins, K.F. & Wellems, T.E. Aberrant 
development of Plasmodium falciparum in hemoglobin CC red cells: 
implications for the malaria protective effect of the homozygous state. Blood 
101, 3309-3315 (2003). 
 199 
334. Rosenthal, P.J. & Meshnick, S.R. Hemoglobin catabolism and iron utilization by 
malaria parasites. Mol Biochem Parasitol 83, 131-139 (1996). 
335. Pandey, A.V., et al. Hemozoin formation in malaria: a two-step process 
involving histidine-rich proteins and lipids. Biochem Biophys Res Commun 308, 
736-743 (2003). 
336. Coban, C., et al. Toll-like receptor 9 mediates innate immune activation by the 
malaria pigment hemozoin. J Exp Med 201, 19-25 (2005). 
337. Parroche, P., et al. Malaria hemozoin is immunologically inert but radically 
enhances innate responses by presenting malaria DNA to Toll-like receptor 9. 
Proc Natl Acad Sci U S A 104, 1919-1924 (2007). 
338. Coban, C., et al. Immunogenicity of whole-parasite vaccines against 
Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host 
Microbe 7, 50-61 (2010). 
339. Franklin, B.S., et al. Therapeutical targeting of nucleic acid-sensing Toll-like 
receptors prevents experimental cerebral malaria. Proc Natl Acad Sci U S A 
108, 3689-3694 (2011). 
340. Reimer, T., et al. Experimental cerebral malaria progresses independently of 
the Nlrp3 inflammasome. Eur J Immunol 40, 764-769 (2010). 
341. Dostert, C., et al. Malarial hemozoin is a Nalp3 inflammasome activating danger 
signal. PLoS One 4, e6510 (2009). 
342. Shio, M.T., et al. Malarial hemozoin activates the NLRP3 inflammasome 
through Lyn and Syk kinases. PLoS Pathog 5, e1000559 (2009). 
343. Griffith, J.W., Sun, T., McIntosh, M.T. & Bucala, R. Pure Hemozoin is 
inflammatory in vivo and activates the NALP3 inflammasome via release of uric 
acid. J Immunol 183, 5208-5220 (2009). 
344. Orengo, J.M., et al. Plasmodium-induced inflammation by uric acid. PLoS 
Pathog 4, e1000013 (2008). 
345. Orengo, J.M., et al. Uric acid is a mediator of the Plasmodium falciparum-
induced inflammatory response. PLoS One 4, e5194 (2009). 
346. deWalick, S., et al. Cutting edge: conventional dendritic cells are the critical 
APC required for the induction of experimental cerebral malaria. J Immunol 178, 
6033-6037 (2007). 
347. Amante, F.H., et al. Immune-mediated mechanisms of parasite tissue 
sequestration during experimental cerebral malaria. J Immunol 185, 3632-3642 
(2010). 
348. Belnoue, E., et al. On the pathogenic role of brain-sequestered alphabeta CD8+ 
T cells in experimental cerebral malaria. J Immunol 169, 6369-6375 (2002). 
349. Belnoue, E., et al. CCR5 deficiency decreases susceptibility to experimental 
cerebral malaria. Blood 101, 4253-4259 (2003). 
350. Campanella, G.S., et al. Chemokine receptor CXCR3 and its ligands CXCL9 
and CXCL10 are required for the development of murine cerebral malaria. Proc 
Natl Acad Sci U S A 105, 4814-4819 (2008). 
351. Miu, J., et al. Chemokine gene expression during fatal murine cerebral malaria 
and protection due to CXCR3 deficiency. J Immunol 180, 1217-1230 (2008). 
352. Nitcheu, J., et al. Perforin-dependent brain-infiltrating cytotoxic CD8+ T 
lymphocytes mediate experimental cerebral malaria pathogenesis. J Immunol 
170, 2221-2228 (2003). 
353. Haque, A., et al. Granzyme B expression by CD8+ T cells is required for the 
development of experimental cerebral malaria. J Immunol 186, 6148-6156 
(2011). 
354. Haque, A., et al. CD4+ natural regulatory T cells prevent experimental cerebral 
malaria via CTLA-4 when expanded in vivo. PLoS Pathog 6, e1001221 (2010). 
355. Claser, C., et al. CD8+ T cells and IFN-gamma mediate the time-dependent 
accumulation of infected red blood cells in deep organs during experimental 
cerebral malaria. PLoS One 6, e18720 (2011). 
356. Baptista, F.G., et al. Accumulation of Plasmodium berghei-infected red blood 
cells in the brain is crucial for the development of cerebral malaria in mice. 
Infect Immun 78, 4033-4039 (2010). 
357. Epiphanio, S., et al. Heme oxygenase-1 is an anti-inflammatory host factor that 
promotes murine plasmodium liver infection. Cell Host Microbe 3, 331-338 
(2008). 
 200 
358. Wieckiewicz, J., Goto, R. & Wood, K.J. T regulatory cells and the control of 
alloimmunity: from characterisation to clinical application. Curr Opin Immunol 
22, 662-668 (2010). 
359. Belkaid, Y. & Tarbell, K. Regulatory T cells in the control of host-microorganism 
interactions (*). Annu Rev Immunol 27, 551-589 (2009). 
360. da Costa, T.B., Sardinha, L.R., Larocca, R., Peron, J.P. & Rizzo, L.V. 
Allogeneic apoptotic thymocyte-stimulated dendritic cells expand functional 
regulatory T cells. Immunology 133, 123-132 (2010). 
361. Nairz, M., et al. Erythropoietin contrastingly affects bacterial infection and 
experimental colitis by inhibiting nuclear factor-kappaB-inducible immune 
pathways. Immunity 34, 61-74 (2011). 
362. Papanikolaou, G., et al. Hepcidin in iron overload disorders. Blood 105, 4103-
4105 (2005). 
363. Kearney, S.L., et al. Urinary hepcidin in congenital chronic anemias. Pediatr 
Blood Cancer 48, 57-63 (2007). 
364. Origa, R., et al. Liver iron concentrations and urinary hepcidin in beta-
thalassemia. Haematologica 92, 583-588 (2007). 
365. Gardenghi, S., et al. Ineffective erythropoiesis in beta-thalassemia is 
characterized by increased iron absorption mediated by down-regulation of 
hepcidin and up-regulation of ferroportin. Blood 109, 5027-5035 (2007). 
366. Nicolas, G., et al. The gene encoding the iron regulatory peptide hepcidin is 
regulated by anemia, hypoxia, and inflammation. J Clin Invest 110, 1037-1044 
(2002). 
367. Trudel, M., et al. Sickle cell disease of transgenic SAD mice. Blood 84, 3189-
3197 (1994). 
368. Trudel, M., et al. Towards a transgenic mouse model of sickle cell disease: 
hemoglobin SAD. EMBO J 10, 3157-3165 (1991). 
369. Pinto, J.P., et al. Erythropoietin mediates hepcidin expression in hepatocytes 
through EPOR signaling and regulation of C/EBPalpha. Blood 111, 5727-5733 
(2008). 
370. Brinkmann, M., et al. Expression of iron transport proteins divalent metal 
transporter-1, Ferroportin-1, HFE and transferrin receptor-1 in human 
monocyte-derived dendritic cells. Cell Biochem Funct 25, 287-296 (2007). 
371. Cherayil, B.J. Iron and immunity: immunological consequences of iron 
deficiency and overload. Arch Immunol Ther Exp (Warsz) 58, 407-415 (2010). 
372. Cox, M.A., Harrington, L.E. & Zajac, A.J. Cytokines and the inception of CD8 T 
cell responses. Trends Immunol 32, 180-186 (2011). 
373. Williams, T.N., et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a 
retrospective cohort and case-control study. Lancet 374, 1364-1370 (2009). 
374. Menendez, C., et al. Randomised placebo-controlled trial of iron 
supplementation and malaria chemoprophylaxis for prevention of severe 
anaemia and malaria in Tanzanian infants. Lancet 350, 844-850 (1997). 
375. Nyakeriga, A.M., et al. Iron deficiency and malaria among children living on the 
coast of Kenya. J Infect Dis 190, 439-447 (2004). 
376. Smith, A.W., Hendrickse, R.G., Harrison, C., Hayes, R.J. & Greenwood, B.M. 
The effects on malaria of treatment of iron-deficiency anaemia with oral iron in 
Gambian children. Ann Trop Paediatr 9, 17-23 (1989). 
377. Sazawal, S., et al. Effects of routine prophylactic supplementation with iron and 
folic acid on admission to hospital and mortality in preschool children in a high 
malaria transmission setting: community-based, randomised, placebo-controlled 
trial. Lancet 367, 133-143 (2006). 
378. Oppenheimer, S.J., et al. Iron supplementation increases prevalence and 
effects of malaria: report on clinical studies in Papua New Guinea. Trans R Soc 
Trop Med Hyg 80, 603-612 (1986). 
379. Prentice, A.M. Iron metabolism, malaria, and other infections: what is all the 
fuss about? J Nutr 138, 2537-2541 (2008). 
380. Portugal, S., et al. Host-mediated regulation of superinfection in malaria. Nat 
Med 17, 732-737. 
 
 
 201 
Appendix 
 I 
Appendix: Control of Immunopathology During 
Plasmodium Infection by Hepcidin 
 
Ivo Marguti1 
 
1Instituto Gulbenkian de Ciência, Oeiras, Portugal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manuscript submmited for publication. 
 II 
1. ABSTRACT 
Malaria is a major health problem affecting millions of 
people annually especially in underdeveloped countries. 
Mutations causing alterations in hemoglobin production or 
structure are known to afford protection against the development 
of severe forms of malaria. Not surprisingly, these hemoglobin 
disorders are present at high frequency in areas where malaria is 
endemic, indicating a survival advantage for individuals carrying 
them. Despite many years of research, the exact mechanisms 
underlying the protection afforded by hemoglobinopathies against 
severe forms of malaria have not yet found a definitive answer. 
One feature of hemoglobinopathies, observed both in humans 
and mice, is the fact that individuals carrying these disorders 
express low levels of the hormone hepcidin that plays a major 
role in iron homeostasis. Hepcidin acts by binding to the iron 
exporter ferroportin and inducing its degradation. When hepcidin 
levels are low, ferroportin expression in cells is sustained leading 
to export of intracellular iron. Importantly, low intracellular iron 
content may affect activation of innate immune cells leading to 
diminished production of proinflammatory cytokines. Notably, 
several lines of evidence support the notion that development of 
severe forms of malaria is dependent on immune-mediated 
damage, caused by unfettered immune responses. Herein the 
hypothesis that hemoglobinopathies afford protection against 
severe forms of malaria by limiting exacerbated immune 
activation, via a mechanism that involves low hepcidin 
expression, is discussed. 
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2. BACKGROUND 
Malaria, caused by infection with Plasmodium parasites, 
constitutes a major health problem. In 2009, the World Health 
Organization reported a total of 225 million cases of malaria 
infection worldwide, with 781 thousand leading to death1. Natural 
infection occurs when Plasmodium infective sporozoites are 
delivered to host’s bloodstream via infected Anopheles 
mosquitoes bite2. The most lethal form of malaria in humans is 
cerebral malaria (CM), which affects mainly children in Africa and 
adults in Southeast Asia. CM develops in individuals infected with 
Plasmodium falciparum, and is characterized by development of 
impaired consciousness, seizures and subsequent coma3,4.  
The use of animal models of Plasmodium infection, in 
which a syndrome similar to cerebral malaria occurs, termed 
experimental cerebral malaria (ECM), allowed the identification of 
several components of the immune system as important players 
in ECM pathology. Hemozoin, a polymer of heme molecules 
produced by Plasmodium after digestion of hemoglobin inside 
red blood cells [5], coupled or not with DNA, can activate Toll-like 
receptor 9 (TLR9) and NALP3 in innate immune cells, inducing 
the production of proinflammatory cytokines [6-9]. Importantly, 
interfering with Plasmodium-mediated TLR9 or NALP3 activation 
prevents ECM development [9, 10]. Furthermore, several lines of 
evidence support the notion that exacerbated adaptive immune 
activation precipitates ECM development. First, recombination 
activating gene-2 deficient mice (Rag2-/-) and severe combined 
immune deficient (SCID) mice, both lacking T and B cells, are 
protected against ECM development [11, 12]. Second, depletion 
of CD4+ cells early after infection, and CD8+ cells until the first 
symptoms of ECM appear, can prevent ECM [13]. Third, 
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expression of the cytotoxic molecules perforin and granzyme B, 
by CD8+ T cells, is essential for ECM development [14, 15]. Fifth, 
induction of regulatory T cells (TREG) expansion during infection 
protects mice against ECM, concomitantly with a reduced CD4+ 
and CD8+ T cell response [16]. These data strongly suggest that 
ECM pathology is mainly driven by an excessive immune 
response leading to immunopathology and ultimately to death. 
A long known observation, first put forward as a 
hypothesis by Haldane17, is the fact that hemoglobinopathies, 
affecting hemoglobin production or structure, afford protection 
against development of severe forms of malaria in humans. 
These hemoglobinopathies include thalassemias, sickle cell trait 
(HbAS), hemoglobin C (HbC) and hemoglobin E (HbE) (reviewed 
in18,19). Several studies have tried to clarify the mechanisms by 
which protection is granted by these alterations in hemoglobin, 
and multiple mechanisms have been implicated20-24. 
Nonetheless, a definitive mechanism is still missing. 
Hemoglobinopathies have been linked to decreased 
levels of the hormone hepcidin in humans and mice25-28. Hepcidin 
regulates systemic iron homeostasis by controlling dietary iron 
intake, and mobilization of iron from cellular iron stores, such as 
macrophages and hepatocytes (reviewed in29,30). The 
fundamental role played by hepcidin in iron homeostasis is 
strikingly demonstrated by the severe iron overload phenotype 
observed when the hepcidin gene (Hamp) is disrupted31,32 and, 
on the other hand, by the severe iron deficiency associated with 
hepcidin overexpression33,34. On the molecular level, hepcidin 
works by binding to the iron transporter ferroportin and inducing 
its degradation35. When hepcidin levels are high, ferroportin 
degradation limits iron absorption from the diet and iron 
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mobilization from cellular iron stores. On the other hand, in the 
case of decreased hepcidin levels, high ferroportin expression 
leads to increased dietary iron absorption and export from 
cellular stores. Therefore, in conditions where hepcidin 
expression is diminished it is expected that macrophages will 
present lower intracellular iron levels. 
The role of iron in controlling immune and inflammatory 
responses has been addressed in different systems. Adequate 
levels of intracellular iron are required for proper activation of 
nuclear factor- B (NF- B) in macrophages36,37. Accordingly, 
conditions where the intracellular iron pool is diminished, due to 
low hepcidin levels, have been associated with impaired immune 
responses. The hemochromatosis gene (Hfe) is involved in 
regulation of hepcidin expression in homeostasis, and in its 
absence hepcidin levels are reduced38 and iron overload is 
observed, due to increased dietary intake and export from 
cellular stores39,40. Hfe-deficient mice (Hfe-/-) present high levels 
of ferroportin expression in splenocytes and low intracellular iron 
levels in peritoneal macrophages41. Furthermore, overexpression 
of ferroportin in a macrophage cell line41 and iron chelation42, 
leads to decreased pro-inflammatory cytokine production.  
Accordingly, macrophages obtained from Hfe-/- animals produce 
lower amounts of interleukin-6 (IL-6), tumor necrosis factor (TNF) 
and interferon-  (IFN- ) in response to stimulation via TLR4, and 
upon Salmonella typhimurium infection as compared to WT 
mice41,42. Intestinal inflammation mediated by Salmonella 
typhimurium infection is also reduced in Hfe-/- animals41, and 
treatment of WT animals with inhibitors of hepcidin expression 
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leads to decreased T cell-mediated43 and Salmonella 
typhimurium-induced42 intestinal inflammation. 
Herein it is proposed that decreased hepcidin production, 
as seen in hemoglobinopathies, leads to intracellular iron 
depletion in innate immune cells, limiting their inflammatory 
potential and preventing the generation of pathological immune 
responses after Plasmodium infection. 
 
3. HYPOTHESIS 
 The association between hemoglobinopathies and 
decreased hepcidin levels has been reported in humans and 
mice. In these circumstances, macrophages should have their 
intracellular iron pool depleted, due to sustained ferroportin 
expression. Low levels of intracellular iron in macrophages, and 
possibly other immune cells, decrease their ability to properly 
activate NF-kB and produce pro-inflammatory cytokines. 
Therefore, low hepcidin levels, as seen in individuals carrying 
hemoglobinopathies, would have an immunomodulatory effect by 
limiting unfettered immune responses upon Plasmodium 
infection. Importantly, the immunomodulatory effect of low 
intracellular iron would influence the immune response against 
Plasmodium in a way that allows parasitemia control while limits 
immunopathology. 
 
4. DISCUSSION 
The protection afforded by hemoglobinopathies against 
malaria is not associated with diminished infection rate, but rather 
to a diminished incidence of severe forms of malaria19. 
Furthermore, in some reports parasite densities are comparable 
between individuals carrying normal hemoglobin and individuals 
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with hemoglobinopathies44-47. These observations support the 
notion that the mechanisms via which hemoglobinopathies afford 
protection against severe forms of malaria are active during 
ongoing Plasmodium infection, and do not depend on decreased 
parasitemias. Therefore, limiting potentially pathological immune 
responses against Plasmodium could act as one such protective 
mechanism.  
A possible way to control immunopathology during 
Plasmodium infection would be to regulate intracellular iron levels 
on innate immune cells, thus avoiding unfettered immune 
activation. In keeping with the notion that intracellular iron levels 
can regulate immune function, it has been shown that ferroportin 
overexpression on macrophages leads to increased iron export48, 
and reduced pro-inflammatory cytokine production41. Accordingly, 
macrophages obtained from Hfe-/- mice have low intracellular iron 
levels41 and produce lower levels of pro-inflammatory cytokines 
as compared to WT mice42. Therefore, conditions leading to low 
intracellular iron levels would be expected to protect against 
immunopathology during Plasmodium infection by preventing 
immune responses to reach pathological levels. 
Hemoglobinopathies25-28 and iron deficiency49,50 have 
been associated with low levels of hepcidin. On the other hand, 
iron supplementation increase hepcidin expression51. 
Remarkably, while hemoglobinopathies and iron deficiency have 
been associated with protection against the development of 
severe forms of malaria in endemic zones19,52, iron 
supplementation was shown to increase the likelihood of severe 
malaria episodes53. This data suggests that conditions leading to 
alterations in hepcidin levels might profoundly impact the 
outcome of Plasmodium infection. 
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It was recently demonstrated that genetically modified 
mice carrying mutated human hemoglobin (HbSAD), leading to a 
mild sickle cell disease phenotype54,55, are protected from ECM 
development24. The protection is associated with decreased 
levels of activated Plasmodium-specific CD8+ T cells, known to 
be the effector cells leading to ECM development13. The exact 
mechanism through which CD8+ T cell response is suppressed in 
these animals is currently unknown, but could be explained by 
the mechanism proposed above since HbSAD mice, despite 
showing no signs of anemia, present increased erythropoietin 
levels and erythropoiesis55, two conditions that induce a 
decrease in hepcidin levels56,57. Importantly, HbSAD mice, despite 
diminished CD8+ T cell activation, still retain the capacity to 
control infection as demonstrated by similar parasitemias as 
compared to wild type animals24. This data reinforces the 
hypothesis that low intracellular iron could affect the immune 
response against Plasmodium, allowing protective immunity to 
occur while preventing harmful responses. 
The use of experimental models of severe malaria would 
be of great help in unequivocally determining a role for hepcidin 
in controlling fatal outcomes of Plasmodium infection. Moreover, 
the thorough study of the role played by hepcidin in animal 
models of Plasmodium infection, could provide valuable insights 
to the development of new therapeutical strategies to limit severe 
malaria in humans. 
 Systematic studies designed to address the levels of 
hepcidin in patients carrying protective hemoglobinopathies 
against severe forms of malaria, and its correlation with 
protection, would be extremely informative. Furthermore, 
correlating severity of malaria with hepcidin levels in patients 
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without protective hemoglobinopathies could reveal a more 
general role for hepcidin in controlling severe malaria. In addition, 
determining whether hemochromatosis patients, in which 
hepcidin production is diminished, are protected against severe 
forms of malaria would give further strength to the hypothesis 
proposed herein. 
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